<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006994</article-id><article-id pub-id-type="pmc">PMC11861813</article-id><article-id pub-id-type="doi">10.3390/v17020239</article-id><article-id pub-id-type="publisher-id">viruses-17-00239</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0386-5064</contrib-id><name><surname>Zwi-Dantsis</surname><given-names>Limor</given-names></name><xref rid="af1-viruses-17-00239" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohamed</surname><given-names>Saira</given-names></name><xref rid="af1-viruses-17-00239" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5986-6082</contrib-id><name><surname>Massaro</surname><given-names>Giulia</given-names></name><xref rid="af2-viruses-17-00239" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7019-3907</contrib-id><name><surname>Moeendarbary</surname><given-names>Emad</given-names></name><xref rid="af1-viruses-17-00239" ref-type="aff">1</xref><xref rid="c1-viruses-17-00239" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Seto</surname><given-names>Donald</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00239"><label>1</label>Department of Mechanical Engineering, Roberts Building, University College London, London WC1E 6BT, UK</aff><aff id="af2-viruses-17-00239"><label>2</label>UCL School of Pharmacy, University College London, London WC1N 1AX, UK</aff><author-notes><corresp id="c1-viruses-17-00239"><label>*</label>Correspondence: <email>e.moeendarbary@ucl.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>239</elocation-id><history><date date-type="received"><day>22</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>27</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Gene therapy offers promising potential as an efficacious and long-lasting therapeutic option for genetic conditions, by correcting defective mutations using engineered vectors to deliver genetic material to host cells. Among these vectors, adeno-associated viruses (AAVs) stand out for their efficiency, versatility, and safety, making them one of the leading platforms in gene therapy. The enormous potential of AAVs has been demonstrated through their use in over 225 clinical trials and the FDA&#x02019;s approval of six AAV-based gene therapy products, positioning these vectors at the forefront of the field. This review highlights the evolution and current applications of AAVs in gene therapy, focusing on their clinical successes, ongoing developments, and the manufacturing processes required for the rapid commercial growth anticipated in the AAV therapy market. It also discusses the broader implications of these advancements for future therapeutic strategies targeting more complex and multi-systemic conditions and biological processes such as aging. Finally, we explore some of the major challenges currently confronting the field.</p></abstract><kwd-group><kwd>adeno-associated virus (AAV)</kwd><kwd>gene therapy</kwd><kwd>vector manufacturing</kwd><kwd>clinical trials</kwd></kwd-group><funding-group><award-group><funding-source>BBSRC</funding-source><award-id>BB/V001418/1</award-id></award-group><award-group><funding-source>Cancer Research UK Multidisciplinary Award</funding-source><award-id>C57744/A22057</award-id></award-group><award-group><funding-source>EPSRC</funding-source><award-id>EP/W009889/1</award-id></award-group><award-group><funding-source>Animal Free Research UK</funding-source><award-id>8455839</award-id></award-group><funding-statement>We are grateful for financial support from the BBSRC (BB/V001418/1), the Cancer Research UK Multidisciplinary Award (C57744/A22057), and EPSRC (EP/W009889/1) to E.M. GM has received funds from Animal Free Research UK (8455839).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00239"><title>1. Introduction</title><p>Gene therapy involves introducing genetic material into patients to alter gene or protein expression and is a promising treatment option for a number of diseases such as cancer, inherited disorders, and certain viral infections [<xref rid="B1-viruses-17-00239" ref-type="bibr">1</xref>]. Generally, genetic diseases driven by mutations in the human genome are ideal targets for gene therapy. While this technology usually targets disorders with well-defined patho-physiological mechanisms and gene functions, in more recent years gene therapies have been investigated for the treatments of complex multigenic conditions such as Alzheimer&#x02019;s and Parkinson&#x02019;s diseases. Gene therapy technology utilizes a vector and its payload to correct genetic diseases in three ways: (1) replacing the defective gene with a functional copy, (2) silencing the mutated version of the gene, or (3) adding or overexpressing a distinct therapeutic gene or synthetic molecule [<xref rid="B2-viruses-17-00239" ref-type="bibr">2</xref>]. There are two main gene therapy strategies: ex vivo and in vivo. Ex vivo gene therapy involves the removal of somatic cells or tissues from the patient&#x02019;s body; specific genes in these cells are genetically modified outside the body and then reintroduced back into the patient [<xref rid="B3-viruses-17-00239" ref-type="bibr">3</xref>]. In vivo gene therapy, on the other hand, delivers therapeutic genetic material directly into the somatic cells of the target organs or tissues of the patient&#x02019;s body, achieving long-lasting expression within the host cells [<xref rid="B4-viruses-17-00239" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00239" ref-type="bibr">5</xref>].</p><p>Numerous gene delivery systems, including viral vectors (such as adenoviruses, AAVs, and lentiviruses) [<xref rid="B6-viruses-17-00239" ref-type="bibr">6</xref>] and non-viral vectors (such as lipid nanoparticles, cationic polymers, inorganic particles, and conjugate complexes) [<xref rid="B1-viruses-17-00239" ref-type="bibr">1</xref>], have been introduced for the gene therapy of human genetic diseases. Non-viral vectors are praised for their low immunogenicity, cost-effectiveness, and flexibility in handling large DNA sizes and targeting specific cells [<xref rid="B7-viruses-17-00239" ref-type="bibr">7</xref>] and have shown promising gene transfer results in animals [<xref rid="B8-viruses-17-00239" ref-type="bibr">8</xref>]. Nevertheless, non-viral gene delivery systems face challenges such as low transfection efficiency and the limited viability of the transferred cells. Additionally, these systems often lack effective targeting capabilities, which can limit their practical application in therapeutic settings [<xref rid="B9-viruses-17-00239" ref-type="bibr">9</xref>]. In contrast, viral vectors provide a robust alternative. Utilizing the virus&#x02019;s innate capability to penetrate cell nuclei and deliver genetic material, viral vector platforms offer several advantages, including high transfection efficiency, improved safety, and extensive development over decades, which have led to successful clinical outcomes in treating a variety of diseases [<xref rid="B10-viruses-17-00239" ref-type="bibr">10</xref>].</p><p>Among virus-derived vectors, AAVs have become a prominent vector for in vivo gene transfer and have emerged as one of the most efficient and relatively safe vehicles. AAVs&#x02019; low pathogenicity and immunogenicity and wide cellular tropism, combined with their ability to provide sustained transgene expression, make them a preferred vector in gene therapy [<xref rid="B11-viruses-17-00239" ref-type="bibr">11</xref>]. Notably, AAVs do not alter the sequence and structure of the genome, as the majority of the genomic material remains episomal, thus reducing the risk of insertion mutagenesis and preventing the introduction of genome instability factors and enhancing safety. However, it is estimated that approximately 0.1% of the wild-type genome integrates with the AAVS1 site in chromosome 19 [<xref rid="B12-viruses-17-00239" ref-type="bibr">12</xref>]. Nevertheless, rAAV-mediated gene replacement has been widely used in clinical trials involving a variety of gene therapies to treat various inherited and acquired human diseases, including congenital blindness, hemophilia, neuromuscular disease, and immune disorders, among many others. This successful strategy is now undergoing accelerated clinical and commercial development, with several products recently receiving approval in the USA and Europe [<xref rid="B13-viruses-17-00239" ref-type="bibr">13</xref>]. The global market value of AAV therapies reached USD 1.5 billion in 2023 and is expected to peak at USD 22.3 billion in 2029, based on GlobalData forecasts.</p><p>This review discusses the foundations and recent breakthroughs in the field of using AAVs for gene therapy, providing a summary of AAV biology, manufacturing, current clinical trials, and challenges. In addition, we review representative target genes and strategies for employing the AAV gene therapy platform for treating aging or age-related diseases.</p></sec><sec id="sec2-viruses-17-00239"><title>2. Main Review</title><sec id="sec2dot1-viruses-17-00239"><title>2.1. AAV Structure and Function</title><p>The wild-type AAV is a small, non-enveloped virus belonging to the <italic toggle="yes">Parvoviridiae</italic> family, first identified in 1965 as a contaminant of adenovirus preparations. AAV particles are approximately 25 nm in diameter, with a single-stranded DNA (ssDNA) genome of approximately 4.7 kb in size [<xref rid="B4-viruses-17-00239" ref-type="bibr">4</xref>,<xref rid="B14-viruses-17-00239" ref-type="bibr">14</xref>]. From a structural proteins perspective, the icosahedral capsid is composed of 60 subunits with a mixture of three capsid (Cap) proteins&#x02014;VP1, VP2, and VP3&#x02014;at a molar ratio of 1:1:10 which are involved in structural stability, receptor binding, cellular entry, and DNA encapsidation. Additionally, it includes four non-structural replication (Rep) proteins essential for AAV replication, transcriptional regulation, and genome packaging&#x02014;Rep78, Rep68, Rep52, and Rep40&#x02014;and the assembly-activating protein (AAP), which provides a scaffold for capsid assembly [<xref rid="B15-viruses-17-00239" ref-type="bibr">15</xref>,<xref rid="B16-viruses-17-00239" ref-type="bibr">16</xref>]. In addition, a novel frameshift open reading frame in the VP1 region producing the membrane-associated accessory protein MAAP [<xref rid="B17-viruses-17-00239" ref-type="bibr">17</xref>] has been identified to play a role in the release of AAV particles from the cell [<xref rid="B18-viruses-17-00239" ref-type="bibr">18</xref>].</p><p>The AAV genome includes the <italic toggle="yes">rep</italic> and <italic toggle="yes">cap</italic> genes, essential for the AAV&#x02019;s life cycle, flanked by two AAV-specific palindromic 145 bp inverted terminal repeats (ITRs), characterized by T-shaped hairpin structures (<xref rid="viruses-17-00239-f001" ref-type="fig">Figure 1</xref>A). The ITRs play essential roles in host genome integration, vector production, and persistent cell transduction [<xref rid="B19-viruses-17-00239" ref-type="bibr">19</xref>,<xref rid="B20-viruses-17-00239" ref-type="bibr">20</xref>]. Despite their widespread presence, with over 100 identified natural variants and several serologically distinct serotypes [<xref rid="B21-viruses-17-00239" ref-type="bibr">21</xref>], AAV infections are typically harmless and asymptomatic, occurring primarily in early childhood. However, AAVs rely on co-infection with helper viruses like Adenovirus or Herpes simplex virus for replication due to their inherent replication deficiency [<xref rid="B4-viruses-17-00239" ref-type="bibr">4</xref>].</p><p>For gene therapy applications, recombinant AAVs (rAAVs) are engineered to provide long-term gene expression with limited chromosomal integration [<xref rid="B22-viruses-17-00239" ref-type="bibr">22</xref>], thus preserving the host&#x02019;s genome integrity [<xref rid="B6-viruses-17-00239" ref-type="bibr">6</xref>,<xref rid="B23-viruses-17-00239" ref-type="bibr">23</xref>]. In the rAAV system, most of the viral genome, including the <italic toggle="yes">rep</italic> and <italic toggle="yes">cap</italic> genes, is replaced by an expression cassette. This cassette contains a gene of interest (GOI), flanked by two ITRs, and features a promoter upstream to initiate expression and a polyadenylation (polyA) tail downstream to enhance the mRNA stability and promote efficient translation. These elements can drive and regulate the expression of the gene of interest in specific cell types. The foreign DNA packaging capacity is approximately 4.5 kb (<xref rid="viruses-17-00239-f001" ref-type="fig">Figure 1</xref>B). This configuration prevents rAAVs from replicating on their own, necessitating external sources of <italic toggle="yes">cap</italic> and <italic toggle="yes">rep</italic> genes to assemble functional virus particles [<xref rid="B24-viruses-17-00239" ref-type="bibr">24</xref>]. Consequently, rAAVs are extremely safe vectors for delivering and maintaining transgene expression following a single infection, making them ideal for clinical applications [<xref rid="B16-viruses-17-00239" ref-type="bibr">16</xref>].</p><p>An innovative modification to the initial recombinant AAV (rAAV) design involves creating a self-complementary rAAV cassette (scAAV). The synthesis of the complementary DNA strand following the translocation of the genome into the nucleus is considered a rate-limiting factor for the transduction efficiency. Therefore, a second generation of vectors with double-stranded DNA have been developed [<xref rid="B25-viruses-17-00239" ref-type="bibr">25</xref>]. In this adaptation, the 5&#x02032; ITR is altered by deleting the AAV terminal resolution site and D sequence, prompting the single-stranded genome to fold back on itself and form a double-stranded, or self-complementary, structure [<xref rid="B26-viruses-17-00239" ref-type="bibr">26</xref>]. This alteration effectively halves the cargo DNA packaging capacity to approximately 2.2 kb (<xref rid="viruses-17-00239-f001" ref-type="fig">Figure 1</xref>C). Despite the reduction in the DNA capacity, this structural transformation significantly enhances the transduction efficiency, potentially increasing it by tenfold or more compared to that of a traditional single-stranded AAV. This increase is due to the elimination of the need for the host cell to convert the single-stranded DNA into double-stranded DNA. Additionally, this change leads to more stable transgene expression, leveraging the intrinsic advantages of the double-stranded format while maintaining similar elements to those in the single-stranded rAAV cassette [<xref rid="B27-viruses-17-00239" ref-type="bibr">27</xref>,<xref rid="B28-viruses-17-00239" ref-type="bibr">28</xref>].</p><p>The process of infecting and transducing cells using AAVs involves a sequence of events, starting with the AAV capsid binding to proteoglycan receptors on the cell surface (both primary receptors and coreceptors) of the host. Following this initial interaction, the AAV is internalized into the cell through endocytosis. After undergoing a structural transformation, AAV virions escape the endosome and accumulate in the perinuclear region of the cell [<xref rid="B29-viruses-17-00239" ref-type="bibr">29</xref>,<xref rid="B30-viruses-17-00239" ref-type="bibr">30</xref>]. Subsequently, they enter the nucleus through the nuclear pore. Once in the nucleus, the virus uncoats, releasing ssDNA, which is converted to double-stranded DNA (dsDNA), followed by transcription, mRNA translation, and the expression of the therapeutic transgene (<xref rid="viruses-17-00239-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B31-viruses-17-00239" ref-type="bibr">31</xref>]. AAV genomes mostly exist as circular episomes, although a low frequency of integration into the host chromosomes has been reported [<xref rid="B22-viruses-17-00239" ref-type="bibr">22</xref>]. Modifications in the AAV vector design to target specific steps in this transduction pathway can significantly influence the efficiency of transduction. For instance, the phosphorylation of threonine (T) residues exposed on the AAV capsid can impede nuclear transport. Consequently, substituting a threonine residue with valine (T491V or T492V) in serotypes such as AAV2 and AAV6 has been found to enhance nuclear entry and improve the overall transduction efficiency [<xref rid="B32-viruses-17-00239" ref-type="bibr">32</xref>].</p><p>The most used methods for AAV delivery into various tissues include intravenous (IV), intrathecal (IT), intramuscular (IM), intraocular, and intraperitoneal (IP) injections. IV methods offer systemic distribution, IT methods target the central nervous system, IM methods are used for muscle conditions, intraocular methods are for retinal diseases, and IP methods are employed in animal models for broader exposure. Each method has its advantages and limitations, as described in <xref rid="viruses-17-00239-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot2-viruses-17-00239"><title>2.2. AAV Serotypes and Tropisms</title><p>To date, at least 13 natural serotypes and over 100 variants have been identified and characterized, which allow for the targeting of a broad range of cells and tissues [<xref rid="B33-viruses-17-00239" ref-type="bibr">33</xref>]. Depending on their serotype, AAVs can have a specific tropism for certain organs and tissues of the body, with distinct tissue-specific transduction efficiencies [<xref rid="B34-viruses-17-00239" ref-type="bibr">34</xref>]. The diversity of AAV serotypes is leveraged in gene therapy to target different types of cells or tissues.</p><p>AAV1, initially identified as a contaminant in adenovirus preparations, was the first viral vector to be approved for use in gene therapy [<xref rid="B35-viruses-17-00239" ref-type="bibr">35</xref>]. It is distinguished by its inability to bind heparin and its lack of post-translational modifications. Nevertheless, this serotype excels in gene therapy applications due to its sialic acid-based cell entry mechanism and broad efficacy in transducing skeletal muscles, neurons, and various other tissues (such as the heart [<xref rid="B36-viruses-17-00239" ref-type="bibr">36</xref>,<xref rid="B37-viruses-17-00239" ref-type="bibr">37</xref>], endothelial and vascular smooth muscles [<xref rid="B38-viruses-17-00239" ref-type="bibr">38</xref>], and the retina [<xref rid="B39-viruses-17-00239" ref-type="bibr">39</xref>]) across multiple species. AAV2, discovered in 1965 and recognized for its affinity for heparan sulfate, is the most studied among all AAVs and utilized in research and clinical trials [<xref rid="B40-viruses-17-00239" ref-type="bibr">40</xref>], showing a broad tissue tropism, including for renal tissue [<xref rid="B41-viruses-17-00239" ref-type="bibr">41</xref>,<xref rid="B42-viruses-17-00239" ref-type="bibr">42</xref>], hepatocytes [<xref rid="B43-viruses-17-00239" ref-type="bibr">43</xref>,<xref rid="B44-viruses-17-00239" ref-type="bibr">44</xref>], the retina [<xref rid="B45-viruses-17-00239" ref-type="bibr">45</xref>,<xref rid="B46-viruses-17-00239" ref-type="bibr">46</xref>], the central nervous system (CNS) [<xref rid="B47-viruses-17-00239" ref-type="bibr">47</xref>,<xref rid="B48-viruses-17-00239" ref-type="bibr">48</xref>], and skeletal muscles [<xref rid="B40-viruses-17-00239" ref-type="bibr">40</xref>]. AAV3, initially overlooked as a potential AAV vector for gene therapy due to its low in vitro transduction efficiency in murine cell lines, later revealed significant potential for targeting human liver cancer cells and hepatocytes [<xref rid="B49-viruses-17-00239" ref-type="bibr">49</xref>,<xref rid="B50-viruses-17-00239" ref-type="bibr">50</xref>,<xref rid="B51-viruses-17-00239" ref-type="bibr">51</xref>]. AAV4 and AAV5, with distinct antigenic profiles and unique receptor usages, demonstrate specialized tissue transduction capabilities, such as for the CNS [<xref rid="B52-viruses-17-00239" ref-type="bibr">52</xref>] and retinal cells [<xref rid="B53-viruses-17-00239" ref-type="bibr">53</xref>]. AAV6 shows high transduction efficiency across various tissues, including airway epithelia [<xref rid="B54-viruses-17-00239" ref-type="bibr">54</xref>,<xref rid="B55-viruses-17-00239" ref-type="bibr">55</xref>,<xref rid="B56-viruses-17-00239" ref-type="bibr">56</xref>] and skeletal muscles [<xref rid="B57-viruses-17-00239" ref-type="bibr">57</xref>]. AAV7, AAV8, and AAV9, isolated from non-human primates and humans, exhibit strong tropisms for liver cells and skeletal and cardiac muscles, with AAV9 additionally crossing the blood&#x02013;brain barrier (BBB) and being the most favored for neurological applications [<xref rid="B58-viruses-17-00239" ref-type="bibr">58</xref>]. The newly identified AAV10 and AAV11, displaying broad tissue tropisms and distinct cellular targets, along with AAV12 and AAV13, expanding the understanding of AAVs&#x02019; cell entry mechanisms and potential therapeutic applications, showcase the evolving landscape of AAV research [<xref rid="B59-viruses-17-00239" ref-type="bibr">59</xref>]. <xref rid="viruses-17-00239-t002" ref-type="table">Table 2</xref> provides a comparative overview of AAV serotypes and their tissue specificity.</p><p>The selection of an AAV serotype for gene therapy is influenced by specific requirements, including the target tissue, the desired level of gene expression, and the duration of expression [<xref rid="B13-viruses-17-00239" ref-type="bibr">13</xref>]. In recent years, innovative engineering strategies such as the creation of mosaic, chimeric, and combinatorial vector libraries have been utilized to develop novel hybrid vectors and serotypes with the aim of enhancing the targeting specificity, efficiency, and safety in gene therapy applications [<xref rid="B30-viruses-17-00239" ref-type="bibr">30</xref>]. Techniques like cross-packaging, where the viral genome of one serotype is packaged into the capsid of another type, represent another strategy to increase the transduction efficiency and minimize immune recognition, thus expanding AAVs&#x02019; therapeutic potential [<xref rid="B60-viruses-17-00239" ref-type="bibr">60</xref>,<xref rid="B61-viruses-17-00239" ref-type="bibr">61</xref>]. More recent advancements involve the rational design of novel vectors, where site-specific modifications to the capsid improve the tissue specificity or modify antigenic sites [<xref rid="B62-viruses-17-00239" ref-type="bibr">62</xref>,<xref rid="B63-viruses-17-00239" ref-type="bibr">63</xref>,<xref rid="B64-viruses-17-00239" ref-type="bibr">64</xref>], and direct evolution, where capsid libraries are generated via an iterative selection process of selective pressure and the isolation of variants with specific desired traits [<xref rid="B65-viruses-17-00239" ref-type="bibr">65</xref>,<xref rid="B66-viruses-17-00239" ref-type="bibr">66</xref>]. This was the case for the neurotropic PHP AAV capsid family (PHP.B and PHP.eB), developed by Deverman and which evolved from the naturally occurring AAV9 serotype, with improved brain penetrance and CNS transduction abilities [<xref rid="B67-viruses-17-00239" ref-type="bibr">67</xref>].</p></sec><sec id="sec2dot3-viruses-17-00239"><title>2.3. AAV Manufacturing</title><p>The large-scale production of AAV vectors is essential for both preclinical and clinical uses, requiring substantial amounts of highly pure rAAV particles at high yields. As more gene therapies gain approval, the demand for commercial-scale production increases; yet, scaling up these processes remains a significant challenge. Larger doses are necessary to achieve the desired therapeutic effects, which in turn increases manufacturing costs. Strategies must also be employed to improve the production yield and efficacy while minimizing the presence of empty capsids. Empty AAV capsids form due to imbalances during the vector production process. Common reasons include the insufficient availability of the viral genome template, incomplete packaging, or the overproduction of capsid proteins relative to the DNA template. Notably, in the transient transfection of HEK293 cells, empty AAV capsids can account for 50&#x02013;90% of the total AAV particles generated in a cell culture [<xref rid="B68-viruses-17-00239" ref-type="bibr">68</xref>]. These empty capsids are generally considered impurities and can elicit immune responses due to an increased viral load during dosing, thereby reducing the efficacy of gene therapy treatments [<xref rid="B69-viruses-17-00239" ref-type="bibr">69</xref>]. Here, we present an overview of the main methodologies for AAV production, purification, and characterization to meet these demands (<xref rid="viruses-17-00239-f003" ref-type="fig">Figure 3</xref>).</p><sec id="sec2dot3dot1-viruses-17-00239"><title>2.3.1. Upstream Process</title><p>The plasmid-based transient transfection of adherent HEK293 cells (a human embryonic kidney cell line) grown in serum-containing media remains the most commonly used method to produce AAV vectors for preclinical research. This method involves transfecting three plasmids using co-precipitation strategies, such as using calcium phosphate, polyethylenimine (PEI), or cationic lipids [<xref rid="B70-viruses-17-00239" ref-type="bibr">70</xref>]. However, this conventional method faces scalability issues, as it would require exponentially increasing the number of culture flasks or cell factories. This makes it impractical due to space, cost, and labor constraints, and it is not compliant with current GMP (Good Manufacturing Practice) standards [<xref rid="B71-viruses-17-00239" ref-type="bibr">71</xref>]. To address these challenges, newer methods have been developed that utilize suspension HEK293 cells, which can be grown in animal component-free and antibiotic-free media in various bioreactor types, such as shaker flasks, orbitally shaken bioreactors, wave bioreactors, and stirred tank bioreactors [<xref rid="B72-viruses-17-00239" ref-type="bibr">72</xref>,<xref rid="B73-viruses-17-00239" ref-type="bibr">73</xref>,<xref rid="B74-viruses-17-00239" ref-type="bibr">74</xref>,<xref rid="B75-viruses-17-00239" ref-type="bibr">75</xref>,<xref rid="B76-viruses-17-00239" ref-type="bibr">76</xref>]. These methods have been shown to produce a high purity and yield of AAV particles, typically exceeding 10<sup>5</sup> vector genomes per cell and 10<sup>14</sup> vector genomes per liter of culture [<xref rid="B75-viruses-17-00239" ref-type="bibr">75</xref>]. Additionally, the serum-free conditions increase safety by eliminating a potential source of adventitious agents, simplify downstream purification, and reduce analytical testing requirements.</p><p>Stable cell lines derived from HeLa cells, such as packaging and producer lines, represent another approach for producing high yields of rAAV particles, comparable to those from transfection methods, while limiting the risk of plasmid DNA contamination and reducing the costs of the GMP-grade starting material [<xref rid="B77-viruses-17-00239" ref-type="bibr">77</xref>,<xref rid="B78-viruses-17-00239" ref-type="bibr">78</xref>,<xref rid="B79-viruses-17-00239" ref-type="bibr">79</xref>]. Packaging cell lines produce rAAVs following either transfection with an AAV construct and co-infection with an Ad helper virus or infection with a recombinant Ad/AAV hybrid helper virus. Producer cells, which contain both AAV <italic toggle="yes">rep</italic>/<italic toggle="yes">cap</italic> genes and the rAAV genome, require just a single infection step with an Ad helper virus for production [<xref rid="B80-viruses-17-00239" ref-type="bibr">80</xref>,<xref rid="B81-viruses-17-00239" ref-type="bibr">81</xref>]. However, their use in clinical settings is limited due to the complexity of creating and maintaining these lines, including ensuring genetic stability and removing contaminants like wild-type Ad5 from the final product [<xref rid="B80-viruses-17-00239" ref-type="bibr">80</xref>,<xref rid="B81-viruses-17-00239" ref-type="bibr">81</xref>].</p><p>Ongoing efforts are focused on optimizing the upstream processes of AAV production to improve the yield and reduce the presence of empty AAVs. For example, adjusting the ratio of plasmids used in triple transfection protocols, particularly between the packaging plasmid and the plasmid encoding the viral genome, ensures the efficient encapsulation of genetic material while also reducing backbone plasmid contamination [<xref rid="B82-viruses-17-00239" ref-type="bibr">82</xref>]. Fine-tuning process parameters, such as the pH, temperature, and ionic strength during production, can further enhance the assembly efficiency. Additionally, efforts have been made to identify small-molecule chemical additives that boost rAAV production or to create a hybrid rep gene, resulting in a 2&#x02013;4-fold increase in full capsids [<xref rid="B82-viruses-17-00239" ref-type="bibr">82</xref>].</p></sec><sec id="sec2dot3dot2-viruses-17-00239"><title>2.3.2. Downstream Process</title><p>The overall success of AAV clinical manufacturing critically relies on downstream purification steps to generate a final clinical product of a high yield, high potency, and high purity. The purification of rAAVs involves addressing several challenges, including separation from cellular and viral impurities, the removal of empty AAV capsids, and maintaining the potency and stability of the viral particles. Different methods are tailored to these needs, specific to the capsid serotypes and production scales.</p><p>A widely used method for rAAV purification in laboratory settings is standard affinity chromatography or density gradient ultracentrifugation using iodixanol or cesium chloride (CsCl). This technique is particularly effective at separating full from empty AAV particles based on their shape, size, and isopycnic point. While the initial round significantly reduces impurities, achieving higher purity may require two or three rounds. Therefore, these methods are time-consuming and not suitable for large-scale production due to challenges in implementing them in a GMP-compliant manner [<xref rid="B83-viruses-17-00239" ref-type="bibr">83</xref>,<xref rid="B84-viruses-17-00239" ref-type="bibr">84</xref>].</p><p>To overcome this limitation, other methods such as affinity or ion exchange chromatography (IEC) are widely used, due to their efficiency, versatility, and scalability. Affinity chromatography relies on specific substrate attachment, mimicking cellular receptors, while IEC utilizes electrostatic interactions between charged AAV capsids and ionized groups in the column matrix. Both methods involve elution by increasing the salt concentration. Chromatography systems offer several advantages, including achieving over 98% purity with a stable yield and purity between batches, automated processing, regenerable resins, dynamic interactions in mild conditions, and an adjustable scale [<xref rid="B71-viruses-17-00239" ref-type="bibr">71</xref>,<xref rid="B85-viruses-17-00239" ref-type="bibr">85</xref>,<xref rid="B86-viruses-17-00239" ref-type="bibr">86</xref>,<xref rid="B87-viruses-17-00239" ref-type="bibr">87</xref>]. Notably, while affinity chromatography cannot differentiate between empty and full capsids, IEC effectively removes empty capsids based on their charges, making it crucial for reducing the potential immunogenicity [<xref rid="B88-viruses-17-00239" ref-type="bibr">88</xref>,<xref rid="B89-viruses-17-00239" ref-type="bibr">89</xref>]. Challenges include suitability issues for certain serotypes, limitations in the resin lifespan, waste generation during regeneration, and potential pollution from improper storage conditions. For large-scale downstream processing, rAAVs need to be recovered from dozens of liters of the cell lysate or medium. Obtaining sufficiently pure rAAV vectors that meet clinical requirements often involves a two-step chromatography process. In the first step, capture chromatography captures rAAVs from raw materials, while the second step, separation chromatography, isolates rAAVs from the elution fraction, primarily to enhance the vector purity by eliminating the remaining contaminants. In some cases, a third or fourth chromatography step is required. Ultracentrifugation could be integrated as a final step to polish the product and eliminate any remaining empty particles after a standard chromatography process.</p><p>The purification processes often conclude with a concentration and/or buffer exchange step for the final formulation. Tangential flow filtration (TFF), based on size exclusion, is the predominant technique for this step. TFF is utilized for clarifying whole cell lysates and significantly reducing production volumes, improving virus titration, and saving time [<xref rid="B90-viruses-17-00239" ref-type="bibr">90</xref>]. A comparison of AAV purification techniques is shown in <xref rid="viruses-17-00239-t003" ref-type="table">Table 3</xref>.</p><p>Overall, the purification process should achieve high-purity vector preparations for all AAV serotypes, with greater than 90% full particles. Of note, there is great variability in the yield between different serotypes and expression cassettes both at preclinical and GMP grades. Therefore, initial small feasibility batches should be manufactured to predict the yield of the final preparation, contributing to increased production costs. In parallel, emerging technologies, such as machine learning algorithms for process optimization and real-time monitoring systems, are driving further improvements in the precision and efficiency of viral vector manufacturing, reducing the prevalence of empty capsids.</p></sec><sec id="sec2dot3dot3-viruses-17-00239"><title>2.3.3. Analytical Analysis</title><p>Characterizing the final AAV product involves assessing the viral genome titer, infectious titer (potency), purity (empty capsids, residual host cell and plasmid DNA contaminants, protein contaminants), stability (aggregation), and the identities of the AAV capsid, genome, and therapeutic gene (expression/activity). Over the past decade and a half, mass spectrometry (MS) has become indispensable for analyzing the AAV capsid integrity and post-translational modifications, as well as identifying impurities in vector preparations [<xref rid="B91-viruses-17-00239" ref-type="bibr">91</xref>]. However, the application of MS is limited by the need for large substrate volumes and specialized equipment. Differential scanning fluorimetry (DSF or AAV-ID), introduced in 2013 [<xref rid="B91-viruses-17-00239" ref-type="bibr">91</xref>] and validated in subsequent studies [<xref rid="B92-viruses-17-00239" ref-type="bibr">92</xref>,<xref rid="B93-viruses-17-00239" ref-type="bibr">93</xref>], offers cost-effective and high-throughput capabilities suitable for monitoring purification processes. It measures the AAV capsid thermostability (melting temperature, Tm) using SYPRO Orange dye and has been particularly useful in mixed samples and for ensuring batch consistency [<xref rid="B94-viruses-17-00239" ref-type="bibr">94</xref>].</p><p>While advanced MS and DSF techniques provide the precise characterization and quality control of AAV capsids, addressing contamination in AAV samples such as endotoxins and cellular proteins remains critical for producing safe and effective AAV vectors for clinical use. Endotoxins, particularly lipopolysaccharides from Gram-negative bacteria, are prevalent contaminants in AAV stocks and can induce severe immune reactions in recipients. A new protocol has effectively reduced the endotoxin levels in AAV preparations to below detectable thresholds, without affecting the vectors&#x02019; functionality or capsid integrity [<xref rid="B95-viruses-17-00239" ref-type="bibr">95</xref>]. The presence of cellular proteins in AAV preparations also poses a significant challenge. Proteomic studies have identified numerous cellular proteins that co-purify with AAV capsids, which may influence the biology and efficacy of AAV vectors. However, not all cellular impurities are harmful; some may even enhance the vector transduction [<xref rid="B96-viruses-17-00239" ref-type="bibr">96</xref>]. Thus, purification strategies should consider the potential functional benefits of certain co-purifying proteins. Additionally, other testing for the safety attributes of AAV products, such as the sterility, mycoplasma, and adventitious agents (replication-competent AAVs), must be qualified and validated. An overall testing plan should be in place to ensure that the product meets acceptable limits for identity, strength/potency, quality, and purity.</p></sec></sec><sec id="sec2dot4-viruses-17-00239"><title>2.4. Clinical Landscape of AAV Gene Therapy</title><p>The field of AAV-based gene therapy is evolving rapidly, with more than 300 clinical trials&#x02014;both completed and ongoing&#x02014;that involve using AAV drug products to treat 55 diseases conducted to date [<xref rid="B21-viruses-17-00239" ref-type="bibr">21</xref>,<xref rid="B97-viruses-17-00239" ref-type="bibr">97</xref>]. This extensive research has led to multiple approvals across the United States (US) and Europe. The first phase I clinical trial using an AAV product was conducted in the early 2000s, where the safety and efficacy of an AAV2 vector were assessed in cystic fibrosis patients [<xref rid="B98-viruses-17-00239" ref-type="bibr">98</xref>,<xref rid="B99-viruses-17-00239" ref-type="bibr">99</xref>,<xref rid="B100-viruses-17-00239" ref-type="bibr">100</xref>]. While the trials failed to meet their therapeutic endpoints and did not demonstrate a significant increase in the CFTR expression levels, they provided valuable insights into the challenges of an AAV-based therapy, such as limited efficacy due to the insufficient transduction of the target cells and hindered transgene expression due to an immune response. Nevertheless, the trials confirmed the therapy was safe, paving the way to the future use of AAV vectors as a safer and more flexible alternative to adenovirus-based therapies. The lesson learnt from the cystic fibrosis trials led the way to the approval in Europe of the first AAV gene therapy product, Glybera, for patients with lipoprotein lipase deficiency [<xref rid="B101-viruses-17-00239" ref-type="bibr">101</xref>,<xref rid="B102-viruses-17-00239" ref-type="bibr">102</xref>,<xref rid="B103-viruses-17-00239" ref-type="bibr">103</xref>]. A single-dose administration of Glybera resulted in the sustained expression of the therapeutic protein and a long-term reduction in the occurrence and severity of acute pancreatitis and hospitalization episodes. However, uniQure did not apply for a renewal of its marketing authorization, and it was discontinued five years later due to its high cost, despite its good safety profile [<xref rid="B104-viruses-17-00239" ref-type="bibr">104</xref>]. In 2017, Luxturna (voretigene neparvovec-rzyl) became the first AAV-based ocular gene therapy approved by the US FDA, designed to improve functional vision in patients with an inherited retinal disease caused by mutations in the RPE65 gene, affecting both adults and children with vision loss [<xref rid="B105-viruses-17-00239" ref-type="bibr">105</xref>]. In May 2019, the FDA approved Zolgensma (onasemnogene abeparvovec) an AAV-based gene therapy drug for the treatment of spinal muscular atrophy [<xref rid="B106-viruses-17-00239" ref-type="bibr">106</xref>]. In 2022, the European Medicines Agency (EMA) approved Upstaza (eladocagene exuparvovec), an AAV2-based gene therapy to treat aromatic L-amino acid decarboxylase (AADC) deficiency. In the same year, the FDA approved Hemgenix (etranacogene dezaparvovec-drlb) for the treatment of adults with hemophilia B (congenital factor IX deficiency). Notably, in 2023, seven gene therapies were approved by the FDA, including two AAV products: Sarepta Therapeutics&#x02019; Elevidys (delandistrogene moxeparvovec-rokl) for treating ambulatory pediatric patients with Duchenne muscular dystrophy (DMD) and BioMarin&#x02019;s Roctavian (valoctocogene roxaparvovec) for treating hemophilia A (factor VIII deficiency). In April 2024, the FDA approved Pfizer&#x02019;s BEQVEZ&#x02122; (fidanacogene elaparvovec-dzkt) as a one-time gene therapy for adults with hemophilia B. <xref rid="viruses-17-00239-t004" ref-type="table">Table 4</xref> summarizes the AAV gene therapies approved by the FDA. These approvals represent significant advances in the field of gene therapy.</p><p>The majority of clinical trials fall into five broad therapeutic areas, where promising results have been observed in patients with eye disorders, blood disorders, neurological disorders, lysosomal storage disorders, and muscular diseases. However, the market is expected to grow in the near future as new approaches and delivery methods continue to emerge. Here, we discuss recent advancements and how they have the potential to improve treatments and outcomes for patients with various diseases.</p><sec id="sec2dot4dot1-viruses-17-00239"><title>2.4.1. Eye Diseases/Disorders</title><p>Inherited eye disorders often lead to retinal degeneration, progressively harming photoreceptor cells and causing vision loss [<xref rid="B107-viruses-17-00239" ref-type="bibr">107</xref>]. A significant breakthrough in treating these conditions was the development of Luxturna for Leber congenital amaurosis caused by the RPE65 mutation, paving the way for clinical trials on various untreatable hereditary eye diseases. The long-term expression of Luxturna was evaluated in a 4-year follow-up study in phase III patients, with positive efficacy and safety results suggesting a long-term benefit. Currently, gene therapy trials focusing on the retina represent the largest segment (34%) in clinical research, with 30 trials using AAV vectors for targeted delivery. Notably, 20% of these trials are in the advanced stages (phase III or II/III), the highest proportion across all disease groups studied [<xref rid="B97-viruses-17-00239" ref-type="bibr">97</xref>]. While most trials have utilized AAV serotypes 2, 4, 5, and 8, variants like AAV.7m8 and AAV2tYF have also been explored, with no severe AAV-related complications reported [<xref rid="B108-viruses-17-00239" ref-type="bibr">108</xref>,<xref rid="B109-viruses-17-00239" ref-type="bibr">109</xref>]. Some patients have shown improvements, indicating the potential for therapeutic benefits. However, the outcomes vary, and the durability of these gene therapies remains uncertain. Since 2017, when Luxturna was approved, no new retinal therapy has been approved despite the numerous clinical trials. For some, the initial therapeutic success decreased over time [<xref rid="B108-viruses-17-00239" ref-type="bibr">108</xref>,<xref rid="B110-viruses-17-00239" ref-type="bibr">110</xref>,<xref rid="B111-viruses-17-00239" ref-type="bibr">111</xref>], possibly due to continued retinal deterioration or immune system reactions [<xref rid="B112-viruses-17-00239" ref-type="bibr">112</xref>], highlighting the complexity of achieving long-lasting treatment effects in inherited retinal diseases.</p></sec><sec id="sec2dot4dot2-viruses-17-00239"><title>2.4.2. Lysosomal Storage Disorders</title><p>Lysosomal storage disorders, rare metabolic conditions caused by deficiencies in lysosomal proteins and enzymes, lead to the accumulation of substances within various organs [<xref rid="B113-viruses-17-00239" ref-type="bibr">113</xref>,<xref rid="B114-viruses-17-00239" ref-type="bibr">114</xref>,<xref rid="B115-viruses-17-00239" ref-type="bibr">115</xref>]. These disorders have multi-organ presentations and often involve the central nervous system (CNS), leading to severe and progressive neurodegeneration that significantly impacts the prognosis. Traditional therapies, including enzyme replacement therapy, have limited efficacy in targeting CNS manifestations due to the BBB. Gene therapy offers a promising solution, particularly in developing replacement therapies for intracellular enzymes. Currently, around 40 clinical trials are registered using gene therapy in LSDs, including long-term follow-up studies. For treating CNS manifestations in LSDs, in vivo gene therapy employing AAVs has become a leading strategy [<xref rid="B116-viruses-17-00239" ref-type="bibr">116</xref>]. These can be administered directly to the brain or cerebrospinal fluid (CSF) through various methods, including intracerebral, intrathecal, intracerebroventricular, or intracisternal routes [<xref rid="B117-viruses-17-00239" ref-type="bibr">117</xref>]. AAV serotypes like AAV9 and AAVrh10, known for their CNS targeting and ability to cross the BBB, are commonly used in clinical settings [<xref rid="B117-viruses-17-00239" ref-type="bibr">117</xref>,<xref rid="B118-viruses-17-00239" ref-type="bibr">118</xref>,<xref rid="B119-viruses-17-00239" ref-type="bibr">119</xref>]. Since lysosomal disorders present with a series of neuro-metabolic pathologies, using a systemic administration approach using AAV9 could be beneficial to treat both the visceral organs and the CNS with one single dosing. Innovative AAV serotypes engineered for an enhanced CNS tropism after intravenous administration are also being explored [<xref rid="B33-viruses-17-00239" ref-type="bibr">33</xref>].</p></sec><sec id="sec2dot4dot3-viruses-17-00239"><title>2.4.3. Neurological Disorders</title><p>The first FDA-approved AAV gene therapy for a neurological disorder was Zolgensma, an AAV9-based gene therapy for type I spinal muscular atrophy (SMA), administered to pediatric patients via a single intravenous dose [<xref rid="B120-viruses-17-00239" ref-type="bibr">120</xref>,<xref rid="B121-viruses-17-00239" ref-type="bibr">121</xref>]. In its clinical trial, all of the first 15 treated patients remained event-free at 20 months of age, a significant improvement compared to the 8% survival rate observed in a historical cohort [<xref rid="B121-viruses-17-00239" ref-type="bibr">121</xref>]. Two deaths were reported during the phase III studies; however, the respiratory complications were not deemed to be related to the therapeutic intervention [<xref rid="B122-viruses-17-00239" ref-type="bibr">122</xref>]. The postmortem analysis of the patients allowed researchers to demonstrate, for the first time, the widespread biodistribution of the AAV9 vector throughout the CNS and peripheral organs following systemic delivery in humans. This success has spurred interest in applying gene therapy to other genetic neurological diseases, with multiple ongoing clinical trials exploring this approach. For monogenic recessive diseases, the target for gene therapy is the mutated gene itself. However, for complex diseases like Parkinson&#x02019;s and Alzheimer&#x02019;s, the focus may be on a protein that could enhance neurological functions or the primary genetic cause [<xref rid="B21-viruses-17-00239" ref-type="bibr">21</xref>]. AAV9 is currently the preferred vector for broad CNS transduction, although studies have also utilized capsids such as AAV2, AAV6, AAV9, AAVrh10, and AAVhu [<xref rid="B123-viruses-17-00239" ref-type="bibr">123</xref>,<xref rid="B124-viruses-17-00239" ref-type="bibr">124</xref>]. For targeting specific brain regions, such as in Parkinson&#x02019;s disease, AAV2 is often chosen due to its well-documented spread and tropism, as well as its relatively limited spread beyond the injection site [<xref rid="B125-viruses-17-00239" ref-type="bibr">125</xref>]. The route of administration is crucial for the biodistribution of gene expression, with several methods being explored in ongoing trials to optimize delivery and therapeutic outcomes. These include intravenous administration that circulates the gene therapy body-wide, intraparenchymal administration (IPa) that targets specific brain areas, and intracerebrospinal fluid (intra-CSF) routes that deliver the AAVs within the CNS [<xref rid="B21-viruses-17-00239" ref-type="bibr">21</xref>].</p></sec><sec id="sec2dot4dot4-viruses-17-00239"><title>2.4.4. Blood Disorders</title><p>Blood disorders, particularly hemophilia A and B, are characterized by deficiencies in coagulation factors VIII (FVIII) and IX (FIX), respectively [<xref rid="B126-viruses-17-00239" ref-type="bibr">126</xref>]. These deficiencies impair blood clotting, leading to severe bleeding episodes. AAV gene therapy represents a promising approach for treating these disorders. It involves a single-dose, intravenous administration aimed at the long-term continuous endogenous synthesis and secretion of the missing coagulation factor to reduce bleeding risks. This approach uses recombinant AAV vectors targeting hepatocytes that deliver FVIII or FIX variant transgenes with liver-specific promoters [<xref rid="B127-viruses-17-00239" ref-type="bibr">127</xref>].</p><p>Hemophilia A is the subject of the most clinical trials, particularly those in late-phase development, indicating a higher likelihood of commercialization. In 2023, the FDA approved Roctavian, a leading gene therapy for adults with severe hemophilia A who do not have pre-existing antibodies against AAV serotype 5. In November 2022, the FDA approved Hemgenix for patients with hemophilia B (congenital factor IX deficiency), followed by its approval of Bevqez in April 2024 for the treatment of adults with moderate to severe hemophilia B, marking Pfizer&#x02019;s first regulatory approval for this type of gene therapy. Various phase I/II clinical trials in the US and Europe have tested AAV vectors (AAV2, AAV5, AAV6, AAV8, the mutant AAV Spark100, and AAV-LK03) in patients with hemophilia A and B at different doses. These trials have demonstrated increases in the clotting factor activity ranging from 5% to 400%. However, some patients experienced elevated liver enzymes 6&#x02013;10 weeks post-administration, indicating potential liver-related side effects [<xref rid="B43-viruses-17-00239" ref-type="bibr">43</xref>,<xref rid="B128-viruses-17-00239" ref-type="bibr">128</xref>,<xref rid="B129-viruses-17-00239" ref-type="bibr">129</xref>,<xref rid="B130-viruses-17-00239" ref-type="bibr">130</xref>,<xref rid="B131-viruses-17-00239" ref-type="bibr">131</xref>]. The use of a modified FVIII has led to a more efficacious therapy, with a decreased dose requirement, increased durability due to the more stable expression of the factor, and reduced intracellular stress.</p></sec><sec id="sec2dot4dot5-viruses-17-00239"><title>2.4.5. Muscular Diseases</title><p>Duchenne muscular dystrophy (DMD) results from the lack of dystrophin, a crucial protein for maintaining the integrity of muscle cells. The absence of dystrophin leads to progressive muscle weakness and deterioration. The FDA&#x02019;s approval of Elevidys marked the first gene therapy for treating pediatric patients aged 4 to 5 with DMD, representing a significant advancement in DMD treatment, which previously had limited options focused primarily on symptom management. Elevidys works by delivering an AAV rh74 vector that produces a modified version of the dystrophin protein, which is absent in individuals with DMD. Administered via a single intravenous dose, Elevidys has shown an increased expression of micro-dystrophin in treated patients, thereby helping to maintain the muscle cell integrity.</p><p>Other clinical studies are ongoing with various AAV serotypes (AAV1, AAV8, AAV9) and transgenes (encoding mini-dystrophin, micro-dystrophin, follistatin, and &#x003b2;-1,4-N-acetylgalactosaminyltransferase 2) to treat Duchenne muscular dystrophy and with the MTM1 transgene to treat patients with X-linked myotubular myopathy [<xref rid="B132-viruses-17-00239" ref-type="bibr">132</xref>,<xref rid="B133-viruses-17-00239" ref-type="bibr">133</xref>].</p></sec></sec><sec id="sec2dot5-viruses-17-00239"><title>2.5. Advancements in Gene Therapy for Aging</title><p>Aging is a natural and complex process marked by a progressive decline in physiological functions, making it a principal risk factor for many diseases, including neurodegenerative disorders, cardiovascular and metabolic diseases, and cancers. It is characterized by the chronic dysregulation of cellular processes, leading to dysfunction at the cellular, tissue, and organ levels [<xref rid="B134-viruses-17-00239" ref-type="bibr">134</xref>]. Key aspects of aging involve primary hallmarks such as genomic instability, telomere attrition, and the loss of proteostasis, alongside antagonistic hallmarks such as mitochondrial dysfunction and cellular senescence, culminating in stem cell exhaustion and impaired intercellular communication [<xref rid="B134-viruses-17-00239" ref-type="bibr">134</xref>]. While aging itself cannot be prevented, interventions aimed at optimizing cellular functions offer a pathway to enhance both the lifespan and health span. Despite the rapid advancements in clinical trials for AAV treatments for rare diseases, gene therapy approaches for treating complex aging or age-related diseases are still in their preclinical stages. Here, we review the current advancements in anti-aging AAV-based gene therapies that target age-related genes, age-associated diseases, and the emerging field of partial reprogramming (<xref rid="viruses-17-00239-f004" ref-type="fig">Figure 4</xref>). These approaches hold significant potential not only to improve the individual quality of life but also to reduce the socioeconomic burdens associated with aging.</p><sec id="sec2dot5dot1-viruses-17-00239"><title>2.5.1. Aging-Related Genes</title><p><italic toggle="yes">TERT</italic>: Research into telomere dysfunction, which is linked to aging through the process of telomere shortening with each cell division, has prompted the exploration of the telomerase reverse transcriptase (<italic toggle="yes">TERT</italic>) gene&#x02014;a vital component of telomerase&#x02014;as a potential therapeutic target [<xref rid="B135-viruses-17-00239" ref-type="bibr">135</xref>]. Several studies have indicated that <italic toggle="yes">TERT</italic> gene therapy is a promising strategy to delay aging and increase longevity without elevating the risk of cancer. Initially, Bernardes de Jesus et al. demonstrated that delivering an AAV&#x02013;mouse <italic toggle="yes">TERT</italic> into mice aged 12 and 24 months resulted in significant enhancements in aging-associated molecular biomarkers (such as cyclin D1 and &#x003b2;-catenin), the reactivation of telomerase activity, and an increased median lifespan compared to a control group with inactive <italic toggle="yes">TERT</italic> [<xref rid="B136-viruses-17-00239" ref-type="bibr">136</xref>]. Subsequently, B&#x000e4;r et al. created an AAV9 vector to express <italic toggle="yes">TERT</italic>, targeting heart failure post-myocardial infarction. This intervention led to reduced cardiac damage, lower mortality rates, and improved health indicators in treated mice [<xref rid="B137-viruses-17-00239" ref-type="bibr">137</xref>]. Further research showed that high doses of this AAV9-<italic toggle="yes">TERT</italic> vector effectively treated aplastic anemia in mice with short telomeres, enhancing bone marrow function, the telomere length, and survival rates [<xref rid="B138-viruses-17-00239" ref-type="bibr">138</xref>]. Povedano et al. then applied this therapy in a mouse model of pulmonary fibrosis induced by low-dose bleomycin [<xref rid="B139-viruses-17-00239" ref-type="bibr">139</xref>], and Whittemore et al. addressed neurodegeneration related to short telomeres, with both studies observing significant improvements [<xref rid="B140-viruses-17-00239" ref-type="bibr">140</xref>]. Transitioning from preclinical research to clinical application, researchers have launched human trials using an AAV-<italic toggle="yes">hTERT</italic> vector, LGT, targeting aging (NCT04133649), Alzheimer&#x02019;s disease (NCT04133454), and critical limb ischemia (NCT04110964) through three separate phase I trials initiated in 2019 [<xref rid="B2-viruses-17-00239" ref-type="bibr">2</xref>]. These clinical trials, utilizing AAV vectors to deliver <italic toggle="yes">TERT</italic> gene therapy, are focused on combating aging and its related diseases, representing a crucial step in translating this research into human health benefits.</p><p><italic toggle="yes">Klotho (KL)</italic>, a molecule with anti-aging properties, has shown promise in its potential to slow down and possibly reverse the effects of aging [<xref rid="B141-viruses-17-00239" ref-type="bibr">141</xref>,<xref rid="B142-viruses-17-00239" ref-type="bibr">142</xref>]. <italic toggle="yes">KL</italic> plays a critical role in pathways linked to chronic age-related conditions, including kidney disease, tissue degeneration, and neurodegenerative diseases [<xref rid="B143-viruses-17-00239" ref-type="bibr">143</xref>,<xref rid="B144-viruses-17-00239" ref-type="bibr">144</xref>]. Preclinical studies have demonstrated <italic toggle="yes">KL</italic>&#x02019;s substantial promise in tackling a broad spectrum of aging-associated diseases. For instance, a systemic increase in the secreted &#x003b1;-klotho hormone has shown an improvement in the synaptic plasticity and cognitive function in mice [<xref rid="B145-viruses-17-00239" ref-type="bibr">145</xref>]. While <italic toggle="yes">KL</italic> is mainly known for its involvement in cognitive functions in aging, this factor is implicated in a series of other cellular processes, including insulin regulation and cell growth in cancer [<xref rid="B145-viruses-17-00239" ref-type="bibr">145</xref>]. Generally, the <italic toggle="yes">KL</italic> promoter is hypermethylated in tumor tissues, with a consequent decrease in the <italic toggle="yes">KL</italic> expression [<xref rid="B146-viruses-17-00239" ref-type="bibr">146</xref>]. <italic toggle="yes">KL</italic> has been linked to the inhibition of insulin and insulin-like growth factor 1 (IGF-1) pathways, which regulate cell proliferation and breast cancer tumorigenesis [<xref rid="B147-viruses-17-00239" ref-type="bibr">147</xref>]. <italic toggle="yes">KL</italic> is mainly expressed in the renal tubules and the brain; however, it is also found in sex hormone-responsive organs, such as the placenta and ovaries. Low <italic toggle="yes">KL</italic> expression is reported in ductal carcinoma and other invasive forms of breast cancer. The normalization of <italic toggle="yes">KL</italic> expression in breast cancer cells reduces tumor growth, activates tumor suppressor elements, and upregulates the fibroblast growth factor (FGF) signaling pathway, reducing the overall clonogenic proliferation. <italic toggle="yes">KL</italic> also acts as a Wnt antagonist [<xref rid="B148-viruses-17-00239" ref-type="bibr">148</xref>], contributing to the reduction in stem cell depletion during aging, and binds to the FGF23 receptor, involved in phosphate homeostasis in the kidney [<xref rid="B149-viruses-17-00239" ref-type="bibr">149</xref>]. In progressive chronic kidney disease, increased levels of circulating FGF23 and low <italic toggle="yes">KL</italic> expression in the kidney lead to severe cardiovascular manifestations, including heart failure and ultimately death. Increased levels of KL have been shown to mitigate cardiovascular complications [<xref rid="B150-viruses-17-00239" ref-type="bibr">150</xref>]. <italic toggle="yes">KL</italic>&#x02019;s antineoplastic effects in breast, lung, cervical, and thyroid cancer [<xref rid="B151-viruses-17-00239" ref-type="bibr">151</xref>] also suggest it could be a valuable therapeutic target with potential applications in gene therapy to improve longevity while treating multiple age-associated disorders and malignancies [<xref rid="B152-viruses-17-00239" ref-type="bibr">152</xref>]. Since <italic toggle="yes">KL</italic> does not cross the BBB, the systemic delivery of gene therapy vectors to increase KL levels is a promising approach for these conditions.</p><p>One gene therapy strategy involves using an AAV-FGF21 vector to enhance the interaction between the fibroblastic growth factor FGF21 and its coreceptor &#x003b2;-klotho, thereby activating the ERK1/2 and MAPK signaling pathways to address metabolic diseases [<xref rid="B153-viruses-17-00239" ref-type="bibr">153</xref>,<xref rid="B154-viruses-17-00239" ref-type="bibr">154</xref>]. Another approach utilizes AAV9 vectors for the intraventricular delivery of klotho isoforms into senescence-accelerated mouse prone 8 (SAMP8) models. Overall, AAV9-mediated <italic toggle="yes">KL</italic> expression has shown promising anti-aging effects, improving both molecular and physiological aspects of aging in SAMP8 mice [<xref rid="B155-viruses-17-00239" ref-type="bibr">155</xref>].</p><p>While gene therapy is a promising tool to deliver <italic toggle="yes">KL</italic>-based treatment, sustained expression levels are needed for a therapeutic benefit in patients with renal and cardiovascular dysfunctions where gene expression is downregulated and <italic toggle="yes">KL</italic> production is impaired [<xref rid="B156-viruses-17-00239" ref-type="bibr">156</xref>]. However, since <italic toggle="yes">KL</italic> expression is generally low in most tissues, off-target overexpression must be carefully evaluated to ensure its safety. While currently there is no indication suggesting that maintaining physiological or supraphysiological levels of <italic toggle="yes">KL</italic> is linked to adverse side effects, high <italic toggle="yes">KL</italic> levels can lead to hypotension, hypophosphatemia, and insulin resistance [<xref rid="B146-viruses-17-00239" ref-type="bibr">146</xref>]. Therefore, the effect of prolonged and widespread <italic toggle="yes">KL</italic> expression should be evaluated, together with a possible interaction with standard cancer treatment regimes.</p><p><italic toggle="yes">APOE</italic>: The <italic toggle="yes">APOE</italic> gene is closely linked to human longevity and plays a crucial role in lipid metabolism, with significant variations affecting the lifespan and Alzheimer&#x02019;s disease (AD) risk [<xref rid="B157-viruses-17-00239" ref-type="bibr">157</xref>]. There are three predominant <italic toggle="yes">APOE</italic> alleles in humans, which confer different levels of risk for developing AD and related dementias. The <italic toggle="yes">APOE4</italic> allele is associated with reduced longevity and a higher risk of sporadic and late-onset AD, with a 15-fold increased risk in homozygotes, while <italic toggle="yes">APOE2</italic> reduces the AD risk by almost half and tends to be protective against these conditions [<xref rid="B158-viruses-17-00239" ref-type="bibr">158</xref>]. Research efforts include modifying the <italic toggle="yes">APOE</italic> expression and function in mouse models, with some studies attempting to switch the <italic toggle="yes">APOE</italic> alleles through gene therapy for therapeutic benefits. A pivotal clinical trial (NCT03634007) has experimented with using AAV vectors to convert <italic toggle="yes">APOE4</italic> to <italic toggle="yes">APOE2</italic>, aiming to mitigate AD&#x02019;s impact [<xref rid="B2-viruses-17-00239" ref-type="bibr">2</xref>]. Ongoing studies focus on unraveling <italic toggle="yes">APOE</italic>&#x02019;s mechanisms and its broader therapeutic potential [<xref rid="B159-viruses-17-00239" ref-type="bibr">159</xref>].</p><p><italic toggle="yes">VEGF</italic>: Vascular endothelial growth factor (<italic toggle="yes">VEGF</italic>) is crucial for maintaining blood vessel networks, whose aging can significantly affect the health of the entire organism [<xref rid="B160-viruses-17-00239" ref-type="bibr">160</xref>]. A study by Grunewald et al. suggested that enhancing <italic toggle="yes">VEGF</italic> signaling in mice, achieved through genetic modification or AAV-<italic toggle="yes">VEGF</italic> delivery, mitigated the effects of aging on blood vessels, improving tissue oxygenation and the blood flow and addressing signs of aging such as mitochondrial dysfunction and inflammation. This approach not only extended the lifespan of mice but also improved their health span by reducing symptoms of aging like fat accumulation, liver dysfunction, muscle and bone loss, and the incidence of spontaneous tumors, thereby offering a broad protective strategy against age-related deterioration [<xref rid="B161-viruses-17-00239" ref-type="bibr">161</xref>]. While preclinical studies have shown that the overexpression of <italic toggle="yes">VEGF</italic> in the heart might cause an inflammatory response in larger animal models [<xref rid="B162-viruses-17-00239" ref-type="bibr">162</xref>], further research into the optimal vector, dose, and route of administration is needed.</p></sec><sec id="sec2dot5dot2-viruses-17-00239"><title>2.5.2. Age-Related Diseases</title><p>Sarcopenia, a condition characterized by the progressive loss of skeletal muscle mass and strength during aging, poses significant health risks for the elderly, leading to increased falls, fractures, and consequent mortality [<xref rid="B163-viruses-17-00239" ref-type="bibr">163</xref>,<xref rid="B164-viruses-17-00239" ref-type="bibr">164</xref>]. Its onset typically begins after the age of 40, escalating significantly beyond the age of 70 and affecting up to half of those over 80 [<xref rid="B165-viruses-17-00239" ref-type="bibr">165</xref>,<xref rid="B166-viruses-17-00239" ref-type="bibr">166</xref>]. While traditional approaches to prevent or manage this condition focus on exercise and nutrition, limitations due to diet, malabsorption, or mobility issues necessitate innovative solutions [<xref rid="B167-viruses-17-00239" ref-type="bibr">167</xref>]. Advances in gene therapy offer promising avenues for mimicking the muscle-preserving effects of exercise, targeting the molecular underpinnings of muscle atrophy. Guo et al. introduced a novel approach to treat sarcopenia by engineering a nuclear-targeted form of PGC-1&#x003b1;4 (<italic toggle="yes">NLS-PGC1&#x003b1;4</italic>) and delivering it into mouse muscles using an AAV vector. This intervention led to an increased muscle size and strength and improved metabolic health markers [<xref rid="B168-viruses-17-00239" ref-type="bibr">168</xref>]. In another study, Ozes et al. demonstrated the efficacy of neurotrophin 3 (<italic toggle="yes">NT-3</italic>) gene therapy in addressing sarcopenia and associated aging effects. By employing a muscle-specific creatine kinase promoter and a self-complementary AAV (scAAV1) for <italic toggle="yes">NT-3</italic> delivery, the therapy resulted in aged C57BL/6J mice showing an enhanced muscle fiber diameter. This was shown alongside improvements in the neuromuscular junction connectivity and anti-inflammatory, antioxidant, and antiapoptotic effects, as well as increased mitochondrial biogenesis [<xref rid="B169-viruses-17-00239" ref-type="bibr">169</xref>]. Overall, these approaches, leveraging AAVs for precise delivery, offer a promising therapeutic strategy against sarcopenia, showcasing the potential to restore muscle function and systemic energy metabolism in the elderly.</p><p>Multiple diseases: Traditional approaches to disease treatment often target single diseases, which overlooks the interconnected nature of age-related conditions, leading to inefficient treatments with the potential for compounded side effects. A study by Davidsohn et al. explored the development of gene therapies aimed at simultaneously treating multiple age-related diseases to improve the health span and longevity. By using three liver-targeted AAV8-based gene therapies targeting longevity-associated genes (fibroblast growth factor 21, FGF21; &#x003b1;-klotho; and the soluble form of mouse transforming growth factor-&#x003b2; receptor 2, sTGF&#x003b2;R2), this research aimed to tackle the combined pathologies of four age-related diseases, obesity, type II diabetes, heart failure, and renal failure, with a single treatment strategy. The study found that individual and combined applications of these gene therapies could effectively treat and, in some cases, reverse these conditions in mouse models. For instance, a notable outcome was a 58% increase in heart function in models of heart failure and a complete reversal of obesity and diabetes phenotypes in models fed a high-fat diet. Furthermore, a single formulation combining two separate therapies (AAV:sTGF&#x003b2;R2 and AAV:FGF21) was capable of addressing all four diseases simultaneously, showcasing the potential of combination gene therapy to effectively improve the health span. This research is therefore paving the way for future treatments that could enhance both longevity and the quality of life [<xref rid="B170-viruses-17-00239" ref-type="bibr">170</xref>].</p></sec><sec id="sec2dot5dot3-viruses-17-00239"><title>2.5.3. Partial Reprogramming</title><p>Partial reprogramming is an emerging approach aimed at rejuvenating cells, tissues, or even whole organisms, potentially reversing aspects of aging and improving health and longevity. Multiple studies have shown that the transient expression of the Yamanaka factors Oct3/4, Sox2, KLF4, and c-Myc (OSKM) can mitigate age-related symptoms and revert aged cells to a more youthful state without losing their full epigenetic identity, thus avoiding the completion of the full reprogramming cycle [<xref rid="B171-viruses-17-00239" ref-type="bibr">171</xref>,<xref rid="B172-viruses-17-00239" ref-type="bibr">172</xref>,<xref rid="B173-viruses-17-00239" ref-type="bibr">173</xref>,<xref rid="B174-viruses-17-00239" ref-type="bibr">174</xref>,<xref rid="B175-viruses-17-00239" ref-type="bibr">175</xref>,<xref rid="B176-viruses-17-00239" ref-type="bibr">176</xref>,<xref rid="B177-viruses-17-00239" ref-type="bibr">177</xref>]. However, the expression of c-Myc may increase the risk of developing teratomas [<xref rid="B178-viruses-17-00239" ref-type="bibr">178</xref>,<xref rid="B179-viruses-17-00239" ref-type="bibr">179</xref>,<xref rid="B180-viruses-17-00239" ref-type="bibr">180</xref>,<xref rid="B181-viruses-17-00239" ref-type="bibr">181</xref>]. Therefore, recent efforts focusing on the delivery of only three reprogramming factors (OSK, without c-Myc) have substantially increased the safety and efficacy of partial reprogramming while reversing signs of aging and degeneration in CNS tissues, specifically in the context of glaucoma and other age-associated conditions. For example, Lu et al. demonstrated that the ectopic expression of an AAV2-tTA and TRE-OSK-inducible system in mouse retinal ganglion cells not only restored youthful DNA methylation patterns and transcriptomes but also promoted axon regeneration after injury and reversed vision loss in models of glaucoma and in aged mice [<xref rid="B174-viruses-17-00239" ref-type="bibr">174</xref>]. In a follow-up year-long study, Karg et al. showed that continuous or cyclic AAV-OSK expression resulted in a remarkable restoration of vision, with effects lasting 11 months post-treatment. This study emphasized the therapeutic potential of OSK-based rejuvenation for glaucoma, underscoring its efficacy and safety even with prolonged expression (up to 21 months) [<xref rid="B182-viruses-17-00239" ref-type="bibr">182</xref>]. Recently, Macip et al. further demonstrated that the systemic expression of AAV9 encoding an inducible OSK system not only extended the median remaining lifespan of 124-week-old male mice by 109% over wild-type controls but also significantly improved health parameters and frailty scores, indicating an enhancement in both the lifespan and health span [<xref rid="B183-viruses-17-00239" ref-type="bibr">183</xref>]. Overall, the safety and efficacy demonstrated in these interventions, particularly with prolonged treatment durations, highlight the therapeutic potential of epigenetic rejuvenation AAV-based therapies not only in extending the lifespan but also in improving the health span and quality of life in aged populations.</p></sec></sec><sec id="sec2dot6-viruses-17-00239"><title>2.6. Challenges in AAV Gene Therapy</title><p>Despite considerable progress in the field of AAV gene therapy, several persistent challenges hinder its transition from preclinical models to effective clinical applications. These challenges are primarily rooted in the unique biological properties and interaction dynamics of AAV vectors with the human immune system, as well as technical limitations in vector design and delivery, discrepancies between animal models and human clinical outcomes, and the need for high vector doses.</p><list list-type="simple"><list-item><label>(i)</label><p>Vector delivery limitations: One of the foremost challenges is the limited gene packaging capacity of AAV vectors (approximately 4.7 kb), which restricts the size of the therapeutic genes they can carry and thus limits their use in treating diseases caused by larger genes. To overcome this limitation, strategies such as engineering &#x02018;mini gene&#x02019; constructs or using dual or triple AAV vectors have been developed. These involve splitting large genes into smaller segments that can be delivered by multiple AAV vectors [<xref rid="B184-viruses-17-00239" ref-type="bibr">184</xref>]. Several studies in animal models have confirmed the effectiveness of the split strategy in delivering larger genes into host cells through the use of dual or triple AAV vectors [<xref rid="B185-viruses-17-00239" ref-type="bibr">185</xref>,<xref rid="B186-viruses-17-00239" ref-type="bibr">186</xref>,<xref rid="B187-viruses-17-00239" ref-type="bibr">187</xref>,<xref rid="B188-viruses-17-00239" ref-type="bibr">188</xref>]. Nevertheless, this approach raises challenges in manufacturing, obtaining regulatory approval, and ensuring consistent therapeutic efficacy. Additionally, potential immune responses due to the higher capsid protein burden and the high cost of development and deployment also pose significant challenges. Another limitation of AAV delivery is the possibility of off-target transduction, where vectors infect cells other than their intended targets, which can lead to unintended effects and reduce the efficiency and durability of gene therapy [<xref rid="B97-viruses-17-00239" ref-type="bibr">97</xref>]. Moving forward, exploring new and more tissue-specific and endogenous promoters is desirable to achieve high and sustained transgene levels in humans.</p></list-item><list-item><label>(ii)</label><p>Immunogenicity: A critical barrier, often unaddressed until the clinical stages, is the immune response elicited by both the AAV capsid and the transgene product. While AAV vectors are not considered a strong elicitor of an innate or adaptive immune response, preclinical and clinical findings have demonstrated that capsids, genomes, and gene products can elicit a response. Humoral and cell-mediated responses can occur following AAV dosing, particularly when the therapy is administered systemically and at high doses. The immune response includes pre-existing antibodies to AAV capsids, limiting the transduction and efficacy. A large segment of the population has pre-existing adaptive immunity against wild-type AAVs, including neutralizing antibodies (NAbs) and T cells that can lead to the loss of transgene expression or the elimination of transduced cells [<xref rid="B189-viruses-17-00239" ref-type="bibr">189</xref>,<xref rid="B190-viruses-17-00239" ref-type="bibr">190</xref>]. In addition, cellular stress from high levels of transgene expression can initiate the apoptotic signaling cascade, leading to cell death. In particular, for conditions like hemophilia, up to 40% of adult patients may be ineligible for liver-directed AAV trials due to pre-existing NAbs and memory T cells directed against the AAV capsid proteins [<xref rid="B191-viruses-17-00239" ref-type="bibr">191</xref>]. Even if NAbs are initially absent, they can develop rapidly after exposure to the vectors, hindering repeated administration and the overall treatment efficacy. This pre-existing immunity not only reduces the clinical efficacy but also prevents the possibility of re-administration and significantly limits the patient eligibility for clinical trials among a large proportion of the general population [<xref rid="B11-viruses-17-00239" ref-type="bibr">11</xref>,<xref rid="B192-viruses-17-00239" ref-type="bibr">192</xref>,<xref rid="B193-viruses-17-00239" ref-type="bibr">193</xref>,<xref rid="B194-viruses-17-00239" ref-type="bibr">194</xref>]. This poses an obvious question on the need for repeated dosing to achieve a therapeutic benefit in the long term, particularly in childhood patients, where the benefit of the therapy could diminish over time due to a reduction in gene expression. To address these challenges, novel strategies are being developed: the sequential administration of different capsids with low cross-reactivity, engineering mutations into the AAV capsid that can prevent NAbs from binding, the conjugation of AAV particles with biological extracellular vesicles [<xref rid="B195-viruses-17-00239" ref-type="bibr">195</xref>], and evolving AAV libraries in an in vitro environment full of Nabs, which can create neutralization-resistant vectors [<xref rid="B196-viruses-17-00239" ref-type="bibr">196</xref>,<xref rid="B197-viruses-17-00239" ref-type="bibr">197</xref>]. Additional techniques, such as pharmacological treatments to degrade circulating IgG, plasmapheresis, and B cell depletion or reduced activation via the administration of rapamycin have shown promise in reducing anti-AAV immune responses [<xref rid="B198-viruses-17-00239" ref-type="bibr">198</xref>,<xref rid="B199-viruses-17-00239" ref-type="bibr">199</xref>,<xref rid="B200-viruses-17-00239" ref-type="bibr">200</xref>,<xref rid="B201-viruses-17-00239" ref-type="bibr">201</xref>]. These approaches offer different prospects and challenges and are in various stages of development requiring extensive preclinical testing and validation before they can be widely implemented in clinical settings. In addition, localized administration to immune-privileged organs such as the eye or the brain could be a valid mitigation strategy for clinical application. The route of administration influences the risk of immunogenicity and the therapeutic efficacy of the treatment, as different organs and tissues present a different immune environment and number of antigen-presenting cells. Since an immune response can arise at any stage of development and treatment, comprehensive risk assessments are needed to evaluate and identify possible risk factors throughout the clinical studies, either related to the product itself (CpG content, serotype, tropism), the manufacturing process (impurities, biosynthetic intermediates), or the patient (pre-existing antibodies, treatment eligibility and regime). Finally, empty capsids can increase the exposure of patients to the AAV load, contributing to a potential immune response and, therefore, hindering the clinical outcome. For example, empty AAV8 capsids can trigger strong B and T cell responses in humans and inhibit the transduction of hepatocytes in mice [<xref rid="B202-viruses-17-00239" ref-type="bibr">202</xref>]. Therefore, a low empty capsid content will increase the ratio of therapeutic DNA per mass of the capsid protein, improving the safety profile of the treatment. The safety risk assessment of gene therapies also includes the analysis of the integrity of the genetic material, including the insertional mutagenesis risk, risk of germline transmission, and possible off-target effects in genome editing studies.</p></list-item><list-item><label>(iii)</label><p>Translational hurdles: Significant challenges in translating AAV gene therapy stem from discrepancies between animal models and human clinical outcomes. Animal studies often fail to predict human immune responses accurately, leading to unforeseen adverse effects in clinical settings. This issue is compounded by species-specific differences in the vector tropism, which can alter the efficiency of gene transfer between preclinical and clinical settings [<xref rid="B203-viruses-17-00239" ref-type="bibr">203</xref>]. These differences in the vector tropism are partly due to the varied expression of cellular receptors. In addition, differences in how the virus is processed within cells post-entry, such as nuclear translocation and the conversion of the genome from single-stranded to double-stranded, also play a significant role. These complexities raise critical questions about the accuracy of animal models in predicting human outcomes and underscore the need for targeted human-based studies to ensure successful clinical translations. Biodistribution and vector processing studies are usually conducted in the preclinical setting, with only limited data in humans, while a more comprehensive understanding of viral shedding is available from clinical trials. Biodistribution studies are required to evaluate the relationship between efficacy and safety outcomes and the exposure of target and non-target tissues to the product. While stand-alone biodistribution data are not always required for early product development, preclinical shedding data are requested before starting the first in-human dosing. A summary of the global guideline documents on biodistribution and shedding is presented in <xref rid="viruses-17-00239-t005" ref-type="table">Table 5</xref>.</p></list-item></list><p>Based on the FDA guidance, the minimum panel of tissue collection in a preclinical GLP-compliant biodistribution study should include the liver, spleen, kidney, lung, heart, brain, gonads, blood, and possibly the injection site. Additional organs might be required for specific routes of administration, e.g., the spinal cord for CSF delivery. An analysis of the kinetics of vector distribution, gene expression, and any clinical pathology can determine whether the treatment correlates with any adverse finding. The vector copy number and transgene expression are the main readouts for biodistribution and toxicology studies. When the native protein product cannot be distinguished from the vector-encoded product, the characterization of mRNA expression is used to identify efficacy endpoints.</p><list list-type="simple"><list-item><label>(iv)</label><p>Dosing regimen: The high vector doses necessary for effective treatment, particularly for multi-systemic indications, have been associated with severe immune reactions such as hepatotoxicity, complement activation, and even acute kidney injury in some cases. A T cell-mediated immune response to high levels of capsid antigens has emerged as the most common adverse effect [<xref rid="B4-viruses-17-00239" ref-type="bibr">4</xref>]. Severe adverse events have been reported in various clinical trials involving high AAV vector doses (6.7 &#x000d7; 10<sup>13</sup>&#x02013;3 &#x000d7; 10<sup>14</sup> vg/kg body weight) administered to neonates and children. These include complement activation and acute kidney injury in the Duchenne muscular dystrophy trial, elevated serum transaminase levels in the SMA1 Novartis trial, and a fatal case in the ASPIRO trial [<xref rid="B97-viruses-17-00239" ref-type="bibr">97</xref>,<xref rid="B204-viruses-17-00239" ref-type="bibr">204</xref>]. To mitigate such risks, future research should prioritize developing optimal dosing regimens that balance toxicity and efficacy, particularly through studies in non-human primates. Dose selection can be particularly complex, as it is based on both efficacy and safety, and the pharmacokinetic/pharmacodynamic properties of AAVs are heavily affected by their biological fate after administration. The No-Adverse Event Level (NOAEL) dose is determined in preclinical studies and is usually used as the upper limit of the dose range when scaling from animals to humans. However, due to the physiological differences between species, animal models might not fully recapitulate the effects in humans. Therefore, the maximum tolerated dose should be based not only on the preclinical NOAEL but also on historical clinical data from trials using the same capsid and route of administration. A positive risk/benefit assessment is essential, particularly if the target population is largely pediatric and if the route of administration requires invasive surgical procedures. The pharmacologically active dose at multiple endpoints should be carefully calculated prior to the first in-human dosing.</p></list-item></list><p>A general dose scaling equation can be used to estimate the translation from animals to humans:<disp-formula>dose<sub>H</sub> = dose<sub>A</sub> &#x000d7; transduction factor &#x000d7; (metric<sub>H</sub>/metric<sub>A</sub>)</disp-formula>
with the metrics including either the body weight for intravenously administered AAVs or the organ mass or volume for localized administration.</p><p>For Zolgensma, the dose scaling was based on the efficacy studies in the SMA mouse model, using the total body weight as a morphological factor, with a transduction factor of one (US FDA 2019 ZOLGESNMA highlights the prescribing information).</p><list list-type="simple"><list-item><label>(v)</label><p>Safety concerns and biomarker assessment: Preclinical safety profiles and clinical pharmacology data indicate that AAV gene therapy is efficacious overall and well tolerated. However, in recent years an association between AAV gene therapy and specific safety findings, particularly hepatotoxicity and thrombotic microangiopathy, has been reported, with some treatments leading to serious adverse events and the death of study subjects. Other toxicity events, such as dorsal root ganglia and peripheral nerve toxicity, have been reported only in animal models. The assessment of biomarkers is essential to evaluate pathogenic processes and the response to the therapeutic intervention. This is of particular importance to assess the genotoxicity, immune-mediated toxicity, study enrolment, and patients&#x02019; stratification (fda.com/biomarker-qualification-program). Substrates and downstream metabolites, assessed via mass spectrometry, histology, or imaging techniques, are usually the primary biomarkers that can indicate disease pathogenesis and progression.</p></list-item></list><p><xref rid="viruses-17-00239-t006" ref-type="table">Table 6</xref> outlines the major challenges in AAV gene therapy described above, and proposed solutions are outlined.</p></sec></sec><sec sec-type="conclusions" id="sec3-viruses-17-00239"><title>3. Conclusions and Future Prospects</title><p>AAV vectors, known for their safety, low immunogenicity, and ability to deliver sustained transgene expression, have become a pivotal tool in gene therapy. Their capacity for long-lasting transgene expression in various types of cells, broad tissue tropism, high transduction efficiency, and strong safety record underscore their widespread use in both clinical and preclinical settings. These vectors have facilitated remarkable clinical successes across diverse therapeutic areas, including retinal diseases, hemophilia, and neuromuscular disorders, demonstrating their versatility and effectiveness. The recent FDA approval of six AAV-based therapies is evidence of their potential to significantly improve patient care and treatment outcomes. Additionally, the potential of gene therapy to address aging and age-related diseases presents an exciting frontier, although it requires further exploration and development. The manufacturing process for AAV vectors continues to evolve, with advances aimed at enhancing the scalability and efficiency to meet the growing demand for these therapies.</p><p>Looking forward, the future of AAV gene therapy appears promising, though overcoming several challenges is necessary to fully realize its potential. While the technology has matured, critical hurdles remain, including immune response management, vector delivery optimization, the scalability of production processes, and cost reduction. Continued efforts in vector engineering, particularly the development of innovative capsid designs, are crucial for evading the immune system and improving gene delivery. For instance, advances in structure-guided evolution and machine learning have enabled the creation of de-immunized capsids that reduce immunogenicity while maintaining high transduction efficiency [<xref rid="B205-viruses-17-00239" ref-type="bibr">205</xref>]. These advancements are exemplified by efforts to treat conditions such as muscular dystrophy [<xref rid="B206-viruses-17-00239" ref-type="bibr">206</xref>] and hemophilia [<xref rid="B130-viruses-17-00239" ref-type="bibr">130</xref>], where targeted delivery and enhanced immune evasion are crucial for successful outcomes. Another emerging approach to mitigating immune responses involves combinatorial AAV therapies, where multiple AAV vectors deliver different therapeutic genes or components to target cells [<xref rid="B207-viruses-17-00239" ref-type="bibr">207</xref>]. Similarly, combinatorial strategies could synergistically target multiple pathways, such as delivering both a therapeutic gene and a regulatory RNA for neurodegenerative or cardiovascular diseases. These approaches offer a platform to expand the AAV applicability to more intricate genetic and multi-system disorders.</p><p>Emerging technologies like CRISPR and other genome-editing tools are also being integrated with AAV systems. AAV vectors are increasingly used to deliver CRISPR-Cas9 nucleases and donor DNA constructs for precise genome editing. This approach allows for targeted modifications and the insertion of therapeutic genes at specific chromosomal locations [<xref rid="B208-viruses-17-00239" ref-type="bibr">208</xref>]. Combining AAVs with CRISPR-Cas9 technology, which has already shown preclinical success [<xref rid="B209-viruses-17-00239" ref-type="bibr">209</xref>], could open new avenues for treating complex genetic diseases more effectively. This strategy enhances the efficacy of gene editing while improving the overall accuracy and safety.</p><p>Bridging the gap between preclinical research and clinical application is another critical challenge for advancing AAV-based therapies. Studies involving non-human primates have provided valuable insights into the long-term expression and safety profiles of gene therapies, informing the design of clinical trials. Additionally, identifying reliable biomarkers to monitor the efficacy and immune responses during trials is expected to streamline clinical development timelines. Combining gene therapy with cell therapy offers another powerful approach to treating complex diseases. For example, AAV vectors can deliver therapeutic genes to stem cells or immune cells to enhance their therapeutic potential. This combined approach is being explored for various conditions, including genetic disorders, cancers, and immune deficiencies. Finally, continued research, collaborative efforts between academia and industry, and supportive regulatory frameworks will be essential to navigate the complexities of gene therapy development. Harnessing the transformative potential of AAV technologies will require a multidisciplinary effort to ensure their safe and effective application in clinical settings.</p></sec></body><back><ack><title>Acknowledgments</title><p>We acknowledge Boris Djordjevic for their support through 199 Biotechnologies Ltd. Images were generated using BioRender. During the preparation of this work, we used OpenAI&#x02019;s ChatGPT-4 to improve the readability and language. After using these tools, we reviewed and edited the text as needed and take full responsibility for the content of the publication.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>L.Z.-D. conceived, designed, and drafted the manuscript and created the graphical illustrations. S.M. contributed to the writing and design. G.M. contributed to the writing and made substantial revisions. E.M. conceived and designed the manuscript, provided oversight, and contributed to substantial revisions. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00239"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sung</surname><given-names>Y.K.</given-names></name>
<name><surname>Kim</surname><given-names>S.W.</given-names></name>
</person-group><article-title>Recent advances in the development of gene delivery systems</article-title><source>Biomater. Res.</source><year>2019</year><volume>23</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.1186/s40824-019-0156-z</pub-id><pub-id pub-id-type="pmid">30915230</pub-id>
</element-citation></ref><ref id="B2-viruses-17-00239"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
</person-group><article-title>Gene Therapy Strategies Targeting Aging-Related Diseases</article-title><source>Aging Dis.</source><year>2023</year><volume>14</volume><fpage>398</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.14336/AD.2022.00725</pub-id><pub-id pub-id-type="pmid">37008065</pub-id>
</element-citation></ref><ref id="B3-viruses-17-00239"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gowing</surname><given-names>G.</given-names></name>
<name><surname>Svendsen</surname><given-names>S.</given-names></name>
<name><surname>Svendsen</surname><given-names>C.N.</given-names></name>
</person-group><article-title>Ex vivo gene therapy for the treatment of neurological disorders</article-title><source>Prog. Brain Res.</source><year>2017</year><volume>230</volume><fpage>99</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/bs.pbr.2016.11.003</pub-id><pub-id pub-id-type="pmid">28552237</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00239"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colella</surname><given-names>P.</given-names></name>
<name><surname>Ronzitti</surname><given-names>G.</given-names></name>
<name><surname>Mingozzi</surname><given-names>F.</given-names></name>
</person-group><article-title>Emerging Issues in AAV-Mediated In Vivo Gene Therapy</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2018</year><volume>8</volume><fpage>87</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2017.11.007</pub-id><pub-id pub-id-type="pmid">29326962</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00239"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Razi Soofiyani</surname><given-names>S.</given-names></name>
<name><surname>Baradaran</surname><given-names>B.</given-names></name>
<name><surname>Lotfipour</surname><given-names>F.</given-names></name>
<name><surname>Kazemi</surname><given-names>T.</given-names></name>
<name><surname>Mohammadnejad</surname><given-names>L.</given-names></name>
</person-group><article-title>Gene therapy, early promises, subsequent problems, and recent breakthroughs</article-title><source>Adv. Pharm. Bull.</source><year>2013</year><volume>3</volume><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.5681/apb.2013.041</pub-id><pub-id pub-id-type="pmid">24312844</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00239"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bulcha</surname><given-names>J.T.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>H.</given-names></name>
<name><surname>Tai</surname><given-names>P.W.L.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
</person-group><article-title>Viral vector platforms within the gene therapy landscape</article-title><source>Signal Transduct. Target. Ther.</source><year>2021</year><volume>6</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00487-6</pub-id><pub-id pub-id-type="pmid">33558455</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00239"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glover</surname><given-names>D.J.</given-names></name>
<name><surname>Lipps</surname><given-names>H.J.</given-names></name>
<name><surname>Jans</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Towards safe, non-viral therapeutic gene expression in humans</article-title><source>Nat. Rev. Genet.</source><year>2005</year><volume>6</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1038/nrg1577</pub-id><pub-id pub-id-type="pmid">15761468</pub-id>
</element-citation></ref><ref id="B8-viruses-17-00239"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lostal&#x000e9;-Seijo</surname><given-names>I.</given-names></name>
<name><surname>Montenegro</surname><given-names>J.</given-names></name>
</person-group><article-title>Synthetic materials at the forefront of gene delivery</article-title><source>Nat. Rev. Chem.</source><year>2018</year><volume>2</volume><fpage>258</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/s41570-018-0039-1</pub-id></element-citation></ref><ref id="B9-viruses-17-00239"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zu</surname><given-names>H.</given-names></name>
<name><surname>Gao</surname><given-names>D.</given-names></name>
</person-group><article-title>Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects</article-title><source>AAPS J.</source><year>2021</year><volume>23</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.1208/s12248-021-00608-7</pub-id><pub-id pub-id-type="pmid">34076797</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00239"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamimura</surname><given-names>K.</given-names></name>
<name><surname>Suda</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
</person-group><article-title>Advances in Gene Delivery Systems</article-title><source>Pharm. Med.</source><year>2011</year><volume>25</volume><fpage>293</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1007/BF03256872</pub-id></element-citation></ref><ref id="B11-viruses-17-00239"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Tai</surname><given-names>P.W.L.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
</person-group><article-title>Adeno-associated virus vector as a platform for gene therapy delivery</article-title><source>Nat. Rev. Drug Discov.</source><year>2019</year><volume>18</volume><fpage>358</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0012-9</pub-id><pub-id pub-id-type="pmid">30710128</pub-id>
</element-citation></ref><ref id="B12-viruses-17-00239"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCarty</surname><given-names>D.M.</given-names></name>
<name><surname>Young</surname><given-names>S.M.</given-names><suffix>Jr.</suffix></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Integration of adeno-associated virus (AAV) and recombinant AAV vectors</article-title><source>Annu. Rev. Genet.</source><year>2004</year><volume>38</volume><fpage>819</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1146/annurev.genet.37.110801.143717</pub-id><pub-id pub-id-type="pmid">15568995</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00239"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendell</surname><given-names>J.R.</given-names></name>
<name><surname>Al-Zaidy</surname><given-names>S.A.</given-names></name>
<name><surname>Rodino-Klapac</surname><given-names>L.R.</given-names></name>
<name><surname>Goodspeed</surname><given-names>K.</given-names></name>
<name><surname>Gray</surname><given-names>S.J.</given-names></name>
<name><surname>Kay</surname><given-names>C.N.</given-names></name>
<name><surname>Boye</surname><given-names>S.L.</given-names></name>
<name><surname>Boye</surname><given-names>S.E.</given-names></name>
<name><surname>George</surname><given-names>L.A.</given-names></name>
<name><surname>Salabarria</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Current Clinical Applications of In Vivo Gene Therapy with AAVs</article-title><source>Mol. Ther.</source><year>2021</year><volume>29</volume><fpage>464</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.12.007</pub-id><pub-id pub-id-type="pmid">33309881</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00239"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atchison</surname><given-names>R.W.</given-names></name>
<name><surname>Casto</surname><given-names>B.C.</given-names></name>
<name><surname>Hammon</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Adenovirus-Associated Defective Virus Particles</article-title><source>Science</source><year>1965</year><volume>149</volume><fpage>754</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1126/science.149.3685.754</pub-id><pub-id pub-id-type="pmid">14325163</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00239"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hocquemiller</surname><given-names>M.</given-names></name>
<name><surname>Giersch</surname><given-names>L.</given-names></name>
<name><surname>Audrain</surname><given-names>M.</given-names></name>
<name><surname>Parker</surname><given-names>S.</given-names></name>
<name><surname>Cartier</surname><given-names>N.</given-names></name>
</person-group><article-title>Adeno-Associated Virus-Based Gene Therapy for CNS Diseases</article-title><source>Hum. Gene Ther.</source><year>2016</year><volume>27</volume><fpage>478</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1089/hum.2016.087</pub-id><pub-id pub-id-type="pmid">27267688</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00239"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naso</surname><given-names>M.F.</given-names></name>
<name><surname>Tomkowicz</surname><given-names>B.</given-names></name>
<name><surname>Perry</surname><given-names>W.L.</given-names><suffix>3rd</suffix></name>
<name><surname>Strohl</surname><given-names>W.R.</given-names></name>
</person-group><article-title>Adeno-Associated Virus (AAV) as a Vector for Gene Therapy</article-title><source>BioDrugs</source><year>2017</year><volume>31</volume><fpage>317</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1007/s40259-017-0234-5</pub-id><pub-id pub-id-type="pmid">28669112</pub-id>
</element-citation></ref><ref id="B17-viruses-17-00239"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogden</surname><given-names>P.J.</given-names></name>
<name><surname>Kelsic</surname><given-names>E.D.</given-names></name>
<name><surname>Sinai</surname><given-names>S.</given-names></name>
<name><surname>Church</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design</article-title><source>Science</source><year>2019</year><volume>366</volume><fpage>1139</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1126/science.aaw2900</pub-id><pub-id pub-id-type="pmid">31780559</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00239"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elmore</surname><given-names>Z.C.</given-names></name>
<name><surname>Patrick Havlik</surname><given-names>L.</given-names></name>
<name><surname>Oh</surname><given-names>D.K.</given-names></name>
<name><surname>Anderson</surname><given-names>L.</given-names></name>
<name><surname>Daaboul</surname><given-names>G.</given-names></name>
<name><surname>Devlin</surname><given-names>G.W.</given-names></name>
<name><surname>Vincent</surname><given-names>H.A.</given-names></name>
<name><surname>Asokan</surname><given-names>A.</given-names></name>
</person-group><article-title>The membrane associated accessory protein is an adeno-associated viral egress factor</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>6239</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-26485-4</pub-id><pub-id pub-id-type="pmid">34716331</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00239"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goncalves</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Adeno-associated virus: From defective virus to effective vector</article-title><source>Virol. J.</source><year>2005</year><volume>2</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-2-43</pub-id><pub-id pub-id-type="pmid">15877812</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00239"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michelfelder</surname><given-names>S.</given-names></name>
<name><surname>Trepel</surname><given-names>M.</given-names></name>
</person-group><article-title>Adeno-associated viral vectors and their redirection to cell-type specific receptors</article-title><source>Adv. Genet.</source><year>2009</year><volume>67</volume><fpage>29</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/S0065-2660(09)67002-4</pub-id><pub-id pub-id-type="pmid">19914449</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00239"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ling</surname><given-names>Q.</given-names></name>
<name><surname>Herstine</surname><given-names>J.A.</given-names></name>
<name><surname>Bradbury</surname><given-names>A.</given-names></name>
<name><surname>Gray</surname><given-names>S.J.</given-names></name>
</person-group><article-title>AAV-based in vivo gene therapy for neurological disorders</article-title><source>Nat. Rev. Drug Discov.</source><year>2023</year><volume>22</volume><fpage>789</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1038/s41573-023-00766-7</pub-id><pub-id pub-id-type="pmid">37658167</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00239"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chadeuf</surname><given-names>G.</given-names></name>
<name><surname>Favre</surname><given-names>D.</given-names></name>
<name><surname>Tessier</surname><given-names>J.</given-names></name>
<name><surname>Provost</surname><given-names>N.</given-names></name>
<name><surname>Nony</surname><given-names>P.</given-names></name>
<name><surname>Kleinschmidt</surname><given-names>J.</given-names></name>
<name><surname>Moullier</surname><given-names>P.</given-names></name>
<name><surname>Salvetti</surname><given-names>A.</given-names></name>
</person-group><article-title>Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome</article-title><source>J. Gene Med.</source><year>2000</year><volume>2</volume><fpage>260</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1002/1521-2254(200007/08)2:4&#x0003c;260::AID-JGM111&#x0003e;3.0.CO;2-8</pub-id><pub-id pub-id-type="pmid">10953917</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00239"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hacker</surname><given-names>U.T.</given-names></name>
<name><surname>Bentler</surname><given-names>M.</given-names></name>
<name><surname>Kaniowska</surname><given-names>D.</given-names></name>
<name><surname>Morgan</surname><given-names>M.</given-names></name>
<name><surname>Buning</surname><given-names>H.</given-names></name>
</person-group><article-title>Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>1889</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12071889</pub-id><pub-id pub-id-type="pmid">32674264</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00239"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mietzsch</surname><given-names>M.</given-names></name>
<name><surname>Jose</surname><given-names>A.</given-names></name>
<name><surname>Chipman</surname><given-names>P.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>N.</given-names></name>
<name><surname>Daneshparvar</surname><given-names>N.</given-names></name>
<name><surname>McKenna</surname><given-names>R.</given-names></name>
<name><surname>Agbandje-McKenna</surname><given-names>M.</given-names></name>
</person-group><article-title>Completion of the AAV Structural Atlas: Serotype Capsid Structures Reveals Clade-Specific Features</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>101</elocation-id><pub-id pub-id-type="doi">10.3390/v13010101</pub-id><pub-id pub-id-type="pmid">33450892</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00239"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Ma</surname><given-names>H.I.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Xiao</surname><given-names>X.</given-names></name>
</person-group><article-title>Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo</article-title><source>Gene Ther.</source><year>2003</year><volume>10</volume><fpage>2105</fpage><lpage>2111</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302133</pub-id><pub-id pub-id-type="pmid">14625564</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00239"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCarty</surname><given-names>D.M.</given-names></name>
<name><surname>Monahan</surname><given-names>P.E.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis</article-title><source>Gene Ther.</source><year>2001</year><volume>8</volume><fpage>1248</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301514</pub-id><pub-id pub-id-type="pmid">11509958</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00239"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCarty</surname><given-names>D.M.</given-names></name>
<name><surname>Fu</surname><given-names>H.</given-names></name>
<name><surname>Monahan</surname><given-names>P.E.</given-names></name>
<name><surname>Toulson</surname><given-names>C.E.</given-names></name>
<name><surname>Naik</surname><given-names>P.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo</article-title><source>Gene Ther.</source><year>2003</year><volume>10</volume><fpage>2112</fpage><lpage>2118</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302134</pub-id><pub-id pub-id-type="pmid">14625565</pub-id>
</element-citation></ref><ref id="B28-viruses-17-00239"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Yin</surname><given-names>C.</given-names></name>
<name><surname>Yin</surname><given-names>F.</given-names></name>
<name><surname>Van Dyke</surname><given-names>T.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
<name><surname>Monahan</surname><given-names>P.E.</given-names></name>
</person-group><article-title>Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose</article-title><source>Mol. Ther.</source><year>2008</year><volume>16</volume><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/sj.mt.6300355</pub-id><pub-id pub-id-type="pmid">18059373</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00239"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bleker</surname><given-names>S.</given-names></name>
<name><surname>Sonntag</surname><given-names>F.</given-names></name>
<name><surname>Kleinschmidt</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Mutational Analysis of Narrow Pores at the Fivefold Symmetry Axes of Adeno-Associated Virus Type 2 Capsids Reveals a Dual Role in Genome Packaging and Activation of Phospholipase A2 Activity</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>2528</fpage><lpage>2540</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.4.2528-2540.2005</pub-id><pub-id pub-id-type="pmid">15681453</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00239"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Asokan</surname><given-names>A.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy</article-title><source>Mol. Ther.</source><year>2006</year><volume>14</volume><fpage>316</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2006.05.009</pub-id><pub-id pub-id-type="pmid">16824801</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00239"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hastie</surname><given-names>E.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Adeno-associated virus at 50: A golden anniversary of discovery, research, and gene therapy success--a personal perspective</article-title><source>Hum. Gene Ther.</source><year>2015</year><volume>26</volume><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1089/hum.2015.025</pub-id><pub-id pub-id-type="pmid">25807962</pub-id>
</element-citation></ref><ref id="B32-viruses-17-00239"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kronenberg</surname><given-names>S.</given-names></name>
<name><surname>B&#x000f6;ttcher</surname><given-names>B.</given-names></name>
<name><surname>von der Lieth</surname><given-names>C.W.</given-names></name>
<name><surname>Bleker</surname><given-names>S.</given-names></name>
<name><surname>Kleinschmidt</surname><given-names>J.A.</given-names></name>
</person-group><article-title>A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>5296</fpage><lpage>5303</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.9.5296-5303.2005</pub-id><pub-id pub-id-type="pmid">15827144</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00239"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Engineering adeno-associated virus vectors for gene therapy</article-title><source>Nat. Rev. Genet.</source><year>2020</year><volume>21</volume><fpage>255</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1038/s41576-019-0205-4</pub-id><pub-id pub-id-type="pmid">32042148</pub-id>
</element-citation></ref><ref id="B34-viruses-17-00239"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vandenberghe</surname><given-names>L.H.</given-names></name>
<name><surname>Wilson</surname><given-names>J.M.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
</person-group><article-title>Tailoring the AAV vector capsid for gene therapy</article-title><source>Gene Ther.</source><year>2009</year><volume>16</volume><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1038/gt.2008.170</pub-id><pub-id pub-id-type="pmid">19052631</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00239"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>L.Y.</given-names></name>
<name><surname>Patel</surname><given-names>A.</given-names></name>
<name><surname>Ng</surname><given-names>R.</given-names></name>
<name><surname>Miller</surname><given-names>E.B.</given-names></name>
<name><surname>Halder</surname><given-names>S.</given-names></name>
<name><surname>McKenna</surname><given-names>R.</given-names></name>
<name><surname>Asokan</surname><given-names>A.</given-names></name>
<name><surname>Agbandje-McKenna</surname><given-names>M.</given-names></name>
</person-group><article-title>Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site</article-title><source>J. Virol.</source><year>2016</year><volume>90</volume><fpage>5219</fpage><lpage>5230</lpage><pub-id pub-id-type="doi">10.1128/JVI.00161-16</pub-id><pub-id pub-id-type="pmid">26962225</pub-id>
</element-citation></ref><ref id="B36-viruses-17-00239"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palomeque</surname><given-names>J.</given-names></name>
<name><surname>Chemaly</surname><given-names>E.R.</given-names></name>
<name><surname>Colosi</surname><given-names>P.</given-names></name>
<name><surname>Wellman</surname><given-names>J.A.</given-names></name>
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Del Monte</surname><given-names>F.</given-names></name>
<name><surname>Hajjar</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo</article-title><source>Gene Ther.</source><year>2007</year><volume>14</volume><fpage>989</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302895</pub-id><pub-id pub-id-type="pmid">17251988</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00239"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>H.</given-names></name>
<name><surname>Yeghiazarians</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>A.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Arakawa-Hoyt</surname><given-names>J.</given-names></name>
<name><surname>Ye</surname><given-names>J.</given-names></name>
<name><surname>Orcino</surname><given-names>G.</given-names></name>
<name><surname>Grossman</surname><given-names>W.</given-names></name>
<name><surname>Kan</surname><given-names>Y.W.</given-names></name>
</person-group><article-title>AAV serotype 1 mediates more efficient gene transfer to pig myocardium than AAV serotype 2 and plasmid</article-title><source>J. Gene Med.</source><year>2008</year><volume>10</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1002/jgm.1129</pub-id><pub-id pub-id-type="pmid">18044793</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00239"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Kapturczak</surname><given-names>M.</given-names></name>
<name><surname>Loiler</surname><given-names>S.A.</given-names></name>
<name><surname>Zolotukhin</surname><given-names>S.</given-names></name>
<name><surname>Glushakova</surname><given-names>O.Y.</given-names></name>
<name><surname>Madsen</surname><given-names>K.M.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
<name><surname>Hauswirth</surname><given-names>W.W.</given-names></name>
<name><surname>Campbell-Thompson</surname><given-names>M.</given-names></name>
<name><surname>Berns</surname><given-names>K.I.</given-names></name>
<etal/>
</person-group><article-title>Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors</article-title><source>Hum. Gene Ther.</source><year>2005</year><volume>16</volume><fpage>235</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1089/hum.2005.16.235</pub-id><pub-id pub-id-type="pmid">15761263</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00239"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Auricchio</surname><given-names>A.</given-names></name>
<name><surname>Kobinger</surname><given-names>G.</given-names></name>
<name><surname>Anand</surname><given-names>V.</given-names></name>
<name><surname>Hildinger</surname><given-names>M.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>E.</given-names></name>
<name><surname>Maguire</surname><given-names>A.M.</given-names></name>
<name><surname>Wilson</surname><given-names>J.M.</given-names></name>
<name><surname>Bennett</surname><given-names>J.</given-names></name>
</person-group><article-title>Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: The retina as a model</article-title><source>Hum. Mol. Genet.</source><year>2001</year><volume>10</volume><fpage>3075</fpage><lpage>3081</lpage><pub-id pub-id-type="doi">10.1093/hmg/10.26.3075</pub-id><pub-id pub-id-type="pmid">11751689</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00239"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lisowski</surname><given-names>L.</given-names></name>
<name><surname>Tay</surname><given-names>S.S.</given-names></name>
<name><surname>Alexander</surname><given-names>I.E.</given-names></name>
</person-group><article-title>Adeno-associated virus serotypes for gene therapeutics</article-title><source>Curr. Opin. Pharmacol.</source><year>2015</year><volume>24</volume><fpage>59</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2015.07.006</pub-id><pub-id pub-id-type="pmid">26291407</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00239"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haddad</surname><given-names>G.</given-names></name>
<name><surname>K&#x000f6;lling</surname><given-names>M.</given-names></name>
<name><surname>Wegmann</surname><given-names>U.A.</given-names></name>
<name><surname>Dettling</surname><given-names>A.</given-names></name>
<name><surname>Seeger</surname><given-names>H.</given-names></name>
<name><surname>Schmitt</surname><given-names>R.</given-names></name>
<name><surname>Soerensen-Zender</surname><given-names>I.</given-names></name>
<name><surname>Haller</surname><given-names>H.</given-names></name>
<name><surname>Kistler</surname><given-names>A.D.</given-names></name>
<name><surname>Dueck</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Renal AAV2-Mediated Overexpression of Long Non-Coding RNA H19 Attenuates Ischemic Acute Kidney Injury Through Sponging of microRNA-30a-5p</article-title><source>J. Am. Soc. Nephrol.</source><year>2021</year><volume>32</volume><fpage>323</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1681/ASN.2020060775</pub-id><pub-id pub-id-type="pmid">33478972</pub-id>
</element-citation></ref><ref id="B42-viruses-17-00239"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takeda</surname><given-names>S.</given-names></name>
<name><surname>Takahashi</surname><given-names>M.</given-names></name>
<name><surname>Mizukami</surname><given-names>H.</given-names></name>
<name><surname>Kobayashi</surname><given-names>E.</given-names></name>
<name><surname>Takeuchi</surname><given-names>K.</given-names></name>
<name><surname>Hakamata</surname><given-names>Y.</given-names></name>
<name><surname>Kaneko</surname><given-names>T.</given-names></name>
<name><surname>Yamamoto</surname><given-names>H.</given-names></name>
<name><surname>Ito</surname><given-names>C.</given-names></name>
<name><surname>Ozawa</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Successful gene transfer using adeno-associated virus vectors into the kidney: Comparison among adeno-associated virus serotype 1-5 vectors in vitro and in vivo</article-title><source>Nephron Exp. Nephrol.</source><year>2004</year><volume>96</volume><fpage>e119</fpage><lpage>e126</lpage><pub-id pub-id-type="doi">10.1159/000077378</pub-id><pub-id pub-id-type="pmid">15122061</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00239"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>George</surname><given-names>L.A.</given-names></name>
<name><surname>Ragni</surname><given-names>M.V.</given-names></name>
<name><surname>Rasko</surname><given-names>J.E.J.</given-names></name>
<name><surname>Raffini</surname><given-names>L.J.</given-names></name>
<name><surname>Samelson-Jones</surname><given-names>B.J.</given-names></name>
<name><surname>Ozelo</surname><given-names>M.</given-names></name>
<name><surname>Hazbon</surname><given-names>M.</given-names></name>
<name><surname>Runowski</surname><given-names>A.R.</given-names></name>
<name><surname>Wellman</surname><given-names>J.A.</given-names></name>
<name><surname>Wachtel</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B</article-title><source>Mol. Ther.</source><year>2020</year><volume>28</volume><fpage>2073</fpage><lpage>2082</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.06.001</pub-id><pub-id pub-id-type="pmid">32559433</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00239"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Logan</surname><given-names>G.J.</given-names></name>
<name><surname>Dane</surname><given-names>A.P.</given-names></name>
<name><surname>Hallwirth</surname><given-names>C.V.</given-names></name>
<name><surname>Smyth</surname><given-names>C.M.</given-names></name>
<name><surname>Wilkie</surname><given-names>E.E.</given-names></name>
<name><surname>Amaya</surname><given-names>A.K.</given-names></name>
<name><surname>Zhu</surname><given-names>E.</given-names></name>
<name><surname>Khandekar</surname><given-names>N.</given-names></name>
<name><surname>Ginn</surname><given-names>S.L.</given-names></name>
<name><surname>Liao</surname><given-names>S.H.Y.</given-names></name>
<etal/>
</person-group><article-title>Identification of liver-specific enhancer-promoter activity in the 3&#x02032; untranslated region of the wild-type AAV2 genome</article-title><source>Nat. Genet.</source><year>2017</year><volume>49</volume><fpage>1267</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1038/ng.3893</pub-id><pub-id pub-id-type="pmid">28628105</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00239"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petrs-Silva</surname><given-names>H.</given-names></name>
<name><surname>Dinculescu</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Deng</surname><given-names>W.T.</given-names></name>
<name><surname>Pang</surname><given-names>J.J.</given-names></name>
<name><surname>Min</surname><given-names>S.H.</given-names></name>
<name><surname>Chiodo</surname><given-names>V.</given-names></name>
<name><surname>Neeley</surname><given-names>A.W.</given-names></name>
<name><surname>Govindasamy</surname><given-names>L.</given-names></name>
<name><surname>Bennett</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina</article-title><source>Mol. Ther.</source><year>2011</year><volume>19</volume><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/mt.2010.234</pub-id><pub-id pub-id-type="pmid">21045809</pub-id>
</element-citation></ref><ref id="B46-viruses-17-00239"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wassmer</surname><given-names>S.J.</given-names></name>
<name><surname>Carvalho</surname><given-names>L.S.</given-names></name>
<name><surname>Gy&#x000f6;rgy</surname><given-names>B.</given-names></name>
<name><surname>Vandenberghe</surname><given-names>L.H.</given-names></name>
<name><surname>Maguire</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>45329</elocation-id><pub-id pub-id-type="doi">10.1038/srep45329</pub-id><pub-id pub-id-type="pmid">28361998</pub-id>
</element-citation></ref><ref id="B47-viruses-17-00239"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Griffey</surname><given-names>M.</given-names></name>
<name><surname>Bible</surname><given-names>E.</given-names></name>
<name><surname>Vogler</surname><given-names>C.</given-names></name>
<name><surname>Levy</surname><given-names>B.</given-names></name>
<name><surname>Gupta</surname><given-names>P.</given-names></name>
<name><surname>Cooper</surname><given-names>J.</given-names></name>
<name><surname>Sands</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis</article-title><source>Neurobiol. Dis.</source><year>2004</year><volume>16</volume><fpage>360</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2004.03.005</pub-id><pub-id pub-id-type="pmid">15193292</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00239"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Griffey</surname><given-names>M.A.</given-names></name>
<name><surname>Wozniak</surname><given-names>D.</given-names></name>
<name><surname>Wong</surname><given-names>M.</given-names></name>
<name><surname>Bible</surname><given-names>E.</given-names></name>
<name><surname>Johnson</surname><given-names>K.</given-names></name>
<name><surname>Rothman</surname><given-names>S.M.</given-names></name>
<name><surname>Wentz</surname><given-names>A.E.</given-names></name>
<name><surname>Cooper</surname><given-names>J.D.</given-names></name>
<name><surname>Sands</surname><given-names>M.S.</given-names></name>
</person-group><article-title>CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis</article-title><source>Mol. Ther.</source><year>2006</year><volume>13</volume><fpage>538</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2005.11.008</pub-id><pub-id pub-id-type="pmid">16364693</pub-id>
</element-citation></ref><ref id="B49-viruses-17-00239"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadi</surname><given-names>M.</given-names></name>
<name><surname>Qutaiba</surname><given-names>B.</given-names></name>
<name><surname>Allela</surname><given-names>O.</given-names></name>
<name><surname>Jabari</surname><given-names>M.</given-names></name>
<name><surname>Jasoor</surname><given-names>A.M.</given-names></name>
<name><surname>Naderloo</surname><given-names>O.</given-names></name>
<name><surname>Yasamineh</surname><given-names>S.</given-names></name>
<name><surname>Gholizadeh</surname><given-names>O.</given-names></name>
<name><surname>Kalantari</surname><given-names>L.</given-names></name>
</person-group><article-title>Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma</article-title><source>Virol. J.</source><year>2024</year><volume>21</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s12985-024-02286-1</pub-id><pub-id pub-id-type="pmid">38216938</pub-id>
</element-citation></ref><ref id="B50-viruses-17-00239"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ling</surname><given-names>C.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Kalsi</surname><given-names>J.K.</given-names></name>
<name><surname>Jayandharan</surname><given-names>G.R.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Cheng</surname><given-names>B.</given-names></name>
<name><surname>Gee</surname><given-names>S.W.</given-names></name>
<name><surname>McGoogan</surname><given-names>K.E.</given-names></name>
<name><surname>Govindasamy</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3</article-title><source>Hum. Gene Ther.</source><year>2010</year><volume>21</volume><fpage>1741</fpage><lpage>1747</lpage><pub-id pub-id-type="doi">10.1089/hum.2010.075</pub-id><pub-id pub-id-type="pmid">20545554</pub-id>
</element-citation></ref><ref id="B51-viruses-17-00239"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vercauteren</surname><given-names>K.</given-names></name>
<name><surname>Hoffman</surname><given-names>B.E.</given-names></name>
<name><surname>Zolotukhin</surname><given-names>I.</given-names></name>
<name><surname>Keeler</surname><given-names>G.D.</given-names></name>
<name><surname>Xiao</surname><given-names>J.W.</given-names></name>
<name><surname>Basner-Tschakarjan</surname><given-names>E.</given-names></name>
<name><surname>High</surname><given-names>K.A.</given-names></name>
<name><surname>Ertl</surname><given-names>H.C.</given-names></name>
<name><surname>Rice</surname><given-names>C.M.</given-names></name>
<name><surname>Srivastava</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid</article-title><source>Mol. Ther.</source><year>2016</year><volume>24</volume><fpage>1042</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1038/mt.2016.61</pub-id><pub-id pub-id-type="pmid">27019999</pub-id>
</element-citation></ref><ref id="B52-viruses-17-00239"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davidson</surname><given-names>B.L.</given-names></name>
<name><surname>Stein</surname><given-names>C.S.</given-names></name>
<name><surname>Heth</surname><given-names>J.A.</given-names></name>
<name><surname>Martins</surname><given-names>I.</given-names></name>
<name><surname>Kotin</surname><given-names>R.M.</given-names></name>
<name><surname>Derksen</surname><given-names>T.A.</given-names></name>
<name><surname>Zabner</surname><given-names>J.</given-names></name>
<name><surname>Ghodsi</surname><given-names>A.</given-names></name>
<name><surname>Chiorini</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>3428</fpage><lpage>3432</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.7.3428</pub-id><pub-id pub-id-type="pmid">10688913</pub-id>
</element-citation></ref><ref id="B53-viruses-17-00239"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weber</surname><given-names>M.</given-names></name>
<name><surname>Rabinowitz</surname><given-names>J.</given-names></name>
<name><surname>Provost</surname><given-names>N.</given-names></name>
<name><surname>Conrath</surname><given-names>H.</given-names></name>
<name><surname>Folliot</surname><given-names>S.</given-names></name>
<name><surname>Briot</surname><given-names>D.</given-names></name>
<name><surname>Ch&#x000e9;rel</surname><given-names>Y.</given-names></name>
<name><surname>Chenuaud</surname><given-names>P.</given-names></name>
<name><surname>Samulski</surname><given-names>J.</given-names></name>
<name><surname>Moullier</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery</article-title><source>Mol. Ther.</source><year>2003</year><volume>7</volume><fpage>774</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/S1525-0016(03)00098-4</pub-id><pub-id pub-id-type="pmid">12788651</pub-id>
</element-citation></ref><ref id="B54-viruses-17-00239"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duncan</surname><given-names>G.A.</given-names></name>
<name><surname>Kim</surname><given-names>N.</given-names></name>
<name><surname>Colon-Cortes</surname><given-names>Y.</given-names></name>
<name><surname>Rodriguez</surname><given-names>J.</given-names></name>
<name><surname>Mazur</surname><given-names>M.</given-names></name>
<name><surname>Birket</surname><given-names>S.E.</given-names></name>
<name><surname>Rowe</surname><given-names>S.M.</given-names></name>
<name><surname>West</surname><given-names>N.E.</given-names></name>
<name><surname>Livraghi-Butrico</surname><given-names>A.</given-names></name>
<name><surname>Boucher</surname><given-names>R.C.</given-names></name>
<etal/>
</person-group><article-title>An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2018</year><volume>9</volume><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2018.03.006</pub-id><pub-id pub-id-type="pmid">30038933</pub-id>
</element-citation></ref><ref id="B55-viruses-17-00239"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halbert</surname><given-names>C.L.</given-names></name>
<name><surname>Allen</surname><given-names>J.M.</given-names></name>
<name><surname>Miller</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors</article-title><source>J. Virol.</source><year>2001</year><volume>75</volume><fpage>6615</fpage><lpage>6624</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.14.6615-6624.2001</pub-id><pub-id pub-id-type="pmid">11413329</pub-id>
</element-citation></ref><ref id="B56-viruses-17-00239"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halbert</surname><given-names>C.L.</given-names></name>
<name><surname>Madtes</surname><given-names>D.K.</given-names></name>
<name><surname>Vaughan</surname><given-names>A.E.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Storb</surname><given-names>R.</given-names></name>
<name><surname>Tapscott</surname><given-names>S.J.</given-names></name>
<name><surname>Miller</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs</article-title><source>Mol. Ther.</source><year>2010</year><volume>18</volume><fpage>1165</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1038/mt.2010.51</pub-id><pub-id pub-id-type="pmid">20372105</pub-id>
</element-citation></ref><ref id="B57-viruses-17-00239"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiao</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
<name><surname>Shin</surname><given-names>J.H.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Jayandharan</surname><given-names>G.R.</given-names></name>
<name><surname>Zhong</surname><given-names>L.</given-names></name>
<name><surname>Srivastava</surname><given-names>A.</given-names></name>
<name><surname>Xiao</surname><given-names>X.</given-names></name>
<name><surname>Duan</surname><given-names>D.</given-names></name>
</person-group><article-title>Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle</article-title><source>Hum. Gene Ther.</source><year>2010</year><volume>21</volume><fpage>1343</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1089/hum.2010.003</pub-id><pub-id pub-id-type="pmid">20497037</pub-id>
</element-citation></ref><ref id="B58-viruses-17-00239"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duque</surname><given-names>S.</given-names></name>
<name><surname>Joussemet</surname><given-names>B.</given-names></name>
<name><surname>Riviere</surname><given-names>C.</given-names></name>
<name><surname>Marais</surname><given-names>T.</given-names></name>
<name><surname>Dubreil</surname><given-names>L.</given-names></name>
<name><surname>Douar</surname><given-names>A.M.</given-names></name>
<name><surname>Fyfe</surname><given-names>J.</given-names></name>
<name><surname>Moullier</surname><given-names>P.</given-names></name>
<name><surname>Colle</surname><given-names>M.A.</given-names></name>
<name><surname>Barkats</surname><given-names>M.</given-names></name>
</person-group><article-title>Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons</article-title><source>Mol. Ther.</source><year>2009</year><volume>17</volume><fpage>1187</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1038/mt.2009.71</pub-id><pub-id pub-id-type="pmid">19367261</pub-id>
</element-citation></ref><ref id="B59-viruses-17-00239"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Issa</surname><given-names>S.S.</given-names></name>
<name><surname>Shaimardanova</surname><given-names>A.A.</given-names></name>
<name><surname>Solovyeva</surname><given-names>V.V.</given-names></name>
<name><surname>Rizvanov</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Various AAV Serotypes and Their Applications in Gene Therapy: An Overview</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>785</elocation-id><pub-id pub-id-type="doi">10.3390/cells12050785</pub-id><pub-id pub-id-type="pmid">36899921</pub-id>
</element-citation></ref><ref id="B60-viruses-17-00239"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rabinowitz</surname><given-names>J.E.</given-names></name>
<name><surname>Bowles</surname><given-names>D.E.</given-names></name>
<name><surname>Faust</surname><given-names>S.M.</given-names></name>
<name><surname>Ledford</surname><given-names>J.G.</given-names></name>
<name><surname>Cunningham</surname><given-names>S.E.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Cross-dressing the virion: The transcapsidation of adeno-associated virus serotypes functionally defines subgroups</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>4421</fpage><lpage>4432</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.9.4421-4432.2004</pub-id><pub-id pub-id-type="pmid">15078923</pub-id>
</element-citation></ref><ref id="B61-viruses-17-00239"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rabinowitz</surname><given-names>J.E.</given-names></name>
<name><surname>Rolling</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Conrath</surname><given-names>H.</given-names></name>
<name><surname>Xiao</surname><given-names>W.</given-names></name>
<name><surname>Xiao</surname><given-names>X.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>791</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.2.791-801.2002</pub-id><pub-id pub-id-type="pmid">11752169</pub-id>
</element-citation></ref><ref id="B62-viruses-17-00239"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000fc;ning</surname><given-names>H.</given-names></name>
<name><surname>Huber</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Meumann</surname><given-names>N.</given-names></name>
<name><surname>Hacker</surname><given-names>U.</given-names></name>
</person-group><article-title>Engineering the AAV capsid to optimize vector-host-interactions</article-title><source>Curr. Opin. Pharmacol.</source><year>2015</year><volume>24</volume><fpage>94</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2015.08.002</pub-id><pub-id pub-id-type="pmid">26302254</pub-id>
</element-citation></ref><ref id="B63-viruses-17-00239"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>E.J.</given-names></name>
<name><surname>Guenther</surname><given-names>C.M.</given-names></name>
<name><surname>Suh</surname><given-names>J.</given-names></name>
</person-group><article-title>Adeno-Associated Virus (AAV) Vectors: Rational Design Strategies for Capsid Engineering</article-title><source>Curr. Opin. Biomed. Eng.</source><year>2018</year><volume>7</volume><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.cobme.2018.09.004</pub-id><pub-id pub-id-type="pmid">31106283</pub-id>
</element-citation></ref><ref id="B64-viruses-17-00239"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zolotukhin</surname><given-names>S.</given-names></name>
<name><surname>Vandenberghe</surname><given-names>L.H.</given-names></name>
</person-group><article-title>AAV capsid design: A Goldilocks challenge</article-title><source>Trends Mol. Med.</source><year>2022</year><volume>28</volume><fpage>183</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2022.01.003</pub-id><pub-id pub-id-type="pmid">35093287</pub-id>
</element-citation></ref><ref id="B65-viruses-17-00239"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choudhury</surname><given-names>S.R.</given-names></name>
<name><surname>Fitzpatrick</surname><given-names>Z.</given-names></name>
<name><surname>Harris</surname><given-names>A.F.</given-names></name>
<name><surname>Maitland</surname><given-names>S.A.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.S.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>R.B.</given-names></name>
<name><surname>Gray-Edwards</surname><given-names>H.L.</given-names></name>
<name><surname>Johnson</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy</article-title><source>Mol. Ther.</source><year>2016</year><volume>24</volume><fpage>1247</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1038/mt.2016.84</pub-id><pub-id pub-id-type="pmid">27117222</pub-id>
</element-citation></ref><ref id="B66-viruses-17-00239"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tabebordbar</surname><given-names>M.</given-names></name>
<name><surname>Lagerborg</surname><given-names>K.A.</given-names></name>
<name><surname>Stanton</surname><given-names>A.</given-names></name>
<name><surname>King</surname><given-names>E.M.</given-names></name>
<name><surname>Ye</surname><given-names>S.</given-names></name>
<name><surname>Tellez</surname><given-names>L.</given-names></name>
<name><surname>Krunnfusz</surname><given-names>A.</given-names></name>
<name><surname>Tavakoli</surname><given-names>S.</given-names></name>
<name><surname>Widrick</surname><given-names>J.J.</given-names></name>
<name><surname>Messemer</surname><given-names>K.A.</given-names></name>
<etal/>
</person-group><article-title>Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>4919</fpage><lpage>4938.e4922</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.08.028</pub-id><pub-id pub-id-type="pmid">34506722</pub-id>
</element-citation></ref><ref id="B67-viruses-17-00239"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deverman</surname><given-names>B.E.</given-names></name>
<name><surname>Pravdo</surname><given-names>P.L.</given-names></name>
<name><surname>Simpson</surname><given-names>B.P.</given-names></name>
<name><surname>Kumar</surname><given-names>S.R.</given-names></name>
<name><surname>Chan</surname><given-names>K.Y.</given-names></name>
<name><surname>Banerjee</surname><given-names>A.</given-names></name>
<name><surname>Wu</surname><given-names>W.-L.</given-names></name>
<name><surname>Yang</surname><given-names>B.</given-names></name>
<name><surname>Huber</surname><given-names>N.</given-names></name>
<name><surname>Pasca</surname><given-names>S.P.</given-names></name>
<etal/>
</person-group><article-title>Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain</article-title><source>Nat. Biotechnol.</source><year>2016</year><volume>34</volume><fpage>204</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/nbt.3440</pub-id><pub-id pub-id-type="pmid">26829320</pub-id>
</element-citation></ref><ref id="B68-viruses-17-00239"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wright</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment</article-title><source>Biomedicines</source><year>2014</year><volume>2</volume><fpage>80</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.3390/biomedicines2010080</pub-id><pub-id pub-id-type="pmid">28548061</pub-id>
</element-citation></ref><ref id="B69-viruses-17-00239"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McColl-Carboni</surname><given-names>A.</given-names></name>
<name><surname>Dollive</surname><given-names>S.</given-names></name>
<name><surname>Laughlin</surname><given-names>S.</given-names></name>
<name><surname>Lushi</surname><given-names>R.</given-names></name>
<name><surname>MacArthur</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Gagnon</surname><given-names>J.</given-names></name>
<name><surname>Smith</surname><given-names>C.A.</given-names></name>
<name><surname>Burnham</surname><given-names>B.</given-names></name>
<name><surname>Horton</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Analytical characterization of full, intermediate, and empty AAV capsids</article-title><source>Gene Ther.</source><year>2024</year><volume>31</volume><fpage>285</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1038/s41434-024-00444-2</pub-id><pub-id pub-id-type="pmid">38374348</pub-id>
</element-citation></ref><ref id="B70-viruses-17-00239"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wright</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Transient transfection methods for clinical adeno-associated viral vector production</article-title><source>Hum. Gene Ther.</source><year>2009</year><volume>20</volume><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1089/hum.2009.064</pub-id><pub-id pub-id-type="pmid">19438300</pub-id>
</element-citation></ref><ref id="B71-viruses-17-00239"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cl&#x000e9;ment</surname><given-names>N.</given-names></name>
<name><surname>Grieger</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Manufacturing of recombinant adeno-associated viral vectors for clinical trials</article-title><source>Mol. Ther.-Methods Clin. Dev.</source><year>2016</year><volume>3</volume><fpage>16002</fpage><pub-id pub-id-type="doi">10.1038/mtm.2016.2</pub-id><pub-id pub-id-type="pmid">27014711</pub-id>
</element-citation></ref><ref id="B72-viruses-17-00239"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blessing</surname><given-names>D.</given-names></name>
<name><surname>Vachey</surname><given-names>G.</given-names></name>
<name><surname>Pythoud</surname><given-names>C.</given-names></name>
<name><surname>Rey</surname><given-names>M.</given-names></name>
<name><surname>Padrun</surname><given-names>V.</given-names></name>
<name><surname>Wurm</surname><given-names>F.M.</given-names></name>
<name><surname>Schneider</surname><given-names>B.L.</given-names></name>
<name><surname>D&#x000e9;glon</surname><given-names>N.</given-names></name>
</person-group><article-title>Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2019</year><volume>13</volume><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2018.11.004</pub-id><pub-id pub-id-type="pmid">30591923</pub-id>
</element-citation></ref><ref id="B73-viruses-17-00239"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>K.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Varadkar</surname><given-names>T.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.Z.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>X.M.</given-names></name>
</person-group><article-title>Advanced biomanufacturing and evaluation of adeno-associated virus</article-title><source>J. Biol. Eng.</source><year>2024</year><volume>18</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1186/s13036-024-00409-4</pub-id><pub-id pub-id-type="pmid">38360753</pub-id>
</element-citation></ref><ref id="B74-viruses-17-00239"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Durocher</surname><given-names>Y.</given-names></name>
<name><surname>Pham</surname><given-names>P.L.</given-names></name>
<name><surname>St-Laurent</surname><given-names>G.</given-names></name>
<name><surname>Jacob</surname><given-names>D.</given-names></name>
<name><surname>Cass</surname><given-names>B.</given-names></name>
<name><surname>Chahal</surname><given-names>P.</given-names></name>
<name><surname>Lau</surname><given-names>C.J.</given-names></name>
<name><surname>Nalbantoglu</surname><given-names>J.</given-names></name>
<name><surname>Kamen</surname><given-names>A.</given-names></name>
</person-group><article-title>Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells</article-title><source>J. Virol. Methods</source><year>2007</year><volume>144</volume><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2007.03.014</pub-id><pub-id pub-id-type="pmid">17467815</pub-id>
</element-citation></ref><ref id="B75-viruses-17-00239"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grieger</surname><given-names>J.C.</given-names></name>
<name><surname>Soltys</surname><given-names>S.M.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector</article-title><source>Mol. Ther.</source><year>2016</year><volume>24</volume><fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1038/mt.2015.187</pub-id><pub-id pub-id-type="pmid">26437810</pub-id>
</element-citation></ref><ref id="B76-viruses-17-00239"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendes</surname><given-names>J.P.</given-names></name>
<name><surname>Fernandes</surname><given-names>B.</given-names></name>
<name><surname>Pineda</surname><given-names>E.</given-names></name>
<name><surname>Kudugunti</surname><given-names>S.</given-names></name>
<name><surname>Bransby</surname><given-names>M.</given-names></name>
<name><surname>Gantier</surname><given-names>R.</given-names></name>
<name><surname>Peixoto</surname><given-names>C.</given-names></name>
<name><surname>Alves</surname><given-names>P.M.</given-names></name>
<name><surname>Rold&#x000e3;o</surname><given-names>A.</given-names></name>
<name><surname>Silva</surname><given-names>R.J.S.</given-names></name>
</person-group><article-title>AAV process intensification by perfusion bioreaction and integrated clarification</article-title><source>Front. Bioeng. Biotechnol.</source><year>2022</year><volume>10</volume><elocation-id>1020174</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2022.1020174</pub-id><pub-id pub-id-type="pmid">36420444</pub-id>
</element-citation></ref><ref id="B77-viruses-17-00239"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clark</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Recent advances in recombinant adeno-associated virus vector production</article-title><source>Kidney Int.</source><year>2002</year><volume>61</volume><fpage>S9</fpage><lpage>S15</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.0610s1009.x</pub-id><pub-id pub-id-type="pmid">11841606</pub-id>
</element-citation></ref><ref id="B78-viruses-17-00239"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>G.P.</given-names></name>
<name><surname>Qu</surname><given-names>G.</given-names></name>
<name><surname>Faust</surname><given-names>L.Z.</given-names></name>
<name><surname>Engdahl</surname><given-names>R.K.</given-names></name>
<name><surname>Xiao</surname><given-names>W.</given-names></name>
<name><surname>Hughes</surname><given-names>J.V.</given-names></name>
<name><surname>Zoltick</surname><given-names>P.W.</given-names></name>
<name><surname>Wilson</surname><given-names>J.M.</given-names></name>
</person-group><article-title>High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus</article-title><source>Hum. Gene Ther.</source><year>1998</year><volume>9</volume><fpage>2353</fpage><lpage>2362</lpage><pub-id pub-id-type="doi">10.1089/hum.1998.9.16-2353</pub-id><pub-id pub-id-type="pmid">9829534</pub-id>
</element-citation></ref><ref id="B79-viruses-17-00239"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Voulgaropoulou</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Johnson</surname><given-names>P.R.</given-names></name>
<name><surname>Clark</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines</article-title><source>Mol. Ther.</source><year>2000</year><volume>2</volume><fpage>394</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1006/mthe.2000.0132</pub-id><pub-id pub-id-type="pmid">11020356</pub-id>
</element-citation></ref><ref id="B80-viruses-17-00239"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>J.</given-names></name>
<name><surname>Frederick</surname><given-names>A.</given-names></name>
<name><surname>Luo</surname><given-names>Y.</given-names></name>
<name><surname>Jackson</surname><given-names>R.</given-names></name>
<name><surname>Joubert</surname><given-names>M.</given-names></name>
<name><surname>Sol</surname><given-names>B.</given-names></name>
<name><surname>Poulin</surname><given-names>F.</given-names></name>
<name><surname>Pastor</surname><given-names>E.</given-names></name>
<name><surname>Armentano</surname><given-names>D.</given-names></name>
<name><surname>Wadsworth</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production</article-title><source>Hum. Gene Ther. Methods</source><year>2013</year><volume>24</volume><fpage>253</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1089/hgtb.2013.046</pub-id><pub-id pub-id-type="pmid">23848282</pub-id>
</element-citation></ref><ref id="B81-viruses-17-00239"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>J.N.</given-names></name>
<name><surname>Wolken</surname><given-names>N.</given-names></name>
<name><surname>Brown</surname><given-names>T.</given-names></name>
<name><surname>Dauer</surname><given-names>W.T.</given-names></name>
<name><surname>Ehrlich</surname><given-names>M.E.</given-names></name>
<name><surname>Gonzalez-Alegre</surname><given-names>P.</given-names></name>
</person-group><article-title>Lethal toxicity caused by expression of shRNA in the mouse striatum: Implications for therapeutic design</article-title><source>Gene Ther.</source><year>2011</year><volume>18</volume><fpage>666</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/gt.2011.10</pub-id><pub-id pub-id-type="pmid">21368900</pub-id>
</element-citation></ref><ref id="B82-viruses-17-00239"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.-H.</given-names></name>
<name><surname>Gessler</surname><given-names>D.J.</given-names></name>
<name><surname>Zhan</surname><given-names>W.</given-names></name>
<name><surname>Gallagher</surname><given-names>T.L.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
</person-group><article-title>Adeno-associated virus as a delivery vector for gene therapy of human diseases</article-title><source>Signal Transduct. Target. Ther.</source><year>2024</year><volume>9</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01780-w</pub-id><pub-id pub-id-type="pmid">38565561</pub-id>
</element-citation></ref><ref id="B83-viruses-17-00239"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strobel</surname><given-names>B.</given-names></name>
<name><surname>Miller</surname><given-names>F.D.</given-names></name>
<name><surname>Rist</surname><given-names>W.</given-names></name>
<name><surname>Lamla</surname><given-names>T.</given-names></name>
</person-group><article-title>Comparative Analysis of Cesium Chloride- and Iodixanol-Based Purification of Recombinant Adeno-Associated Viral Vectors for Preclinical Applications</article-title><source>Hum. Gene Ther. Methods</source><year>2015</year><volume>26</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1089/hgtb.2015.051</pub-id><pub-id pub-id-type="pmid">26222983</pub-id>
</element-citation></ref><ref id="B84-viruses-17-00239"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zolotukhin</surname><given-names>S.</given-names></name>
<name><surname>Byrne</surname><given-names>B.J.</given-names></name>
<name><surname>Mason</surname><given-names>E.</given-names></name>
<name><surname>Zolotukhin</surname><given-names>I.</given-names></name>
<name><surname>Potter</surname><given-names>M.</given-names></name>
<name><surname>Chesnut</surname><given-names>K.</given-names></name>
<name><surname>Summerford</surname><given-names>C.</given-names></name>
<name><surname>Samulski</surname><given-names>R.J.</given-names></name>
<name><surname>Muzyczka</surname><given-names>N.</given-names></name>
</person-group><article-title>Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield</article-title><source>Gene Ther.</source><year>1999</year><volume>6</volume><fpage>973</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3300938</pub-id><pub-id pub-id-type="pmid">10455399</pub-id>
</element-citation></ref><ref id="B85-viruses-17-00239"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qu</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>R.</given-names></name>
</person-group><article-title>Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties</article-title><source>Curr. Pharm. Biotechnol.</source><year>2015</year><volume>16</volume><fpage>684</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.2174/1389201016666150505122228</pub-id><pub-id pub-id-type="pmid">25941887</pub-id>
</element-citation></ref><ref id="B86-viruses-17-00239"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>R.H.</given-names></name>
<name><surname>Levy</surname><given-names>J.R.</given-names></name>
<name><surname>Kotin</surname><given-names>R.M.</given-names></name>
</person-group><article-title>A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells</article-title><source>Mol. Ther.</source><year>2009</year><volume>17</volume><fpage>1888</fpage><lpage>1896</lpage><pub-id pub-id-type="doi">10.1038/mt.2009.128</pub-id><pub-id pub-id-type="pmid">19532142</pub-id>
</element-citation></ref><ref id="B87-viruses-17-00239"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>R.H.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Kotin</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Chromatography-based purification of adeno-associated virus</article-title><source>Methods Mol. Biol.</source><year>2008</year><volume>434</volume><fpage>37</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/978-1-60327-248-3_4</pub-id><pub-id pub-id-type="pmid">18470638</pub-id>
</element-citation></ref><ref id="B88-viruses-17-00239"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khanal</surname><given-names>O.</given-names></name>
<name><surname>Kumar</surname><given-names>V.</given-names></name>
<name><surname>Jin</surname><given-names>M.</given-names></name>
</person-group><article-title>Adeno-associated viral capsid stability on anion exchange chromatography column and its impact on empty and full capsid separation</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2023</year><volume>31</volume><fpage>101112</fpage><pub-id pub-id-type="doi">10.1016/j.omtm.2023.101112</pub-id><pub-id pub-id-type="pmid">37868210</pub-id>
</element-citation></ref><ref id="B89-viruses-17-00239"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nass</surname><given-names>S.A.</given-names></name>
<name><surname>Mattingly</surname><given-names>M.A.</given-names></name>
<name><surname>Woodcock</surname><given-names>D.A.</given-names></name>
<name><surname>Burnham</surname><given-names>B.L.</given-names></name>
<name><surname>Ardinger</surname><given-names>J.A.</given-names></name>
<name><surname>Osmond</surname><given-names>S.E.</given-names></name>
<name><surname>Frederick</surname><given-names>A.M.</given-names></name>
<name><surname>Scaria</surname><given-names>A.</given-names></name>
<name><surname>Cheng</surname><given-names>S.H.</given-names></name>
<name><surname>O&#x02019;Riordan</surname><given-names>C.R.</given-names></name>
</person-group><article-title>Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2018</year><volume>9</volume><fpage>33</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2017.12.004</pub-id><pub-id pub-id-type="pmid">29349097</pub-id>
</element-citation></ref><ref id="B90-viruses-17-00239"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>B.</given-names></name>
<name><surname>Bak</surname><given-names>H.</given-names></name>
<name><surname>Tustian</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Moving from the bench towards a large scale, industrial platform process for adeno-associated viral vector purification</article-title><source>Biotechnol. Bioeng.</source><year>2020</year><volume>117</volume><fpage>3199</fpage><lpage>3211</lpage><pub-id pub-id-type="doi">10.1002/bit.27472</pub-id><pub-id pub-id-type="pmid">32573761</pub-id>
</element-citation></ref><ref id="B91-viruses-17-00239"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Nass</surname><given-names>S.</given-names></name>
<name><surname>O&#x02019;Riordan</surname><given-names>C.</given-names></name>
<name><surname>Pastor</surname><given-names>E.</given-names></name>
<name><surname>Zhang</surname><given-names>X.K.</given-names></name>
</person-group><article-title>Direct Liquid Chromatography/Mass Spectrometry Analysis for Complete Characterization of Recombinant Adeno-Associated Virus Capsid Proteins</article-title><source>Hum. Gene Ther. Methods</source><year>2017</year><volume>28</volume><fpage>255</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1089/hgtb.2016.178</pub-id><pub-id pub-id-type="pmid">28627251</pub-id>
</element-citation></ref><ref id="B92-viruses-17-00239"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>A.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>Mietzsch</surname><given-names>M.</given-names></name>
<name><surname>Jose</surname><given-names>A.</given-names></name>
<name><surname>Lins-Austin</surname><given-names>B.</given-names></name>
<name><surname>Yu</surname><given-names>J.C.</given-names></name>
<name><surname>Bothner</surname><given-names>B.</given-names></name>
<name><surname>McKenna</surname><given-names>R.</given-names></name>
<name><surname>Agbandje-McKenna</surname><given-names>M.</given-names></name>
</person-group><article-title>Thermal Stability as a Determinant of AAV Serotype Identity</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2017</year><volume>6</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2017.07.003</pub-id><pub-id pub-id-type="pmid">28828392</pub-id>
</element-citation></ref><ref id="B93-viruses-17-00239"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pacouret</surname><given-names>S.</given-names></name>
<name><surname>Bouzelha</surname><given-names>M.</given-names></name>
<name><surname>Shelke</surname><given-names>R.</given-names></name>
<name><surname>Andres-Mateos</surname><given-names>E.</given-names></name>
<name><surname>Xiao</surname><given-names>R.</given-names></name>
<name><surname>Maurer</surname><given-names>A.</given-names></name>
<name><surname>Mevel</surname><given-names>M.</given-names></name>
<name><surname>Turunen</surname><given-names>H.</given-names></name>
<name><surname>Barungi</surname><given-names>T.</given-names></name>
<name><surname>Penaud-Budloo</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>AAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations</article-title><source>Mol. Ther.</source><year>2017</year><volume>25</volume><fpage>1375</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.04.001</pub-id><pub-id pub-id-type="pmid">28427840</pub-id>
</element-citation></ref><ref id="B94-viruses-17-00239"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rieser</surname><given-names>R.</given-names></name>
<name><surname>Penaud-Budloo</surname><given-names>M.</given-names></name>
<name><surname>Bouzelha</surname><given-names>M.</given-names></name>
<name><surname>Rossi</surname><given-names>A.</given-names></name>
<name><surname>Menzen</surname><given-names>T.</given-names></name>
<name><surname>Biel</surname><given-names>M.</given-names></name>
<name><surname>B&#x000fc;ning</surname><given-names>H.</given-names></name>
<name><surname>Ayuso</surname><given-names>E.</given-names></name>
<name><surname>Winter</surname><given-names>G.</given-names></name>
<name><surname>Michalakis</surname><given-names>S.</given-names></name>
</person-group><article-title>Intrinsic Differential Scanning Fluorimetry for Fast and Easy Identification of Adeno-Associated Virus Serotypes</article-title><source>J. Pharm. Sci.</source><year>2020</year><volume>109</volume><fpage>854</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2019.10.031</pub-id><pub-id pub-id-type="pmid">31639391</pub-id>
</element-citation></ref><ref id="B95-viruses-17-00239"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kondratova</surname><given-names>L.</given-names></name>
<name><surname>Kondratov</surname><given-names>O.</given-names></name>
<name><surname>Ragheb</surname><given-names>R.</given-names></name>
<name><surname>Zolotukhin</surname><given-names>S.</given-names></name>
</person-group><article-title>Removal of Endotoxin from rAAV Samples Using a Simple Detergent-Based Protocol</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2019</year><volume>15</volume><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2019.08.013</pub-id><pub-id pub-id-type="pmid">31649960</pub-id>
</element-citation></ref><ref id="B96-viruses-17-00239"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El Andari</surname><given-names>J.</given-names></name>
<name><surname>Grimm</surname><given-names>D.</given-names></name>
</person-group><article-title>Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors</article-title><source>Biotechnol. J.</source><year>2021</year><volume>16</volume><elocation-id>e2000025</elocation-id><pub-id pub-id-type="doi">10.1002/biot.202000025</pub-id><pub-id pub-id-type="pmid">32975881</pub-id>
</element-citation></ref><ref id="B97-viruses-17-00239"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Au</surname><given-names>H.K.E.</given-names></name>
<name><surname>Isalan</surname><given-names>M.</given-names></name>
<name><surname>Mielcarek</surname><given-names>M.</given-names></name>
</person-group><article-title>Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings</article-title><source>Front. Med.</source><year>2021</year><volume>8</volume><elocation-id>809118</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.809118</pub-id></element-citation></ref><ref id="B98-viruses-17-00239"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moss</surname><given-names>R.B.</given-names></name>
<name><surname>Milla</surname><given-names>C.</given-names></name>
<name><surname>Colombo</surname><given-names>J.</given-names></name>
<name><surname>Accurso</surname><given-names>F.</given-names></name>
<name><surname>Zeitlin</surname><given-names>P.L.</given-names></name>
<name><surname>Clancy</surname><given-names>J.P.</given-names></name>
<name><surname>Spencer</surname><given-names>L.T.</given-names></name>
<name><surname>Pilewski</surname><given-names>J.</given-names></name>
<name><surname>Waltz</surname><given-names>D.A.</given-names></name>
<name><surname>Dorkin</surname><given-names>H.L.</given-names></name>
<etal/>
</person-group><article-title>Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial</article-title><source>Hum. Gene Ther.</source><year>2007</year><volume>18</volume><fpage>726</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1089/hum.2007.022</pub-id><pub-id pub-id-type="pmid">17685853</pub-id>
</element-citation></ref><ref id="B99-viruses-17-00239"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moss</surname><given-names>R.B.</given-names></name>
<name><surname>Rodman</surname><given-names>D.</given-names></name>
<name><surname>Spencer</surname><given-names>L.T.</given-names></name>
<name><surname>Aitken</surname><given-names>M.L.</given-names></name>
<name><surname>Zeitlin</surname><given-names>P.L.</given-names></name>
<name><surname>Waltz</surname><given-names>D.</given-names></name>
<name><surname>Milla</surname><given-names>C.</given-names></name>
<name><surname>Brody</surname><given-names>A.S.</given-names></name>
<name><surname>Clancy</surname><given-names>J.P.</given-names></name>
<name><surname>Ramsey</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis: A Multicenter, Double-Blind, Placebo-Controlled Trial</article-title><source>Chest</source><year>2004</year><volume>125</volume><fpage>509</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1378/chest.125.2.509</pub-id><pub-id pub-id-type="pmid">14769732</pub-id>
</element-citation></ref><ref id="B100-viruses-17-00239"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wagner</surname><given-names>J.A.</given-names></name>
<name><surname>Messner</surname><given-names>A.H.</given-names></name>
<name><surname>Moran</surname><given-names>M.L.</given-names></name>
<name><surname>Daifuku</surname><given-names>R.</given-names></name>
<name><surname>Kouyama</surname><given-names>K.</given-names></name>
<name><surname>Desch</surname><given-names>J.K.</given-names></name>
<name><surname>Manley</surname><given-names>S.</given-names></name>
<name><surname>Norbash</surname><given-names>A.M.</given-names></name>
<name><surname>Conrad</surname><given-names>C.K.</given-names></name>
<name><surname>Friborg</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Safety and Biological Efficacy of an Adeno-Associated Virus Vector&#x02013;Cystic Fibrosis Transmembrane Regulator (AAV-CFTR) in the Cystic Fibrosis Maxillary Sinus</article-title><source>Laryngoscope</source><year>1999</year><volume>109</volume><fpage>266</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1097/00005537-199902000-00017</pub-id><pub-id pub-id-type="pmid">10890777</pub-id>
</element-citation></ref><ref id="B101-viruses-17-00239"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaudet</surname><given-names>D.</given-names></name>
<name><surname>M&#x000e9;thot</surname><given-names>J.</given-names></name>
<name><surname>Kastelein</surname><given-names>J.</given-names></name>
</person-group><article-title>Gene therapy for lipoprotein lipase deficiency</article-title><source>Curr. Opin. Lipidol.</source><year>2012</year><volume>23</volume><fpage>310</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1097/MOL.0b013e3283555a7e</pub-id><pub-id pub-id-type="pmid">22691709</pub-id>
</element-citation></ref><ref id="B102-viruses-17-00239"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>N.</given-names></name>
<name><surname>Yano</surname><given-names>K.</given-names></name>
<name><surname>Tsuyuki</surname><given-names>K.</given-names></name>
<name><surname>Okano</surname><given-names>T.</given-names></name>
<name><surname>Yamato</surname><given-names>M.</given-names></name>
</person-group><article-title>Re-examination of regulatory opinions in Europe: Possible contribution for the approval of the first gene therapy product Glybera</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2015</year><volume>2</volume><fpage>14066</fpage><pub-id pub-id-type="doi">10.1038/mtm.2014.66</pub-id><pub-id pub-id-type="pmid">26052534</pub-id>
</element-citation></ref><ref id="B103-viruses-17-00239"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000fc;ning</surname><given-names>H.</given-names></name>
</person-group><article-title>Gene therapy enters the pharma market: The short story of a long journey</article-title><source>EMBO Mol. Med.</source><year>2013</year><volume>5</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1002/emmm.201202291</pub-id><pub-id pub-id-type="pmid">23283747</pub-id>
</element-citation></ref><ref id="B104-viruses-17-00239"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Senior</surname><given-names>M.</given-names></name>
</person-group><article-title>After Glybera&#x02019;s withdrawal, what&#x02019;s next for gene therapy?</article-title><source>Nat. Biotechnol.</source><year>2017</year><volume>35</volume><fpage>491</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nbt0617-491</pub-id><pub-id pub-id-type="pmid">28591128</pub-id>
</element-citation></ref><ref id="B105-viruses-17-00239"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dunbar</surname><given-names>C.E.</given-names></name>
<name><surname>High</surname><given-names>K.A.</given-names></name>
<name><surname>Joung</surname><given-names>J.K.</given-names></name>
<name><surname>Kohn</surname><given-names>D.B.</given-names></name>
<name><surname>Ozawa</surname><given-names>K.</given-names></name>
<name><surname>Sadelain</surname><given-names>M.</given-names></name>
</person-group><article-title>Gene therapy comes of age</article-title><source>Science</source><year>2018</year><volume>359</volume><pub-id pub-id-type="doi">10.1126/science.aan4672</pub-id><pub-id pub-id-type="pmid">29326244</pub-id>
</element-citation></ref><ref id="B106-viruses-17-00239"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keeler</surname><given-names>A.M.</given-names></name>
<name><surname>Flotte</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?</article-title><source>Annu. Rev. Virol.</source><year>2019</year><volume>6</volume><fpage>601</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-092818-015530</pub-id><pub-id pub-id-type="pmid">31283441</pub-id>
</element-citation></ref><ref id="B107-viruses-17-00239"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>X.</given-names></name>
<name><surname>Fu</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>L.</given-names></name>
<name><surname>Yao</surname><given-names>Y.</given-names></name>
<name><surname>Ge</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Fan</surname><given-names>X.</given-names></name>
</person-group><article-title>AAV for Gene Therapy in Ocular Diseases: Progress and Prospects</article-title><source>Research</source><year>2023</year><volume>6</volume><fpage>0291</fpage><pub-id pub-id-type="doi">10.34133/research.0291</pub-id><pub-id pub-id-type="pmid">38188726</pub-id>
</element-citation></ref><ref id="B108-viruses-17-00239"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moore</surname><given-names>N.A.</given-names></name>
<name><surname>Morral</surname><given-names>N.</given-names></name>
<name><surname>Ciulla</surname><given-names>T.A.</given-names></name>
<name><surname>Bracha</surname><given-names>P.</given-names></name>
</person-group><article-title>Gene therapy for inherited retinal and optic nerve degenerations</article-title><source>Expert Opin. Biol. Ther.</source><year>2018</year><volume>18</volume><fpage>37</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1080/14712598.2018.1389886</pub-id><pub-id pub-id-type="pmid">29057663</pub-id>
</element-citation></ref><ref id="B109-viruses-17-00239"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodrigues</surname><given-names>G.A.</given-names></name>
<name><surname>Shalaev</surname><given-names>E.</given-names></name>
<name><surname>Karami</surname><given-names>T.K.</given-names></name>
<name><surname>Cunningham</surname><given-names>J.</given-names></name>
<name><surname>Slater</surname><given-names>N.K.H.</given-names></name>
<name><surname>Rivers</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye</article-title><source>Pharm. Res.</source><year>2018</year><volume>36</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1007/s11095-018-2554-7</pub-id><pub-id pub-id-type="pmid">30591984</pub-id>
</element-citation></ref><ref id="B110-viruses-17-00239"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bainbridge</surname><given-names>J.W.</given-names></name>
<name><surname>Mehat</surname><given-names>M.S.</given-names></name>
<name><surname>Sundaram</surname><given-names>V.</given-names></name>
<name><surname>Robbie</surname><given-names>S.J.</given-names></name>
<name><surname>Barker</surname><given-names>S.E.</given-names></name>
<name><surname>Ripamonti</surname><given-names>C.</given-names></name>
<name><surname>Georgiadis</surname><given-names>A.</given-names></name>
<name><surname>Mowat</surname><given-names>F.M.</given-names></name>
<name><surname>Beattie</surname><given-names>S.G.</given-names></name>
<name><surname>Gardner</surname><given-names>P.J.</given-names></name>
<etal/>
</person-group><article-title>Long-term effect of gene therapy on Leber&#x02019;s congenital amaurosis</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>1887</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1414221</pub-id><pub-id pub-id-type="pmid">25938638</pub-id>
</element-citation></ref><ref id="B111-viruses-17-00239"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacobson</surname><given-names>S.G.</given-names></name>
<name><surname>Cideciyan</surname><given-names>A.V.</given-names></name>
<name><surname>Roman</surname><given-names>A.J.</given-names></name>
<name><surname>Sumaroka</surname><given-names>A.</given-names></name>
<name><surname>Schwartz</surname><given-names>S.B.</given-names></name>
<name><surname>Heon</surname><given-names>E.</given-names></name>
<name><surname>Hauswirth</surname><given-names>W.W.</given-names></name>
</person-group><article-title>Improvement and decline in vision with gene therapy in childhood blindness</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>1920</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1412965</pub-id><pub-id pub-id-type="pmid">25936984</pub-id>
</element-citation></ref><ref id="B112-viruses-17-00239"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cideciyan</surname><given-names>A.V.</given-names></name>
<name><surname>Jacobson</surname><given-names>S.G.</given-names></name>
<name><surname>Beltran</surname><given-names>W.A.</given-names></name>
<name><surname>Sumaroka</surname><given-names>A.</given-names></name>
<name><surname>Swider</surname><given-names>M.</given-names></name>
<name><surname>Iwabe</surname><given-names>S.</given-names></name>
<name><surname>Roman</surname><given-names>A.J.</given-names></name>
<name><surname>Olivares</surname><given-names>M.B.</given-names></name>
<name><surname>Schwartz</surname><given-names>S.B.</given-names></name>
<name><surname>Kom&#x000e1;romy</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group><article-title>Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>E517</fpage><lpage>E525</lpage><pub-id pub-id-type="doi">10.1073/pnas.1218933110</pub-id><pub-id pub-id-type="pmid">23341635</pub-id>
</element-citation></ref><ref id="B113-viruses-17-00239"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marques</surname><given-names>A.R.A.</given-names></name>
<name><surname>Saftig</surname><given-names>P.</given-names></name>
</person-group><article-title>Lysosomal storage disorders&#x02014;challenges, concepts and avenues for therapy: Beyond rare diseases</article-title><source>J. Cell Sci.</source><year>2019</year><volume>132</volume><pub-id pub-id-type="doi">10.1242/jcs.221739</pub-id><pub-id pub-id-type="pmid">30651381</pub-id>
</element-citation></ref><ref id="B114-viruses-17-00239"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martina</surname><given-names>J.A.</given-names></name>
<name><surname>Raben</surname><given-names>N.</given-names></name>
<name><surname>Puertollano</surname><given-names>R.</given-names></name>
</person-group><article-title>SnapShot: Lysosomal Storage Diseases</article-title><source>Cell</source><year>2020</year><volume>180</volume><fpage>602</fpage><lpage>602.e1</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.01.017</pub-id><pub-id pub-id-type="pmid">32032518</pub-id>
</element-citation></ref><ref id="B115-viruses-17-00239"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Platt</surname><given-names>F.M.</given-names></name>
<name><surname>d&#x02019;Azzo</surname><given-names>A.</given-names></name>
<name><surname>Davidson</surname><given-names>B.L.</given-names></name>
<name><surname>Neufeld</surname><given-names>E.F.</given-names></name>
<name><surname>Tifft</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Lysosomal storage diseases</article-title><source>Nat. Rev. Dis. Primers</source><year>2018</year><volume>4</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1038/s41572-018-0025-4</pub-id><pub-id pub-id-type="pmid">30275469</pub-id>
</element-citation></ref><ref id="B116-viruses-17-00239"><label>116.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kantor</surname><given-names>B.</given-names></name>
<name><surname>Bailey</surname><given-names>R.M.</given-names></name>
<name><surname>Wimberly</surname><given-names>K.</given-names></name>
<name><surname>Kalburgi</surname><given-names>S.N.</given-names></name>
<name><surname>Gray</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Chapter Three&#x02014;Methods for Gene Transfer to the Central Nervous System</article-title><source>Advances in Genetics</source><person-group person-group-type="editor">
<name><surname>Friedmann</surname><given-names>T.</given-names></name>
<name><surname>Dunlap</surname><given-names>J.C.</given-names></name>
<name><surname>Goodwin</surname><given-names>S.F.</given-names></name>
</person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2014</year><volume>Volume 87</volume><fpage>125</fpage><lpage>197</lpage></element-citation></ref><ref id="B117-viruses-17-00239"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bey</surname><given-names>K.</given-names></name>
<name><surname>Deniaud</surname><given-names>J.</given-names></name>
<name><surname>Dubreil</surname><given-names>L.</given-names></name>
<name><surname>Joussemet</surname><given-names>B.</given-names></name>
<name><surname>Cristini</surname><given-names>J.</given-names></name>
<name><surname>Ciron</surname><given-names>C.</given-names></name>
<name><surname>Hordeaux</surname><given-names>J.</given-names></name>
<name><surname>Le Boulc&#x02019;h</surname><given-names>M.</given-names></name>
<name><surname>Marche</surname><given-names>K.</given-names></name>
<name><surname>Maquigneau</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2020</year><volume>17</volume><fpage>771</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2020.04.001</pub-id><pub-id pub-id-type="pmid">32355866</pub-id>
</element-citation></ref><ref id="B118-viruses-17-00239"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cearley</surname><given-names>C.N.</given-names></name>
<name><surname>Vandenberghe</surname><given-names>L.H.</given-names></name>
<name><surname>Parente</surname><given-names>M.K.</given-names></name>
<name><surname>Carnish</surname><given-names>E.R.</given-names></name>
<name><surname>Wilson</surname><given-names>J.M.</given-names></name>
<name><surname>Wolfe</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain</article-title><source>Mol. Ther.</source><year>2008</year><volume>16</volume><fpage>1710</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1038/mt.2008.166</pub-id><pub-id pub-id-type="pmid">18714307</pub-id>
</element-citation></ref><ref id="B119-viruses-17-00239"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piguet</surname><given-names>F.</given-names></name>
<name><surname>Alves</surname><given-names>S.</given-names></name>
<name><surname>Cartier</surname><given-names>N.</given-names></name>
</person-group><article-title>Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future</article-title><source>Hum. Gene Ther.</source><year>2017</year><volume>28</volume><fpage>988</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1089/hum.2017.160</pub-id><pub-id pub-id-type="pmid">29035118</pub-id>
</element-citation></ref><ref id="B120-viruses-17-00239"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Zaidy</surname><given-names>S.A.</given-names></name>
<name><surname>Mendell</surname><given-names>J.R.</given-names></name>
</person-group><article-title>From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1</article-title><source>Pediatr. Neurol.</source><year>2019</year><volume>100</volume><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2019.06.007</pub-id><pub-id pub-id-type="pmid">31371124</pub-id>
</element-citation></ref><ref id="B121-viruses-17-00239"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendell</surname><given-names>J.R.</given-names></name>
<name><surname>Al-Zaidy</surname><given-names>S.</given-names></name>
<name><surname>Shell</surname><given-names>R.</given-names></name>
<name><surname>Arnold</surname><given-names>W.D.</given-names></name>
<name><surname>Rodino-Klapac</surname><given-names>L.R.</given-names></name>
<name><surname>Prior</surname><given-names>T.W.</given-names></name>
<name><surname>Lowes</surname><given-names>L.</given-names></name>
<name><surname>Alfano</surname><given-names>L.</given-names></name>
<name><surname>Berry</surname><given-names>K.</given-names></name>
<name><surname>Church</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>1713</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1706198</pub-id><pub-id pub-id-type="pmid">29091557</pub-id>
</element-citation></ref><ref id="B122-viruses-17-00239"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomsen</surname><given-names>G.</given-names></name>
<name><surname>Burghes</surname><given-names>A.H.M.</given-names></name>
<name><surname>Hsieh</surname><given-names>C.</given-names></name>
<name><surname>Do</surname><given-names>J.</given-names></name>
<name><surname>Chu</surname><given-names>B.T.T.</given-names></name>
<name><surname>Perry</surname><given-names>S.</given-names></name>
<name><surname>Barkho</surname><given-names>B.</given-names></name>
<name><surname>Kaufmann</surname><given-names>P.</given-names></name>
<name><surname>Sproule</surname><given-names>D.M.</given-names></name>
<name><surname>Feltner</surname><given-names>D.E.</given-names></name>
<etal/>
</person-group><article-title>Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>1701</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01483-7</pub-id><pub-id pub-id-type="pmid">34608334</pub-id>
</element-citation></ref><ref id="B123-viruses-17-00239"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deverman</surname><given-names>B.E.</given-names></name>
<name><surname>Ravina</surname><given-names>B.M.</given-names></name>
<name><surname>Bankiewicz</surname><given-names>K.S.</given-names></name>
<name><surname>Paul</surname><given-names>S.M.</given-names></name>
<name><surname>Sah</surname><given-names>D.W.Y.</given-names></name>
</person-group><article-title>Gene therapy for neurological disorders: Progress and prospects</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>641</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.110</pub-id><pub-id pub-id-type="pmid">30093643</pub-id>
</element-citation></ref><ref id="B124-viruses-17-00239"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foust</surname><given-names>K.D.</given-names></name>
<name><surname>Nurre</surname><given-names>E.</given-names></name>
<name><surname>Montgomery</surname><given-names>C.L.</given-names></name>
<name><surname>Hernandez</surname><given-names>A.</given-names></name>
<name><surname>Chan</surname><given-names>C.M.</given-names></name>
<name><surname>Kaspar</surname><given-names>B.K.</given-names></name>
</person-group><article-title>Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes</article-title><source>Nat. Biotechnol.</source><year>2009</year><volume>27</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nbt.1515</pub-id><pub-id pub-id-type="pmid">19098898</pub-id>
</element-citation></ref><ref id="B125-viruses-17-00239"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciesielska</surname><given-names>A.</given-names></name>
<name><surname>Mittermeyer</surname><given-names>G.</given-names></name>
<name><surname>Hadaczek</surname><given-names>P.</given-names></name>
<name><surname>Kells</surname><given-names>A.P.</given-names></name>
<name><surname>Forsayeth</surname><given-names>J.</given-names></name>
<name><surname>Bankiewicz</surname><given-names>K.S.</given-names></name>
</person-group><article-title>Anterograde axonal transport of AAV2-GDNF in rat basal ganglia</article-title><source>Mol. Ther.</source><year>2011</year><volume>19</volume><fpage>922</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1038/mt.2010.248</pub-id><pub-id pub-id-type="pmid">21102559</pub-id>
</element-citation></ref><ref id="B126-viruses-17-00239"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Batty</surname><given-names>P.</given-names></name>
<name><surname>Lillicrap</surname><given-names>D.</given-names></name>
</person-group><article-title>Advances and challenges for hemophilia gene therapy</article-title><source>Hum. Mol. Genet.</source><year>2019</year><volume>28</volume><fpage>R95</fpage><lpage>R101</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddz157</pub-id><pub-id pub-id-type="pmid">31332444</pub-id>
</element-citation></ref><ref id="B127-viruses-17-00239"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nathwani</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Gene therapy for hemophilia</article-title><source>Hematol. Am. Soc. Hematol. Educ. Program.</source><year>2022</year><volume>2022</volume><fpage>569</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1182/hematology.2022000388</pub-id></element-citation></ref><ref id="B128-viruses-17-00239"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>George</surname><given-names>L.A.</given-names></name>
<name><surname>Sullivan</surname><given-names>S.K.</given-names></name>
<name><surname>Giermasz</surname><given-names>A.</given-names></name>
<name><surname>Rasko</surname><given-names>J.E.J.</given-names></name>
<name><surname>Samelson-Jones</surname><given-names>B.J.</given-names></name>
<name><surname>Ducore</surname><given-names>J.</given-names></name>
<name><surname>Cuker</surname><given-names>A.</given-names></name>
<name><surname>Sullivan</surname><given-names>L.M.</given-names></name>
<name><surname>Majumdar</surname><given-names>S.</given-names></name>
<name><surname>Teitel</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>2215</fpage><lpage>2227</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1708538</pub-id><pub-id pub-id-type="pmid">29211678</pub-id>
</element-citation></ref><ref id="B129-viruses-17-00239"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nathwani</surname><given-names>A.C.</given-names></name>
<name><surname>Reiss</surname><given-names>U.M.</given-names></name>
<name><surname>Tuddenham</surname><given-names>E.G.</given-names></name>
<name><surname>Rosales</surname><given-names>C.</given-names></name>
<name><surname>Chowdary</surname><given-names>P.</given-names></name>
<name><surname>McIntosh</surname><given-names>J.</given-names></name>
<name><surname>Della Peruta</surname><given-names>M.</given-names></name>
<name><surname>Lheriteau</surname><given-names>E.</given-names></name>
<name><surname>Patel</surname><given-names>N.</given-names></name>
<name><surname>Raj</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Long-term safety and efficacy of factor IX gene therapy in hemophilia B</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>1994</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1407309</pub-id><pub-id pub-id-type="pmid">25409372</pub-id>
</element-citation></ref><ref id="B130-viruses-17-00239"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perrin</surname><given-names>G.Q.</given-names></name>
<name><surname>Herzog</surname><given-names>R.W.</given-names></name>
<name><surname>Markusic</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Update on clinical gene therapy for hemophilia</article-title><source>Blood</source><year>2019</year><volume>133</volume><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-07-820720</pub-id><pub-id pub-id-type="pmid">30559260</pub-id>
</element-citation></ref><ref id="B131-viruses-17-00239"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rangarajan</surname><given-names>S.</given-names></name>
<name><surname>Walsh</surname><given-names>L.</given-names></name>
<name><surname>Lester</surname><given-names>W.</given-names></name>
<name><surname>Perry</surname><given-names>D.</given-names></name>
<name><surname>Madan</surname><given-names>B.</given-names></name>
<name><surname>Laffan</surname><given-names>M.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Vettermann</surname><given-names>C.</given-names></name>
<name><surname>Pierce</surname><given-names>G.F.</given-names></name>
<name><surname>Wong</surname><given-names>W.Y.</given-names></name>
<etal/>
</person-group><article-title>AAV5-Factor VIII Gene Transfer in Severe Hemophilia A</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>2519</fpage><lpage>2530</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1708483</pub-id><pub-id pub-id-type="pmid">29224506</pub-id>
</element-citation></ref><ref id="B132-viruses-17-00239"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aguti</surname><given-names>S.</given-names></name>
<name><surname>Malerba</surname><given-names>A.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
</person-group><article-title>The progress of AAV-mediated gene therapy in neuromuscular disorders</article-title><source>Expert Opin. Biol. Ther.</source><year>2018</year><volume>18</volume><fpage>681</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1080/14712598.2018.1479739</pub-id><pub-id pub-id-type="pmid">29781327</pub-id>
</element-citation></ref><ref id="B133-viruses-17-00239"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duan</surname><given-names>D.</given-names></name>
</person-group><article-title>Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy</article-title><source>Mol. Ther.</source><year>2018</year><volume>26</volume><fpage>2337</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2018.07.011</pub-id><pub-id pub-id-type="pmid">30093306</pub-id>
</element-citation></ref><ref id="B134-viruses-17-00239"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x000f3;pez-Ot&#x000ed;n</surname><given-names>C.</given-names></name>
<name><surname>Blasco</surname><given-names>M.A.</given-names></name>
<name><surname>Partridge</surname><given-names>L.</given-names></name>
<name><surname>Serrano</surname><given-names>M.</given-names></name>
<name><surname>Kroemer</surname><given-names>G.</given-names></name>
</person-group><article-title>The hallmarks of aging</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>1194</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.05.039</pub-id><pub-id pub-id-type="pmid">23746838</pub-id>
</element-citation></ref><ref id="B135-viruses-17-00239"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nilsson</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Early vascular aging (EVA): Consequences and prevention</article-title><source>Vasc. Health Risk Manag.</source><year>2008</year><volume>4</volume><fpage>547</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.2147/VHRM.S1094</pub-id><pub-id pub-id-type="pmid">18827905</pub-id>
</element-citation></ref><ref id="B136-viruses-17-00239"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bernardes de Jesus</surname><given-names>B.</given-names></name>
<name><surname>Vera</surname><given-names>E.</given-names></name>
<name><surname>Schneeberger</surname><given-names>K.</given-names></name>
<name><surname>Tejera</surname><given-names>A.M.</given-names></name>
<name><surname>Ayuso</surname><given-names>E.</given-names></name>
<name><surname>Bosch</surname><given-names>F.</given-names></name>
<name><surname>Blasco</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer</article-title><source>EMBO Mol. Med.</source><year>2012</year><volume>4</volume><fpage>691</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1002/emmm.201200245</pub-id><pub-id pub-id-type="pmid">22585399</pub-id>
</element-citation></ref><ref id="B137-viruses-17-00239"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000e4;r</surname><given-names>C.</given-names></name>
<name><surname>Bernardes de Jesus</surname><given-names>B.</given-names></name>
<name><surname>Serrano</surname><given-names>R.</given-names></name>
<name><surname>Tejera</surname><given-names>A.</given-names></name>
<name><surname>Ayuso</surname><given-names>E.</given-names></name>
<name><surname>Jimenez</surname><given-names>V.</given-names></name>
<name><surname>Formentini</surname><given-names>I.</given-names></name>
<name><surname>Bobadilla</surname><given-names>M.</given-names></name>
<name><surname>Mizrahi</surname><given-names>J.</given-names></name>
<name><surname>de Martino</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Telomerase expression confers cardioprotection in the adult mouse heart after acute myocardial infarction</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>5863</fpage><pub-id pub-id-type="doi">10.1038/ncomms6863</pub-id><pub-id pub-id-type="pmid">25519492</pub-id>
</element-citation></ref><ref id="B138-viruses-17-00239"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000e4;r</surname><given-names>C.</given-names></name>
<name><surname>Povedano</surname><given-names>J.M.</given-names></name>
<name><surname>Serrano</surname><given-names>R.</given-names></name>
<name><surname>Benitez-Buelga</surname><given-names>C.</given-names></name>
<name><surname>Popkes</surname><given-names>M.</given-names></name>
<name><surname>Formentini</surname><given-names>I.</given-names></name>
<name><surname>Bobadilla</surname><given-names>M.</given-names></name>
<name><surname>Bosch</surname><given-names>F.</given-names></name>
<name><surname>Blasco</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia</article-title><source>Blood</source><year>2016</year><volume>127</volume><fpage>1770</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-08-667485</pub-id><pub-id pub-id-type="pmid">26903545</pub-id>
</element-citation></ref><ref id="B139-viruses-17-00239"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Povedano</surname><given-names>J.M.</given-names></name>
<name><surname>Martinez</surname><given-names>P.</given-names></name>
<name><surname>Serrano</surname><given-names>R.</given-names></name>
<name><surname>Tejera</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>G&#x000f3;mez-L&#x000f3;pez</surname><given-names>G.</given-names></name>
<name><surname>Bobadilla</surname><given-names>M.</given-names></name>
<name><surname>Flores</surname><given-names>J.M.</given-names></name>
<name><surname>Bosch</surname><given-names>F.</given-names></name>
<name><surname>Blasco</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres</article-title><source>Elife</source><year>2018</year><volume>7</volume><pub-id pub-id-type="doi">10.7554/eLife.31299</pub-id></element-citation></ref><ref id="B140-viruses-17-00239"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whittemore</surname><given-names>K.</given-names></name>
<name><surname>Derevyanko</surname><given-names>A.</given-names></name>
<name><surname>Martinez</surname><given-names>P.</given-names></name>
<name><surname>Serrano</surname><given-names>R.</given-names></name>
<name><surname>Pumarola</surname><given-names>M.</given-names></name>
<name><surname>Bosch</surname><given-names>F.</given-names></name>
<name><surname>Blasco</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Telomerase gene therapy ameliorates the effects of neurodegeneration associated to short telomeres in mice</article-title><source>Aging</source><year>2019</year><volume>11</volume><fpage>2916</fpage><lpage>2948</lpage><pub-id pub-id-type="doi">10.18632/aging.101982</pub-id><pub-id pub-id-type="pmid">31140977</pub-id>
</element-citation></ref><ref id="B141-viruses-17-00239"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>C.R.</given-names></name>
<name><surname>Mullen</surname><given-names>P.C.</given-names></name>
<name><surname>Tucker-Zhou</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>C.D.</given-names></name>
<name><surname>Zeldich</surname><given-names>E.</given-names></name>
</person-group><article-title>Klotho Is a Neuroprotective and Cognition-Enhancing Protein</article-title><source>Vitam. Horm.</source><year>2016</year><volume>101</volume><fpage>215</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/bs.vh.2016.02.004</pub-id><pub-id pub-id-type="pmid">27125744</pub-id>
</element-citation></ref><ref id="B142-viruses-17-00239"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubal</surname><given-names>D.B.</given-names></name>
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Sanchez</surname><given-names>P.E.</given-names></name>
<name><surname>Worden</surname><given-names>K.</given-names></name>
<name><surname>Broestl</surname><given-names>L.</given-names></name>
<name><surname>Johnson</surname><given-names>E.</given-names></name>
<name><surname>Ho</surname><given-names>K.</given-names></name>
<name><surname>Yu</surname><given-names>G.Q.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Betourne</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice</article-title><source>J. Neurosci.</source><year>2015</year><volume>35</volume><fpage>2358</fpage><lpage>2371</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5791-12.2015</pub-id><pub-id pub-id-type="pmid">25673831</pub-id>
</element-citation></ref><ref id="B143-viruses-17-00239"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moos</surname><given-names>W.H.</given-names></name>
<name><surname>Faller</surname><given-names>D.V.</given-names></name>
<name><surname>Glavas</surname><given-names>I.P.</given-names></name>
<name><surname>Harpp</surname><given-names>D.N.</given-names></name>
<name><surname>Kanara</surname><given-names>I.</given-names></name>
<name><surname>Mavrakis</surname><given-names>A.N.</given-names></name>
<name><surname>Pernokas</surname><given-names>J.</given-names></name>
<name><surname>Pernokas</surname><given-names>M.</given-names></name>
<name><surname>Pinkert</surname><given-names>C.A.</given-names></name>
<name><surname>Powers</surname><given-names>W.R.</given-names></name>
<etal/>
</person-group><article-title>Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs</article-title><source>Biores Open Access</source><year>2020</year><volume>9</volume><fpage>94</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1089/biores.2020.0004</pub-id><pub-id pub-id-type="pmid">32257625</pub-id>
</element-citation></ref><ref id="B144-viruses-17-00239"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Semba</surname><given-names>R.D.</given-names></name>
<name><surname>Moghekar</surname><given-names>A.R.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>K.</given-names></name>
<name><surname>Turner</surname><given-names>R.</given-names></name>
<name><surname>Ferrucci</surname><given-names>L.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>R.</given-names></name>
</person-group><article-title>Klotho in the cerebrospinal fluid of adults with and without Alzheimer&#x02019;s disease</article-title><source>Neurosci. Lett.</source><year>2014</year><volume>558</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2013.10.058</pub-id><pub-id pub-id-type="pmid">24211693</pub-id>
</element-citation></ref><ref id="B145-viruses-17-00239"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castner</surname><given-names>S.A.</given-names></name>
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Moreno</surname><given-names>A.J.</given-names></name>
<name><surname>Park</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Poon</surname><given-names>Y.</given-names></name>
<name><surname>Groen</surname><given-names>A.</given-names></name>
<name><surname>Greenberg</surname><given-names>K.</given-names></name>
<name><surname>David</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Longevity factor klotho enhances cognition in aged nonhuman primates</article-title><source>Nat. Aging</source><year>2023</year><volume>3</volume><fpage>931</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00441-x</pub-id><pub-id pub-id-type="pmid">37400721</pub-id>
</element-citation></ref><ref id="B146-viruses-17-00239"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mencke</surname><given-names>R.</given-names></name>
<name><surname>Olauson</surname><given-names>H.</given-names></name>
<name><surname>Hillebrands</surname><given-names>J.-L.</given-names></name>
</person-group><article-title>Effects of Klotho on fibrosis and cancer: A renal focus on mechanisms and therapeutic strategies</article-title><source>Adv. Drug Deliv. Rev.</source><year>2017</year><volume>121</volume><fpage>85</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2017.07.009</pub-id><pub-id pub-id-type="pmid">28709936</pub-id>
</element-citation></ref><ref id="B147-viruses-17-00239"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolf</surname><given-names>I.</given-names></name>
<name><surname>Levanon-Cohen</surname><given-names>S.</given-names></name>
<name><surname>Bose</surname><given-names>S.</given-names></name>
<name><surname>Ligumsky</surname><given-names>H.</given-names></name>
<name><surname>Sredni</surname><given-names>B.</given-names></name>
<name><surname>Kanety</surname><given-names>H.</given-names></name>
<name><surname>Kuro-o</surname><given-names>M.</given-names></name>
<name><surname>Karlan</surname><given-names>B.</given-names></name>
<name><surname>Kaufman</surname><given-names>B.</given-names></name>
<name><surname>Koeffler</surname><given-names>H.P.</given-names></name>
<etal/>
</person-group><article-title>Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>7094</fpage><lpage>7105</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.292</pub-id><pub-id pub-id-type="pmid">18762812</pub-id>
</element-citation></ref><ref id="B148-viruses-17-00239"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Fergusson</surname><given-names>M.M.</given-names></name>
<name><surname>Castilho</surname><given-names>R.M.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Cao</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Malide</surname><given-names>D.</given-names></name>
<name><surname>Rovira</surname><given-names>I.I.</given-names></name>
<name><surname>Schimel</surname><given-names>D.</given-names></name>
<name><surname>Kuo</surname><given-names>C.J.</given-names></name>
<etal/>
</person-group><article-title>Augmented Wnt signaling in a mammalian model of accelerated aging</article-title><source>Science</source><year>2007</year><volume>317</volume><fpage>803</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1126/science.1143578</pub-id><pub-id pub-id-type="pmid">17690294</pub-id>
</element-citation></ref><ref id="B149-viruses-17-00239"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Urakawa</surname><given-names>I.</given-names></name>
<name><surname>Yamazaki</surname><given-names>Y.</given-names></name>
<name><surname>Shimada</surname><given-names>T.</given-names></name>
<name><surname>Iijima</surname><given-names>K.</given-names></name>
<name><surname>Hasegawa</surname><given-names>H.</given-names></name>
<name><surname>Okawa</surname><given-names>K.</given-names></name>
<name><surname>Fujita</surname><given-names>T.</given-names></name>
<name><surname>Fukumoto</surname><given-names>S.</given-names></name>
<name><surname>Yamashita</surname><given-names>T.</given-names></name>
</person-group><article-title>Klotho converts canonical FGF receptor into a specific receptor for FGF23</article-title><source>Nature</source><year>2006</year><volume>444</volume><fpage>770</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1038/nature05315</pub-id><pub-id pub-id-type="pmid">17086194</pub-id>
</element-citation></ref><ref id="B150-viruses-17-00239"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edmonston</surname><given-names>D.</given-names></name>
<name><surname>Grabner</surname><given-names>A.</given-names></name>
<name><surname>Wolf</surname><given-names>M.</given-names></name>
</person-group><article-title>FGF23 and klotho at the intersection of kidney and cardiovascular disease</article-title><source>Nat. Rev. Cardiol.</source><year>2024</year><volume>21</volume><fpage>11</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41569-023-00903-0</pub-id><pub-id pub-id-type="pmid">37443358</pub-id>
</element-citation></ref><ref id="B151-viruses-17-00239"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>W.</given-names></name>
</person-group><article-title>Klotho inhibits human follicular thyroid cancer cell growth and promotes apoptosis through regulation of the expression of stanniocalcin-1</article-title><source>Oncol. Rep.</source><year>2016</year><volume>35</volume><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.3892/or.2015.4358</pub-id><pub-id pub-id-type="pmid">26531219</pub-id>
</element-citation></ref><ref id="B152-viruses-17-00239"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sachdeva</surname><given-names>A.</given-names></name>
<name><surname>Gouge</surname><given-names>J.</given-names></name>
<name><surname>Kontovounisios</surname><given-names>C.</given-names></name>
<name><surname>Nikolaou</surname><given-names>S.</given-names></name>
<name><surname>Ashworth</surname><given-names>A.</given-names></name>
<name><surname>Lim</surname><given-names>K.</given-names></name>
<name><surname>Chong</surname><given-names>I.</given-names></name>
</person-group><article-title>Klotho and the Treatment of Human Malignancies</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>1665</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12061665</pub-id><pub-id pub-id-type="pmid">32585905</pub-id>
</element-citation></ref><ref id="B153-viruses-17-00239"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jimenez</surname><given-names>V.</given-names></name>
<name><surname>Jambrina</surname><given-names>C.</given-names></name>
<name><surname>Casana</surname><given-names>E.</given-names></name>
<name><surname>Sacristan</surname><given-names>V.</given-names></name>
<name><surname>Mu&#x000f1;oz</surname><given-names>S.</given-names></name>
<name><surname>Darriba</surname><given-names>S.</given-names></name>
<name><surname>Rod&#x000f3;</surname><given-names>J.</given-names></name>
<name><surname>Mallol</surname><given-names>C.</given-names></name>
<name><surname>Garcia</surname><given-names>M.</given-names></name>
<name><surname>Le&#x000f3;n</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>FGF21 gene therapy as treatment for obesity and insulin resistance</article-title><source>EMBO Mol. Med.</source><year>2018</year><volume>10</volume><pub-id pub-id-type="doi">10.15252/emmm.201708791</pub-id><pub-id pub-id-type="pmid">29987000</pub-id>
</element-citation></ref><ref id="B154-viruses-17-00239"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sponton</surname><given-names>C.H.</given-names></name>
<name><surname>Kajimura</surname><given-names>S.</given-names></name>
</person-group><article-title>AAV-mediated gene therapy as a strategy to fight obesity and metabolic diseases</article-title><source>EMBO Mol. Med.</source><year>2018</year><volume>10</volume><pub-id pub-id-type="doi">10.15252/emmm.201809431</pub-id></element-citation></ref><ref id="B155-viruses-17-00239"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roig-Soriano</surname><given-names>J.</given-names></name>
<name><surname>Gri&#x000f1;&#x000e1;n-Ferr&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>Espinosa-Parrilla</surname><given-names>J.F.</given-names></name>
<name><surname>Abraham</surname><given-names>C.R.</given-names></name>
<name><surname>Bosch</surname><given-names>A.</given-names></name>
<name><surname>Pall&#x000e0;s</surname><given-names>M.</given-names></name>
<name><surname>Chill&#x000f3;n</surname><given-names>M.</given-names></name>
</person-group><article-title>AAV-mediated expression of secreted and transmembrane &#x003b1;Klotho isoforms rescues relevant aging hallmarks in senescent SAMP8 mice</article-title><source>Aging Cell</source><year>2022</year><volume>21</volume><fpage>e13581</fpage><pub-id pub-id-type="doi">10.1111/acel.13581</pub-id><pub-id pub-id-type="pmid">35274439</pub-id>
</element-citation></ref><ref id="B156-viruses-17-00239"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>C.Y.</given-names></name>
<name><surname>Chang</surname><given-names>S.C.</given-names></name>
<name><surname>Wu</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation</article-title><source>Kidney Int.</source><year>2012</year><volume>81</volume><fpage>640</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.445</pub-id><pub-id pub-id-type="pmid">22237753</pub-id>
</element-citation></ref><ref id="B157-viruses-17-00239"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sebastiani</surname><given-names>P.</given-names></name>
<name><surname>Gurinovich</surname><given-names>A.</given-names></name>
<name><surname>Nygaard</surname><given-names>M.</given-names></name>
<name><surname>Sasaki</surname><given-names>T.</given-names></name>
<name><surname>Sweigart</surname><given-names>B.</given-names></name>
<name><surname>Bae</surname><given-names>H.</given-names></name>
<name><surname>Andersen</surname><given-names>S.L.</given-names></name>
<name><surname>Villa</surname><given-names>F.</given-names></name>
<name><surname>Atzmon</surname><given-names>G.</given-names></name>
<name><surname>Christensen</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>APOE Alleles and Extreme Human Longevity</article-title><source>J. Gerontol. A Biol. Sci. Med. Sci.</source><year>2019</year><volume>74</volume><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1093/gerona/gly174</pub-id><pub-id pub-id-type="pmid">30060062</pub-id>
</element-citation></ref><ref id="B158-viruses-17-00239"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Ji</surname><given-names>Q.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Ren</surname><given-names>J.</given-names></name>
<name><surname>Yan</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Chu</surname><given-names>Q.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Destabilizing heterochromatin by APOE mediates senescence</article-title><source>Nat. Aging</source><year>2022</year><volume>2</volume><fpage>303</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1038/s43587-022-00186-z</pub-id><pub-id pub-id-type="pmid">37117743</pub-id>
</element-citation></ref><ref id="B159-viruses-17-00239"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>L.G.</given-names></name>
<name><surname>March</surname><given-names>Z.M.</given-names></name>
<name><surname>Stephenson</surname><given-names>R.A.</given-names></name>
<name><surname>Narayan</surname><given-names>P.S.</given-names></name>
</person-group><article-title>Apolipoprotein E in lipid metabolism and neurodegenerative disease</article-title><source>Trends Endocrinol. Metab.</source><year>2023</year><volume>34</volume><fpage>430</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2023.05.002</pub-id><pub-id pub-id-type="pmid">37357100</pub-id>
</element-citation></ref><ref id="B160-viruses-17-00239"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ungvari</surname><given-names>Z.</given-names></name>
<name><surname>Tarantini</surname><given-names>S.</given-names></name>
<name><surname>Kiss</surname><given-names>T.</given-names></name>
<name><surname>Wren</surname><given-names>J.D.</given-names></name>
<name><surname>Giles</surname><given-names>C.B.</given-names></name>
<name><surname>Griffin</surname><given-names>C.T.</given-names></name>
<name><surname>Murfee</surname><given-names>W.L.</given-names></name>
<name><surname>Pacher</surname><given-names>P.</given-names></name>
<name><surname>Csiszar</surname><given-names>A.</given-names></name>
</person-group><article-title>Endothelial dysfunction and angiogenesis impairment in the ageing vasculature</article-title><source>Nat. Rev. Cardiol.</source><year>2018</year><volume>15</volume><fpage>555</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1038/s41569-018-0030-z</pub-id><pub-id pub-id-type="pmid">29795441</pub-id>
</element-citation></ref><ref id="B161-viruses-17-00239"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grunewald</surname><given-names>M.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Sharife</surname><given-names>H.</given-names></name>
<name><surname>Volinsky</surname><given-names>E.</given-names></name>
<name><surname>Gileles-Hillel</surname><given-names>A.</given-names></name>
<name><surname>Licht</surname><given-names>T.</given-names></name>
<name><surname>Permyakova</surname><given-names>A.</given-names></name>
<name><surname>Hinden</surname><given-names>L.</given-names></name>
<name><surname>Azar</surname><given-names>S.</given-names></name>
<name><surname>Friedmann</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span</article-title><source>Science</source><year>2021</year><volume>373</volume><pub-id pub-id-type="doi">10.1126/science.abc8479</pub-id></element-citation></ref><ref id="B162-viruses-17-00239"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Korpela</surname><given-names>H.</given-names></name>
<name><surname>Lampela</surname><given-names>J.</given-names></name>
<name><surname>Airaksinen</surname><given-names>J.</given-names></name>
<name><surname>J&#x000e4;rvel&#x000e4;inen</surname><given-names>N.</given-names></name>
<name><surname>Siimes</surname><given-names>S.</given-names></name>
<name><surname>Valli</surname><given-names>K.</given-names></name>
<name><surname>Nieminen</surname><given-names>T.</given-names></name>
<name><surname>Turunen</surname><given-names>M.</given-names></name>
<name><surname>Gr&#x000f6;nman</surname><given-names>M.</given-names></name>
<name><surname>Saraste</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>AAV2-VEGF-B gene therapy failed to induce angiogenesis in ischemic porcine myocardium due to inflammatory responses</article-title><source>Gene Ther.</source><year>2022</year><volume>29</volume><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1038/s41434-022-00322-9</pub-id><pub-id pub-id-type="pmid">35132204</pub-id>
</element-citation></ref><ref id="B163-viruses-17-00239"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cruz-Jentoft</surname><given-names>A.J.</given-names></name>
<name><surname>Sayer</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Sarcopenia</article-title><source>Lancet</source><year>2019</year><volume>393</volume><fpage>2636</fpage><lpage>2646</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31138-9</pub-id><pub-id pub-id-type="pmid">31171417</pub-id>
</element-citation></ref><ref id="B164-viruses-17-00239"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Larsson</surname><given-names>L.</given-names></name>
<name><surname>Degens</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Salviati</surname><given-names>L.</given-names></name>
<name><surname>Lee</surname><given-names>Y.I.</given-names></name>
<name><surname>Thompson</surname><given-names>W.</given-names></name>
<name><surname>Kirkland</surname><given-names>J.L.</given-names></name>
<name><surname>Sandri</surname><given-names>M.</given-names></name>
</person-group><article-title>Sarcopenia: Aging-Related Loss of Muscle Mass and Function</article-title><source>Physiol. Rev.</source><year>2019</year><volume>99</volume><fpage>427</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1152/physrev.00061.2017</pub-id><pub-id pub-id-type="pmid">30427277</pub-id>
</element-citation></ref><ref id="B165-viruses-17-00239"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitchell</surname><given-names>W.K.</given-names></name>
<name><surname>Williams</surname><given-names>J.</given-names></name>
<name><surname>Atherton</surname><given-names>P.</given-names></name>
<name><surname>Larvin</surname><given-names>M.</given-names></name>
<name><surname>Lund</surname><given-names>J.</given-names></name>
<name><surname>Narici</surname><given-names>M.</given-names></name>
</person-group><article-title>Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review</article-title><source>Front. Physiol.</source><year>2012</year><volume>3</volume><elocation-id>260</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2012.00260</pub-id><pub-id pub-id-type="pmid">22934016</pub-id>
</element-citation></ref><ref id="B166-viruses-17-00239"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murton</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Muscle protein turnover in the elderly and its potential contribution to the development of sarcopenia</article-title><source>Proc. Nutr. Soc.</source><year>2015</year><volume>74</volume><fpage>387</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1017/S0029665115000130</pub-id><pub-id pub-id-type="pmid">25826683</pub-id>
</element-citation></ref><ref id="B167-viruses-17-00239"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dasarathy</surname><given-names>S.</given-names></name>
<name><surname>Merli</surname><given-names>M.</given-names></name>
</person-group><article-title>Sarcopenia from mechanism to diagnosis and treatment in liver disease</article-title><source>J. Hepatol.</source><year>2016</year><volume>65</volume><fpage>1232</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.07.040</pub-id><pub-id pub-id-type="pmid">27515775</pub-id>
</element-citation></ref><ref id="B168-viruses-17-00239"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>Z.</given-names></name>
<name><surname>Zuo</surname><given-names>H.</given-names></name>
<name><surname>Yao</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Meng</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>AAV-Mediated nuclear localized PGC1&#x003b1;4 delivery in muscle ameliorates sarcopenia and aging-associated metabolic dysfunctions</article-title><source>Aging Cell</source><year>2023</year><volume>22</volume><fpage>e13961</fpage><pub-id pub-id-type="doi">10.1111/acel.13961</pub-id><pub-id pub-id-type="pmid">37584432</pub-id>
</element-citation></ref><ref id="B169-viruses-17-00239"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ozes</surname><given-names>B.</given-names></name>
<name><surname>Tong</surname><given-names>L.</given-names></name>
<name><surname>Myers</surname><given-names>M.</given-names></name>
<name><surname>Moss</surname><given-names>K.</given-names></name>
<name><surname>Ridgley</surname><given-names>A.</given-names></name>
<name><surname>Sahenk</surname><given-names>Z.</given-names></name>
</person-group><article-title>AAV1.NT-3 gene therapy prevents age-related sarcopenia</article-title><source>Aging</source><year>2023</year><volume>15</volume><fpage>1306</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.18632/aging.204577</pub-id><pub-id pub-id-type="pmid">36897179</pub-id>
</element-citation></ref><ref id="B170-viruses-17-00239"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davidsohn</surname><given-names>N.</given-names></name>
<name><surname>Pezone</surname><given-names>M.</given-names></name>
<name><surname>Vernet</surname><given-names>A.</given-names></name>
<name><surname>Graveline</surname><given-names>A.</given-names></name>
<name><surname>Oliver</surname><given-names>D.</given-names></name>
<name><surname>Slomovic</surname><given-names>S.</given-names></name>
<name><surname>Punthambaker</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Liao</surname><given-names>R.</given-names></name>
<name><surname>Bonventre</surname><given-names>J.V.</given-names></name>
<etal/>
</person-group><article-title>A single combination gene therapy treats multiple age-related diseases</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>23505</fpage><lpage>23511</lpage><pub-id pub-id-type="doi">10.1073/pnas.1910073116</pub-id><pub-id pub-id-type="pmid">31685628</pub-id>
</element-citation></ref><ref id="B171-viruses-17-00239"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alle</surname><given-names>Q.</given-names></name>
<name><surname>Le Borgne</surname><given-names>E.</given-names></name>
<name><surname>Bensadoun</surname><given-names>P.</given-names></name>
<name><surname>Lemey</surname><given-names>C.</given-names></name>
<name><surname>B&#x000e9;chir</surname><given-names>N.</given-names></name>
<name><surname>Gabanou</surname><given-names>M.</given-names></name>
<name><surname>Estermann</surname><given-names>F.</given-names></name>
<name><surname>Bertrand-Gaday</surname><given-names>C.</given-names></name>
<name><surname>Pessemesse</surname><given-names>L.</given-names></name>
<name><surname>Toupet</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>A single short reprogramming early in life initiates and propagates an epigenetically related mechanism improving fitness and promoting an increased healthy lifespan</article-title><source>Aging Cell</source><year>2022</year><volume>21</volume><fpage>e13714</fpage><pub-id pub-id-type="doi">10.1111/acel.13714</pub-id><pub-id pub-id-type="pmid">36251933</pub-id>
</element-citation></ref><ref id="B172-viruses-17-00239"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Browder</surname><given-names>K.C.</given-names></name>
<name><surname>Reddy</surname><given-names>P.</given-names></name>
<name><surname>Yamamoto</surname><given-names>M.</given-names></name>
<name><surname>Haghani</surname><given-names>A.</given-names></name>
<name><surname>Guillen</surname><given-names>I.G.</given-names></name>
<name><surname>Sahu</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Luque</surname><given-names>Y.</given-names></name>
<name><surname>Prieto</surname><given-names>J.</given-names></name>
<name><surname>Shi</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice</article-title><source>Nat. Aging</source><year>2022</year><volume>2</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1038/s43587-022-00183-2</pub-id><pub-id pub-id-type="pmid">37118377</pub-id>
</element-citation></ref><ref id="B173-viruses-17-00239"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gill</surname><given-names>D.</given-names></name>
<name><surname>Parry</surname><given-names>A.</given-names></name>
<name><surname>Santos</surname><given-names>F.</given-names></name>
<name><surname>Okkenhaug</surname><given-names>H.</given-names></name>
<name><surname>Todd</surname><given-names>C.D.</given-names></name>
<name><surname>Hernando-Herraez</surname><given-names>I.</given-names></name>
<name><surname>Stubbs</surname><given-names>T.M.</given-names></name>
<name><surname>Milagre</surname><given-names>I.</given-names></name>
<name><surname>Reik</surname><given-names>W.</given-names></name>
</person-group><article-title>Multi-omic rejuvenation of human cells by maturation phase transient reprogramming</article-title><source>Elife</source><year>2022</year><volume>11</volume><pub-id pub-id-type="doi">10.7554/eLife.71624</pub-id><pub-id pub-id-type="pmid">35390271</pub-id>
</element-citation></ref><ref id="B174-viruses-17-00239"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Brommer</surname><given-names>B.</given-names></name>
<name><surname>Tian</surname><given-names>X.</given-names></name>
<name><surname>Krishnan</surname><given-names>A.</given-names></name>
<name><surname>Meer</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Vera</surname><given-names>D.L.</given-names></name>
<name><surname>Zeng</surname><given-names>Q.</given-names></name>
<name><surname>Yu</surname><given-names>D.</given-names></name>
<name><surname>Bonkowski</surname><given-names>M.S.</given-names></name>
<etal/>
</person-group><article-title>Reprogramming to recover youthful epigenetic information and restore vision</article-title><source>Nature</source><year>2020</year><volume>588</volume><fpage>124</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2975-4</pub-id><pub-id pub-id-type="pmid">33268865</pub-id>
</element-citation></ref><ref id="B175-viruses-17-00239"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olova</surname><given-names>N.</given-names></name>
<name><surname>Simpson</surname><given-names>D.J.</given-names></name>
<name><surname>Marioni</surname><given-names>R.E.</given-names></name>
<name><surname>Chandra</surname><given-names>T.</given-names></name>
</person-group><article-title>Partial reprogramming induces a steady decline in epigenetic age before loss of somatic identity</article-title><source>Aging Cell</source><year>2019</year><volume>18</volume><fpage>e12877</fpage><pub-id pub-id-type="doi">10.1111/acel.12877</pub-id><pub-id pub-id-type="pmid">30450724</pub-id>
</element-citation></ref><ref id="B176-viruses-17-00239"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarkar</surname><given-names>T.J.</given-names></name>
<name><surname>Quarta</surname><given-names>M.</given-names></name>
<name><surname>Mukherjee</surname><given-names>S.</given-names></name>
<name><surname>Colville</surname><given-names>A.</given-names></name>
<name><surname>Paine</surname><given-names>P.</given-names></name>
<name><surname>Doan</surname><given-names>L.</given-names></name>
<name><surname>Tran</surname><given-names>C.M.</given-names></name>
<name><surname>Chu</surname><given-names>C.R.</given-names></name>
<name><surname>Horvath</surname><given-names>S.</given-names></name>
<name><surname>Qi</surname><given-names>L.S.</given-names></name>
<etal/>
</person-group><article-title>Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1545</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15174-3</pub-id><pub-id pub-id-type="pmid">32210226</pub-id>
</element-citation></ref><ref id="B177-viruses-17-00239"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Ramirez-Matias</surname><given-names>J.</given-names></name>
<name><surname>Hauptschein</surname><given-names>M.</given-names></name>
<name><surname>Sun</surname><given-names>E.D.</given-names></name>
<name><surname>Lunger</surname><given-names>J.C.</given-names></name>
<name><surname>Buckley</surname><given-names>M.T.</given-names></name>
<name><surname>Brunet</surname><given-names>A.</given-names></name>
</person-group><article-title>Restoration of neuronal progenitors by partial reprogramming in the aged neurogenic niche</article-title><source>Nat. Aging</source><year>2024</year><volume>4</volume><fpage>546</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/s43587-024-00594-3</pub-id><pub-id pub-id-type="pmid">38553564</pub-id>
</element-citation></ref><ref id="B178-viruses-17-00239"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abad</surname><given-names>M.</given-names></name>
<name><surname>Mosteiro</surname><given-names>L.</given-names></name>
<name><surname>Pantoja</surname><given-names>C.</given-names></name>
<name><surname>Canamero</surname><given-names>M.</given-names></name>
<name><surname>Rayon</surname><given-names>T.</given-names></name>
<name><surname>Ors</surname><given-names>I.</given-names></name>
<name><surname>Grana</surname><given-names>O.</given-names></name>
<name><surname>Megias</surname><given-names>D.</given-names></name>
<name><surname>Dominguez</surname><given-names>O.</given-names></name>
<name><surname>Martinez</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Reprogramming in vivo produces teratomas and iPS cells with totipotency features</article-title><source>Nature</source><year>2013</year><volume>502</volume><fpage>340</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nature12586</pub-id><pub-id pub-id-type="pmid">24025773</pub-id>
</element-citation></ref><ref id="B179-viruses-17-00239"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ocampo</surname><given-names>A.</given-names></name>
<name><surname>Reddy</surname><given-names>P.</given-names></name>
<name><surname>Martinez-Redondo</surname><given-names>P.</given-names></name>
<name><surname>Platero-Luengo</surname><given-names>A.</given-names></name>
<name><surname>Hatanaka</surname><given-names>F.</given-names></name>
<name><surname>Hishida</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Lam</surname><given-names>D.</given-names></name>
<name><surname>Kurita</surname><given-names>M.</given-names></name>
<name><surname>Beyret</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>1719</fpage><lpage>1733.e12</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.11.052</pub-id><pub-id pub-id-type="pmid">27984723</pub-id>
</element-citation></ref><ref id="B180-viruses-17-00239"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ohnishi</surname><given-names>K.</given-names></name>
<name><surname>Semi</surname><given-names>K.</given-names></name>
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
<name><surname>Shimizu</surname><given-names>M.</given-names></name>
<name><surname>Tanaka</surname><given-names>A.</given-names></name>
<name><surname>Mitsunaga</surname><given-names>K.</given-names></name>
<name><surname>Okita</surname><given-names>K.</given-names></name>
<name><surname>Osafune</surname><given-names>K.</given-names></name>
<name><surname>Arioka</surname><given-names>Y.</given-names></name>
<name><surname>Maeda</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation</article-title><source>Cell</source><year>2014</year><volume>156</volume><fpage>663</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.01.005</pub-id><pub-id pub-id-type="pmid">24529372</pub-id>
</element-citation></ref><ref id="B181-viruses-17-00239"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Senis</surname><given-names>E.</given-names></name>
<name><surname>Mosteiro</surname><given-names>L.</given-names></name>
<name><surname>Wilkening</surname><given-names>S.</given-names></name>
<name><surname>Wiedtke</surname><given-names>E.</given-names></name>
<name><surname>Nowrouzi</surname><given-names>A.</given-names></name>
<name><surname>Afzal</surname><given-names>S.</given-names></name>
<name><surname>Fronza</surname><given-names>R.</given-names></name>
<name><surname>Landerer</surname><given-names>H.</given-names></name>
<name><surname>Abad</surname><given-names>M.</given-names></name>
<name><surname>Niopek</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>AAVvector-mediated in vivo reprogramming into pluripotency</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>2651</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05059-x</pub-id><pub-id pub-id-type="pmid">29985406</pub-id>
</element-citation></ref><ref id="B182-viruses-17-00239"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karg</surname><given-names>M.M.</given-names></name>
<name><surname>Lu</surname><given-names>Y.R.</given-names></name>
<name><surname>Refaian</surname><given-names>N.</given-names></name>
<name><surname>Cameron</surname><given-names>J.</given-names></name>
<name><surname>Hoffmann</surname><given-names>E.</given-names></name>
<name><surname>Hoppe</surname><given-names>C.</given-names></name>
<name><surname>Shirahama</surname><given-names>S.</given-names></name>
<name><surname>Shah</surname><given-names>M.</given-names></name>
<name><surname>Krasniqi</surname><given-names>D.</given-names></name>
<name><surname>Krishnan</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma</article-title><source>Cell. Reprogramming</source><year>2023</year><volume>25</volume><fpage>288</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1089/cell.2023.0074</pub-id><pub-id pub-id-type="pmid">38060815</pub-id>
</element-citation></ref><ref id="B183-viruses-17-00239"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Macip</surname><given-names>C.C.</given-names></name>
<name><surname>Hasan</surname><given-names>R.</given-names></name>
<name><surname>Hoznek</surname><given-names>V.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>Y.R.</given-names></name>
<name><surname>Metzger</surname><given-names>L.E.t.</given-names></name>
<name><surname>Sethna</surname><given-names>S.</given-names></name>
<name><surname>Davidsohn</surname><given-names>N.</given-names></name>
</person-group><article-title>Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice</article-title><source>Cell. Reprogramming</source><year>2024</year><volume>26</volume><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1089/cell.2023.0072</pub-id></element-citation></ref><ref id="B184-viruses-17-00239"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akil</surname><given-names>O.</given-names></name>
</person-group><article-title>Dual and triple AAV delivery of large therapeutic gene sequences into the inner ear</article-title><source>Hear. Res.</source><year>2020</year><volume>394</volume><fpage>107912</fpage><pub-id pub-id-type="doi">10.1016/j.heares.2020.107912</pub-id><pub-id pub-id-type="pmid">32067799</pub-id>
</element-citation></ref><ref id="B185-viruses-17-00239"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dyka</surname><given-names>F.M.</given-names></name>
<name><surname>Boye</surname><given-names>S.L.</given-names></name>
<name><surname>Chiodo</surname><given-names>V.A.</given-names></name>
<name><surname>Hauswirth</surname><given-names>W.W.</given-names></name>
<name><surname>Boye</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A</article-title><source>Hum. Gene Ther. Methods</source><year>2014</year><volume>25</volume><fpage>166</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1089/hgtb.2013.212</pub-id><pub-id pub-id-type="pmid">24568220</pub-id>
</element-citation></ref><ref id="B186-viruses-17-00239"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maddalena</surname><given-names>A.</given-names></name>
<name><surname>Tornabene</surname><given-names>P.</given-names></name>
<name><surname>Tiberi</surname><given-names>P.</given-names></name>
<name><surname>Minopoli</surname><given-names>R.</given-names></name>
<name><surname>Manfredi</surname><given-names>A.</given-names></name>
<name><surname>Mutarelli</surname><given-names>M.</given-names></name>
<name><surname>Rossi</surname><given-names>S.</given-names></name>
<name><surname>Simonelli</surname><given-names>F.</given-names></name>
<name><surname>Naggert</surname><given-names>J.K.</given-names></name>
<name><surname>Cacchiarelli</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Triple Vectors Expand AAV Transfer Capacity in the Retina</article-title><source>Mol. Ther.</source><year>2018</year><volume>26</volume><fpage>524</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.11.019</pub-id><pub-id pub-id-type="pmid">29292161</pub-id>
</element-citation></ref><ref id="B187-viruses-17-00239"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McClements</surname><given-names>M.E.</given-names></name>
<name><surname>MacLaren</surname><given-names>R.E.</given-names></name>
</person-group><article-title>Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes</article-title><source>Yale J. Biol. Med.</source><year>2017</year><volume>90</volume><fpage>611</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">29259525</pub-id>
</element-citation></ref><ref id="B188-viruses-17-00239"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Duan</surname><given-names>D.</given-names></name>
</person-group><article-title>Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma</article-title><source>Hum. Gene Ther.</source><year>2012</year><volume>23</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1089/hum.2011.131</pub-id><pub-id pub-id-type="pmid">21933029</pub-id>
</element-citation></ref><ref id="B189-viruses-17-00239"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kruzik</surname><given-names>A.</given-names></name>
<name><surname>Fetahagic</surname><given-names>D.</given-names></name>
<name><surname>Hartlieb</surname><given-names>B.</given-names></name>
<name><surname>Dorn</surname><given-names>S.</given-names></name>
<name><surname>Koppensteiner</surname><given-names>H.</given-names></name>
<name><surname>Horling</surname><given-names>F.M.</given-names></name>
<name><surname>Scheiflinger</surname><given-names>F.</given-names></name>
<name><surname>Reipert</surname><given-names>B.M.</given-names></name>
<name><surname>de la Rosa</surname><given-names>M.</given-names></name>
</person-group><article-title>Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2019</year><volume>14</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2019.05.014</pub-id><pub-id pub-id-type="pmid">31338384</pub-id>
</element-citation></ref><ref id="B190-viruses-17-00239"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vandamme</surname><given-names>C.</given-names></name>
<name><surname>Adjali</surname><given-names>O.</given-names></name>
<name><surname>Mingozzi</surname><given-names>F.</given-names></name>
</person-group><article-title>Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial</article-title><source>Hum. Gene Ther.</source><year>2017</year><volume>28</volume><fpage>1061</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1089/hum.2017.150</pub-id><pub-id pub-id-type="pmid">28835127</pub-id>
</element-citation></ref><ref id="B191-viruses-17-00239"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>High</surname><given-names>K.A.</given-names></name>
<name><surname>Anguela</surname><given-names>X.M.</given-names></name>
</person-group><article-title>Adeno-associated viral vectors for the treatment of hemophilia</article-title><source>Hum. Mol. Genet.</source><year>2016</year><volume>25</volume><fpage>R36</fpage><lpage>R41</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv475</pub-id><pub-id pub-id-type="pmid">26614390</pub-id>
</element-citation></ref><ref id="B192-viruses-17-00239"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calcedo</surname><given-names>R.</given-names></name>
<name><surname>Vandenberghe</surname><given-names>L.H.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Wilson</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>199</volume><fpage>381</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1086/595830</pub-id><pub-id pub-id-type="pmid">19133809</pub-id>
</element-citation></ref><ref id="B193-viruses-17-00239"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klamroth</surname><given-names>R.</given-names></name>
<name><surname>Hayes</surname><given-names>G.</given-names></name>
<name><surname>Andreeva</surname><given-names>T.</given-names></name>
<name><surname>Gregg</surname><given-names>K.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
<name><surname>Mitha</surname><given-names>I.H.</given-names></name>
<name><surname>Hardesty</surname><given-names>B.</given-names></name>
<name><surname>Shima</surname><given-names>M.</given-names></name>
<name><surname>Pollock</surname><given-names>T.</given-names></name>
<name><surname>Slev</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A</article-title><source>Hum. Gene Ther.</source><year>2022</year><volume>33</volume><fpage>432</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1089/hum.2021.287</pub-id><pub-id pub-id-type="pmid">35156839</pub-id>
</element-citation></ref><ref id="B194-viruses-17-00239"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Louis Jeune</surname><given-names>V.</given-names></name>
<name><surname>Joergensen</surname><given-names>J.A.</given-names></name>
<name><surname>Hajjar</surname><given-names>R.J.</given-names></name>
<name><surname>Weber</surname><given-names>T.</given-names></name>
</person-group><article-title>Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy</article-title><source>Hum. Gene Ther. Methods</source><year>2013</year><volume>24</volume><fpage>59</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1089/hgtb.2012.243</pub-id><pub-id pub-id-type="pmid">23442094</pub-id>
</element-citation></ref><ref id="B195-viruses-17-00239"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meliani</surname><given-names>A.</given-names></name>
<name><surname>Boisgerault</surname><given-names>F.</given-names></name>
<name><surname>Fitzpatrick</surname><given-names>Z.</given-names></name>
<name><surname>Marmier</surname><given-names>S.</given-names></name>
<name><surname>Leborgne</surname><given-names>C.</given-names></name>
<name><surname>Collaud</surname><given-names>F.</given-names></name>
<name><surname>Simon Sola</surname><given-names>M.</given-names></name>
<name><surname>Charles</surname><given-names>S.</given-names></name>
<name><surname>Ronzitti</surname><given-names>G.</given-names></name>
<name><surname>Vignaud</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors</article-title><source>Blood Adv.</source><year>2017</year><volume>1</volume><fpage>2019</fpage><lpage>2031</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2017010181</pub-id><pub-id pub-id-type="pmid">29296848</pub-id>
</element-citation></ref><ref id="B196-viruses-17-00239"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>C.</given-names></name>
<name><surname>Scheideler</surname><given-names>O.</given-names></name>
<name><surname>Schaffer</surname><given-names>D.</given-names></name>
</person-group><article-title>Engineering the AAV capsid to evade immune responses</article-title><source>Curr. Opin. Biotechnol.</source><year>2019</year><volume>60</volume><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2019.01.002</pub-id><pub-id pub-id-type="pmid">30807882</pub-id>
</element-citation></ref><ref id="B197-viruses-17-00239"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartel</surname><given-names>M.</given-names></name>
<name><surname>Schaffer</surname><given-names>D.</given-names></name>
<name><surname>B&#x000fc;ning</surname><given-names>H.</given-names></name>
</person-group><article-title>Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity</article-title><source>Front. Microbiol.</source><year>2011</year><volume>2</volume><elocation-id>204</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2011.00204</pub-id><pub-id pub-id-type="pmid">22065962</pub-id>
</element-citation></ref><ref id="B198-viruses-17-00239"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elmore</surname><given-names>Z.C.</given-names></name>
<name><surname>Oh</surname><given-names>D.K.</given-names></name>
<name><surname>Simon</surname><given-names>K.E.</given-names></name>
<name><surname>Fanous</surname><given-names>M.M.</given-names></name>
<name><surname>Asokan</surname><given-names>A.</given-names></name>
</person-group><article-title>Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme</article-title><source>JCI Insight</source><year>2020</year><volume>5</volume><pub-id pub-id-type="doi">10.1172/jci.insight.139881</pub-id></element-citation></ref><ref id="B199-viruses-17-00239"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gross</surname><given-names>D.A.</given-names></name>
<name><surname>Tedesco</surname><given-names>N.</given-names></name>
<name><surname>Leborgne</surname><given-names>C.</given-names></name>
<name><surname>Ronzitti</surname><given-names>G.</given-names></name>
</person-group><article-title>Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>857276</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.857276</pub-id><pub-id pub-id-type="pmid">35464422</pub-id>
</element-citation></ref><ref id="B200-viruses-17-00239"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leborgne</surname><given-names>C.</given-names></name>
<name><surname>Barbon</surname><given-names>E.</given-names></name>
<name><surname>Alexander</surname><given-names>J.M.</given-names></name>
<name><surname>Hanby</surname><given-names>H.</given-names></name>
<name><surname>Delignat</surname><given-names>S.</given-names></name>
<name><surname>Cohen</surname><given-names>D.M.</given-names></name>
<name><surname>Collaud</surname><given-names>F.</given-names></name>
<name><surname>Muraleetharan</surname><given-names>S.</given-names></name>
<name><surname>Lupo</surname><given-names>D.</given-names></name>
<name><surname>Silverberg</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1096</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0911-7</pub-id><pub-id pub-id-type="pmid">32483358</pub-id>
</element-citation></ref><ref id="B201-viruses-17-00239"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meliani</surname><given-names>A.</given-names></name>
<name><surname>Boisgerault</surname><given-names>F.</given-names></name>
<name><surname>Hardet</surname><given-names>R.</given-names></name>
<name><surname>Marmier</surname><given-names>S.</given-names></name>
<name><surname>Collaud</surname><given-names>F.</given-names></name>
<name><surname>Ronzitti</surname><given-names>G.</given-names></name>
<name><surname>Leborgne</surname><given-names>C.</given-names></name>
<name><surname>Costa Verdera</surname><given-names>H.</given-names></name>
<name><surname>Simon Sola</surname><given-names>M.</given-names></name>
<name><surname>Charles</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>4098</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06621-3</pub-id><pub-id pub-id-type="pmid">30291246</pub-id>
</element-citation></ref><ref id="B202-viruses-17-00239"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Zhong</surname><given-names>L.</given-names></name>
<name><surname>Su</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>He</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Hendricks</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side-Effects</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2014</year><volume>1</volume><fpage>20139</fpage><pub-id pub-id-type="doi">10.1038/mtm.2013.9</pub-id><pub-id pub-id-type="pmid">25485285</pub-id>
</element-citation></ref><ref id="B203-viruses-17-00239"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watakabe</surname><given-names>A.</given-names></name>
<name><surname>Ohtsuka</surname><given-names>M.</given-names></name>
<name><surname>Kinoshita</surname><given-names>M.</given-names></name>
<name><surname>Takaji</surname><given-names>M.</given-names></name>
<name><surname>Isa</surname><given-names>K.</given-names></name>
<name><surname>Mizukami</surname><given-names>H.</given-names></name>
<name><surname>Ozawa</surname><given-names>K.</given-names></name>
<name><surname>Isa</surname><given-names>T.</given-names></name>
<name><surname>Yamamori</surname><given-names>T.</given-names></name>
</person-group><article-title>Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex</article-title><source>Neurosci. Res.</source><year>2015</year><volume>93</volume><fpage>144</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.neures.2014.09.002</pub-id><pub-id pub-id-type="pmid">25240284</pub-id>
</element-citation></ref><ref id="B204-viruses-17-00239"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Massaro</surname><given-names>G.</given-names></name>
<name><surname>Geard</surname><given-names>A.F.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Coombe-Tennant</surname><given-names>O.</given-names></name>
<name><surname>Waddington</surname><given-names>S.N.</given-names></name>
<name><surname>Baruteau</surname><given-names>J.</given-names></name>
<name><surname>Gissen</surname><given-names>P.</given-names></name>
<name><surname>Rahim</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>611</elocation-id><pub-id pub-id-type="doi">10.3390/biom11040611</pub-id><pub-id pub-id-type="pmid">33924076</pub-id>
</element-citation></ref><ref id="B205-viruses-17-00239"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wec</surname><given-names>A.Z.</given-names></name>
<name><surname>Lin</surname><given-names>K.S.</given-names></name>
<name><surname>Kwasnieski</surname><given-names>J.C.</given-names></name>
<name><surname>Sinai</surname><given-names>S.</given-names></name>
<name><surname>Gerold</surname><given-names>J.</given-names></name>
<name><surname>Kelsic</surname><given-names>E.D.</given-names></name>
</person-group><article-title>Overcoming Immunological Challenges Limiting Capsid-Mediated Gene Therapy With Machine Learning</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>674021</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.674021</pub-id><pub-id pub-id-type="pmid">33986759</pub-id>
</element-citation></ref><ref id="B206-viruses-17-00239"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vu Hong</surname><given-names>A.</given-names></name>
<name><surname>Suel</surname><given-names>L.</given-names></name>
<name><surname>Petat</surname><given-names>E.</given-names></name>
<name><surname>Dubois</surname><given-names>A.</given-names></name>
<name><surname>Le Brun</surname><given-names>P.-R.</given-names></name>
<name><surname>Guerchet</surname><given-names>N.</given-names></name>
<name><surname>Veron</surname><given-names>P.</given-names></name>
<name><surname>Poupiot</surname><given-names>J.</given-names></name>
<name><surname>Richard</surname><given-names>I.</given-names></name>
</person-group><article-title>An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>7965</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-52002-4</pub-id><pub-id pub-id-type="pmid">39261465</pub-id>
</element-citation></ref><ref id="B207-viruses-17-00239"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rana</surname><given-names>J.</given-names></name>
<name><surname>Kumar</surname><given-names>S.R.</given-names></name>
<name><surname>Munoz</surname><given-names>M.</given-names></name>
<name><surname>Yamada</surname><given-names>K.</given-names></name>
<name><surname>Bertollini</surname><given-names>T.</given-names></name>
<name><surname>Markusic</surname><given-names>D.M.</given-names></name>
<name><surname>Corti</surname><given-names>M.</given-names></name>
<name><surname>Byrne</surname><given-names>B.J.</given-names></name>
<name><surname>Herzog</surname><given-names>R.W.</given-names></name>
<name><surname>Biswas</surname><given-names>M.</given-names></name>
</person-group><article-title>Combination Therapy to Enable AAV Re-Dosing and Mitigate Transgene Immunity in Liver-Targeted Gene Therapy</article-title><source>Blood</source><year>2022</year><volume>140</volume><fpage>311</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1182/blood-2022-169848</pub-id></element-citation></ref><ref id="B208-viruses-17-00239"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Janssen</surname><given-names>J.M.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Tasca</surname><given-names>F.</given-names></name>
<name><surname>Hoeben</surname><given-names>R.C.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>M.A.F.V.</given-names></name>
</person-group><article-title>Precision genome editing using combinatorial viral vector delivery of CRISPR-Cas9 nucleases and donor DNA constructs</article-title><source>Nucleic Acids Res.</source><year>2024</year><volume>53</volume><pub-id pub-id-type="doi">10.1093/nar/gkae1213</pub-id></element-citation></ref><ref id="B209-viruses-17-00239"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
</person-group><article-title>CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>136</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.023</pub-id><pub-id pub-id-type="pmid">32243786</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00239-f001"><label>Figure 1</label><caption><p>AAV vector structure. (<bold>A</bold>) The wild-type (WT) AAV genome contains the <italic toggle="yes">rep</italic> (replication) and <italic toggle="yes">cap</italic> (capsid) genes, along with regulatory elements like polyadenylation (PolyA). These are flanked by two inverted terminal repeats (ITRs), which form T-shaped hairpin structures critical for genome replication and packaging. (<bold>B</bold>) In single-stranded recombinant AAVs (rAAV), the <italic toggle="yes">rep</italic> and <italic toggle="yes">cap</italic> genes are removed and replaced with a transgene expression cassette that includes a promoter, additional enhancers or a Kozak consensus sequence (yellow box), gene of interest, and PolyA, flanked by ITRs. The foreign DNA packaging capacity is approximately 4.5&#x02009;kb. (<bold>C</bold>) In self-complementary rAAVs (scAAVs), the 5&#x02032; ITR is mutated, allowing the single-stranded genome to fold into a double-stranded structure, reducing the genome size to 2.2 kb but increasing the transduction efficiency. rAAVs can be tailored at the capsid and promoter levels, where the capsid&#x02019;s serotype determines the tissue tropism, while the promoter drives tissue-specific or widespread transgene expression.</p></caption><graphic xlink:href="viruses-17-00239-g001" position="float"/></fig><fig position="float" id="viruses-17-00239-f002"><label>Figure 2</label><caption><p>AAV transduction pathway. Main steps in the AAV transduction pathway: The rAAV capsid binds to cell surface receptors, triggering the internalization of the virus via endocytosis, which forms endosomes. Following endosomal escape, the AAV is transported into the nucleus and uncoats. The single-stranded AAV genome converts to double-stranded DNA (except in scAAV, which skips this step for faster transduction). The AAV DNA is then transcribed into mRNA, which exits the nucleus and is translated into therapeutic proteins.</p></caption><graphic xlink:href="viruses-17-00239-g002" position="float"/></fig><fig position="float" id="viruses-17-00239-f003"><label>Figure 3</label><caption><p>A schematic overview of AAV vector manufacturing. Upstream process: Cells are expanded and transferred into a production bioreactor (50&#x02013;200 L) based on the scale of AAVs required. A triple transfection process with three plasmids (transgene, packaging, and helper) is then performed to produce AAV vectors designed to deliver therapeutic genes. A few days later, the cells are lysed to release both full and empty AAV vectors, as well as other cellular components. Downstream process: Purification methods are employed, including affinity chromatography and ion exchange chromatography, which are crucial for separating full AAV capsids from empty ones, ensuring high purity and potency. Tangential flow filtration (TFF) is often used for concentration and buffer exchange, ensuring sterility. The final gene therapy product is packaged into vials and undergoes detailed characterization, including assessments of the viral genome titer, purity, and stability to ensure safe, clinical-grade AAV vectors.</p></caption><graphic xlink:href="viruses-17-00239-g003" position="float"/></fig><fig position="float" id="viruses-17-00239-f004"><label>Figure 4</label><caption><p>Advancements in gene therapy for aging. Schematic representation of recent advancements in gene therapy targeting aging and age-related diseases. Top panel: AAV vectors for the delivery of therapeutic genes are being explored for various aging-related targets, for example, <italic toggle="yes">TERT</italic> to extend the lifespan and <italic toggle="yes">klotho</italic> to treat age-related diseases and improve cognition. <italic toggle="yes">APOE</italic> (for Alzheimer&#x02019;s) and <italic toggle="yes">VEGF</italic> (for vascular health) are also under investigation. The AAV-mediated delivery of PGC-1&#x003b1;4 and NT-3 has demonstrated the restoration of muscle function in sarcopenia in mouse models, while AAV8-based therapies targeting longevity-associated genes (FGF21, &#x003b1;-klotho, and sTGF&#x003b2;R2) have enhanced the health span and longevity in multiple age-related disease models. Bottom panel: Emerging strategies like partial reprogramming, using the AAV-mediated delivery of Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc; OSKM), aim to rejuvenate cells, tissues, and organisms, showing the potential to reverse aging-related symptoms and improve longevity. Gene therapy approaches for targeting age-related diseases and phenotypes are still largely in the preclinical stages (animal models and early testing), with clinical trials expected to follow.</p></caption><graphic xlink:href="viruses-17-00239-g004" position="float"/></fig><table-wrap position="float" id="viruses-17-00239-t001"><object-id pub-id-type="pii">viruses-17-00239-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of AAV-mediated delivery methods.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delivery Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Tissue/Organ</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Limitations</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous (IV)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver, muscle, central nervous system (CNS), systemic tissues</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Non-invasive</p></list-item><list-item><p>Broad distribution to multiple organs</p></list-item><list-item><p>Suitable for systemic disorders</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Risk of immune response</p></list-item><list-item><p>Potential off-target effects</p></list-item><list-item><p>Limited targeting specificity</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intrathecal (IT)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Central nervous system (spinal cord, brain)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Direct delivery to CNS</p></list-item><list-item><p>Bypasses blood&#x02013;brain barrier</p></list-item><list-item><p>Lower systemic exposure</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Requires expertise</p></list-item><list-item><p>Invasive</p></list-item><list-item><p>May need repeated administration</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular (IM)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skeletal muscle</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Localized and sustained expression</p></list-item><list-item><p>Minimally invasive</p></list-item><list-item><p>Easy administration</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limited to muscle-targeted applications</p></list-item><list-item><p>Risk of immune response at injection site</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intraperitoneal (IP)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abdominal organs (e.g., liver, pancreas)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Localized delivery to abdominal cavity</p></list-item><list-item><p>Minimally invasive</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limited applicability for systemic diseases</p></list-item><list-item><p>Risk of peritoneal adhesions</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intraocular</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retina</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Localized delivery</p></list-item><list-item><p>Bypasses systemic circulation</p></list-item><list-item><p>Direct access to target tissue</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Invasive</p></list-item><list-item><p>Limited to ocular applications</p></list-item><list-item><p>Risk of complications such as retinal detachment</p></list-item></list>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00239-t002"><object-id pub-id-type="pii">viruses-17-00239-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparative overview of AAV serotypes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AAV Serotype</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tropism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Transduction <break/>Efficiency</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune <break/>Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical <break/>Applications</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skeletal muscle, heart, CNS, retina</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High for skeletal muscle and cardiac tissues</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate humoral immune response; reduced immune recognition due to lack of heparin binding</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gene therapy for muscular and cardiovascular disorders, ocular therapies</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver, retina, CNS, skeletal muscles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High; recognized for its versatility in multiple tissues</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High pre-existing immunity in humans</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Widely used in research and clinical trials, including for Parkinson&#x02019;s disease and blindness caused by Leber congenital amaurosis, hemophilia B, and CNS-related therapies</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver, hepatic cancer cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High for human hepatocytes; low in murine cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emerging applications in liver-targeted therapies</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retina, CNS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate for CNS and retinal cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ocular gene therapy, CNS-related therapies, and retinal applications</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Airway epithelia, liver, murine retinal cells, neural cells (Purkinje, basket neurons)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High for retinal and neural tissues</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retinal gene therapy, airway-related diseases, and CNS therapies</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV6</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skeletal muscle, liver, airway epithelia</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High for skeletal muscles and cardiac tissues</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory disease therapies and muscle-targeted treatments</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skeletal muscle, liver, CNS, retina</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High in muscle tissues and hepatocytes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS-related applications, retinal gene therapy</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver, skeletal and cardiac muscles </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Highest efficiency for liver and muscle cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low immune response compared to other serotypes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver-directed gene therapies, retinal disorders, and muscular dystrophies</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV9</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS, heart, skeletal muscle, liver, retina</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High for CNS and peripheral tissues</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low to moderate; capable of crossing BBB</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological disorders (e.g., SMA), cardiac gene therapies</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV10</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intestines, liver, lymph nodes, kidneys, adrenal glands, retina</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High for a broad range of tissues</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emerging gene therapy applications, including for intestinal and retinal disorders</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV11</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS, murine projection neurons and astrocytes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate; less studied</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS-targeted therapies</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Salivary glands, nasal epithelia</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory gene therapy and experimental applications</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00239-t003"><object-id pub-id-type="pii">viruses-17-00239-t003_Table 3</object-id><label>Table 3</label><caption><p>Comparison of AAV purification techniques.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Purification <break/>Technique</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Purity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Yield</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Scalability</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cost</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Grade Compliance</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Affinity <break/>Chromatography</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High (&#x0003e;98% purity), but does not separate empty and full capsids</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stable yield across batches</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scalable with automated processes; requires specific resins</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate to high due to resin costs and regeneration needs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMP-compatible; suitable for large-scale production</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ion Exchange Chromatography (IEC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High (&#x0003e;98% purity); removes empty capsids effectively</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High and consistent yields</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scalable with automated systems; resin lifetime may vary</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate due to resin limitations and process complexity</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMP-compatible; effective for clinical-grade vectors</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ultracentrifugation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High purity; effective for separating full from empty capsids</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower yields compared to chromatography</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited scalability due to time and equipment constraints</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low for small scale, high for larger scale due to labor and equipment</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Challenging to scale; not ideal for GMP compliance</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tangential Flow Filtration (TFF)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complements other techniques, achieving &#x0003e;90% full particles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Supports concentration and buffer exchange; retains high yield</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scalable and suitable for large volumes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cost-effective for downstream steps</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMP-compatible when integrated into purification workflows</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00239-t004"><object-id pub-id-type="pii">viruses-17-00239-t004_Table 4</object-id><label>Table 4</label><caption><p>FDA-approved AAV gene therapies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Product Name</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year of Approval</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vector Type</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Manufacturer</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BEQVEZ (fidanacogene elaparvovec-dzkt)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2024</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adult hemophilia B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rAAVrh74var</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarepta Therapeutics, Inc. Cambridge, MA, USA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevidys (delandistrogene moxeparvovec-rokl)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duchenne muscular dystrophy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rAAVrh74</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarepta Therapeutics, Inc. Cambridge, MA, USA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemgenix (etranacogene dezaparvovec-drlb)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adult hemophilia B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rAAV5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CSL Behring LLC. King of Prussia, PA, USA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Luxturna (voretigene neparvovec-rzyl)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biallelic RPE65 mutation-associated Leber congenital amaurosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rAAV2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spark Therapeutics, Inc. Cambridge, MA, USA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roctavian (valoctocogene roxaparvovec-rvox)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adult hemophilia A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rAAV5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BioMarin Pharmaceutical, Inc. San Rafael, CA, USA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zolgensma (onasemnogene abeparvovec-xioi)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spinal muscular atrophy type I</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rAAV9</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Novartis Gene Therapies, Inc. Bannockburn, IL, USA</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00239-t005"><object-id pub-id-type="pii">viruses-17-00239-t005_Table 5</object-id><label>Table 5</label><caption><p>International regulatory guidance documents.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Document</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Committee</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guideline S12 on non-clinical biodistribution considerations for gene therapy product (2023)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICH</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reflection paper on expectations for biodistribution assessment for gene therapy product (2018)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPRP</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long-term follow-up after administration of human gene therapy products (2020)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guideline on the quality, nonclinical, and clinical aspects of gene therapy medicinal products (2018)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMA</td></tr></tbody></table><table-wrap-foot><fn><p>ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; IPRP: International Pharmaceutical Regulators Programme; FDA: Food and Drug Administration; EMA: European Medicines Agency.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00239-t006"><object-id pub-id-type="pii">viruses-17-00239-t006_Table 6</object-id><label>Table 6</label><caption><p>Major challenges in AAV gene therapy and proposed solutions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Challenge</bold>
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Description</bold>
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Proposed Solutions</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited Packaging <break/>Capacity</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAV vectors can carry only ~4.7 kb, restricting their use for larger therapeutic genes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Use of &#x02018;mini gene&#x02019; constructs</p></list-item><list-item><p>Dual or triple AAV vectors to deliver split genes</p></list-item><list-item><p>Advanced capsid engineering for more efficient packaging</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunogenicity</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immune responses to capsid proteins, transgenes, or pre-existing antibodies limit efficacy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Engineering capsids resistant to neutralizing antibodies</p></list-item><list-item><p>Sequential administration with low-cross-reactivity capsids</p></list-item><list-item><p>Immune suppression (e.g., rapamycin, plasmapheresis)</p></list-item><list-item><p>Localized administration to immune-privileged sites like the eye or brain</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vector Delivery Limitations</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk of off-target transduction and inconsistent therapeutic efficacy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Tissue-specific promoters for higher specificity</p></list-item><list-item><p>Endogenous promoter designs for sustained transgene expression</p></list-item><list-item><p>Improved vector targeting through capsid modifications</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Translational Hurdles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discrepancies between animal models and human outcomes, affecting immune response predictions</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Human-based studies to enhance translation accuracy</p></list-item><list-item><p>Comprehensive biodistribution and shedding studies preclinically and in humans</p></list-item><list-item><p>GLP-compliant data collection and analysis for preclinical safety</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High Vector Doses</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Large doses required for efficacy lead to toxicity and severe immune reactions</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Dose optimization based on preclinical and historical clinical trial data</p></list-item><list-item><p>Non-human primate studies for dosing regimens</p></list-item><list-item><p>Pharmacokinetic/pharmacodynamic modeling for safer dosing</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safety Concerns</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risks include hepatotoxicity, thrombotic microangiopathy, and other adverse effects</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Biomarker assessment for toxicity and disease monitoring</p></list-item><list-item><p>Comprehensive preclinical safety profiling</p></list-item><list-item><p>Monitoring and mitigation of genotoxicity risks</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn><p>
<bold>Challenge</bold>
</p></fn></table-wrap-foot><table-wrap-foot><fn><p>
<bold>Description</bold>
</p></fn></table-wrap-foot><table-wrap-foot><fn><p>
<bold>Proposed Solutions</bold>
</p></fn></table-wrap-foot></table-wrap></floats-group></article>